Document:

PLATFORM DEVELOPMENT FUNDING AGREEMENT

 Exhibit 10.44 
 CONFIDENTIAL TREATMENT 
 Execution Version 

PLATFORM DEVELOPMENT FUNDING AGREEMENT 
 Dated as of October 21, 2010 
 among 

OMEROS CORPORATION, 
 VULCAN INC. 
 and 

COUGAR INVESTMENT HOLDINGS LLC 

 CONFIDENTIAL TREATMENT 
  

 Table of Contents 

 

									
	 	  	 	 	 	  	Page	 
	Article I DEFINITIONS	  	 	1	  
				
		  	Section 1.01	 	Definitions	  	 	1	  
		
	 Article II FUNDING AND TRANSFER OF ASSIGNED INTERESTS
	  	 	13	  
				
		  	Section 2.01	 	Funding and Transfer	  	 	13	  
				
		  	Section 2.02	 	Payments in Respect of the Assigned Interests	  	 	13	  
				
		  	Section 2.03	 	Warrants	  	 	14	  
				
		  	Section 2.04	 	Funding Amount	  	 	14	  
				
		  	Section 2.05	 	No Assumed Obligations	  	 	14	  
				
		  	Section 2.06	 	Excluded Assets	  	 	15	  
		
	 Article III REPRESENTATIONS AND WARRANTIES OF OMEROS
	  	 	15	  
				
		  	Section 3.01	 	Organization	  	 	15	  
				
		  	Section 3.02	 	Corporate Authorization	  	 	15	  
				
		  	Section 3.03	 	Governmental Authorization	  	 	16	  
				
		  	Section 3.04	 	Capitalization	  	 	16	  
				
		  	Section 3.05	 	Ownership	  	 	16	  
				
		  	Section 3.06	 	Litigation	  	 	16	  
				
		  	Section 3.07	 	Compliance with Laws	  	 	17	  
				
		  	Section 3.08	 	Conflicts	  	 	17	  
				
		  	Section 3.09	 	Commission Documents, Financial Statements	  	 	17	  
				
		  	Section 3.10	 	Material Contracts	  	 	18	  
				
		  	Section 3.11	 	Place of Business	  	 	18	  
				
		  	Section 3.12	 	Broker’s Fees	  	 	18	  
				
		  	Section 3.13	 	Human Class A Orphan GPCRs	  	 	18	  
				
		  	Section 3.14	 	No Material Adverse Effect	  	 	18	  
				
		  	Section 3.15	 	No Undisclosed Liabilities	  	 	19	  
				
		  	Section 3.16	 	No Undisclosed Events or Circumstances	  	 	19	  
				
		  	Section 3.17	 	Indebtedness; Solvency	  	 	19	  
				
		  	Section 3.18	 	Intellectual Property	  	 	19	  
				
		  	Section 3.19	 	Investment Company Act Status	  	 	20	  
				
		  	Section 3.20	 	Disclosure	  	 	20	  
		
	 Article IV REPRESENTATIONS AND WARRANTIES OF VULCAN
	  	 	20	  
				
		  	Section 4.01	 	Organization	  	 	20	  

  
 - i -

 CONFIDENTIAL TREATMENT 
  

									
				
		 	Section 4.02	 	Authorization	  	 	20	  
				
		 	Section 4.03	 	Broker’s Fees	  	 	20	  
				
		 	Section 4.04	 	Conflicts	  	 	21	  
				
		 	Section 4.05	 	Consents	  	 	21	  
				
		 	Section 4.06	 	Accredited Investor	  	 	21	  
		
	Article V COVENANTS	  	 	21	  
				
		 	Section 5.01	 	Platform; Development	  	 	21	  
				
		 	Section 5.02	 	Information; Access; Audits	  	 	22	  
				
		 	Section 5.03	 	Capitalization	  	 	24	  
				
		 	Section 5.04	 	Compliance with Law	  	 	24	  
				
		 	Section 5.05	 	Confidentiality; Public Announcement	  	 	24	  
				
		 	Section 5.06	 	Further Assurance	  	 	25	  
				
		 	Section 5.07	 	Intellectual Property	  	 	25	  
				
		 	Section 5.08	 	Negative Pledge	  	 	25	  
				
		 	Section 5.09	 	Insurance	  	 	26	  
				
		 	Section 5.10	 	Notice	  	 	26	  
				
		 	Section 5.11	 	Third Party Agreements	  	 	26	  
				
		 	Section 5.12	 	Platform and Product Transfer	  	 	26	  
		
	Article VI THE CLOSING; CONDITIONS TO CLOSING	  	 	27	  
				
		 	Section 6.01	 	Closing	  	 	27	  
				
		 	Section 6.02	 	Conditions Applicable to Vulcan	  	 	27	  
				
		 	Section 6.03	 	Conditions Applicable to Omeros	  	 	28	  
		
	Article VII COLLATERAL	  	 	29	  
				
		 	Section 7.01	 	Grant of Security Interest	  	 	29	  
				
		 	Section 7.02	 	No Assumption of Liability	  	 	29	  
				
		 	Section 7.03	 	Further Assurances	  	 	29	  
				
		 	Section 7.04	 	Exclusions from the Collateral	  	 	29	  
				
		 	Section 7.05	 	Release of Liens	  	 	30	  
		
	Article VIII EVENTS OF DEFAULT	  	 	30	  
				
		 	Section 8.01	 	Events of Default	  	 	30	  
				
		 	Section 8.02	 	Remedies Upon Event of Default	  	 	31	  
		
	Article IX TERMINATION	  	 	31	  
				
		 	Section 9.01	 	Termination Date	  	 	31	  
				
		 	Section 9.02	 	Effect of Termination	  	 	32	  

  
 - ii -

 CONFIDENTIAL TREATMENT 
  

									
	Article X MISCELLANEOUS	  	 	32	  
				
		 	Section 10.01	  	Specific Performance	  	 	32	  
				
		 	Section 10.02	  	Notices	  	 	32	  
				
		 	Section 10.03	  	Successors and Assigns	  	 	33	  
				
		 	Section 10.04	  	Indemnification	  	 	34	  
				
		 	Section 10.05	  	Nature of Relationship	  	 	35	  
				
		 	Section 10.06	  	Tax	  	 	35	  
				
		 	Section 10.07	  	Entire Agreement	  	 	37	  
				
		 	Section 10.08	  	Amendments; No Waivers	  	 	37	  
				
		 	Section 10.09	  	Interpretation	  	 	38	  
				
		 	Section 10.10	  	Headings and Captions	  	 	38	  
				
		 	Section 10.11	  	Counterparts; Effectiveness	  	 	38	  
				
		 	Section 10.12	  	Severability	  	 	38	  
				
		 	Section 10.13	  	Expenses	  	 	38	  
				
		 	Section 10.14	  	Governing Law; Jurisdiction	  	 	38	  
				
		 	Section 10.15	  	Force Majeure	  	 	39	  
				
		 	Section 10.16	  	Waiver of Jury Trial	  	 	39	  

  
 - iii -

 CONFIDENTIAL TREATMENT 
  

 EXHIBITS AND SCHEDULES 

 

					
	 EXHIBITS
  
	  		    	
	 Exhibit A
  
	  	-	    	Form of Warrant
	 SCHEDULES
  
	  		    	
	Schedule 1	  	-	    	List of Human Class A Orphan GPCRs
	Schedule 1.01	  	-	    	Selected Definitions
	Schedule 3	  	-	    	Disclosure Schedule
	Schedule 7.01	  	-	    	Collateral

  
 - iv -

 CONFIDENTIAL TREATMENT 
  

 PLATFORM DEVELOPMENT FUNDING AGREEMENT 

This PLATFORM DEVELOPMENT FUNDING AGREEMENT (as amended, supplemented or otherwise modified from time to time, this
“Agreement”) is made and entered into as of October 21, 2010 by and among Omeros Corporation, a Washington corporation (“Omeros”), Vulcan Inc., a Washington corporation (together with its permitted successors
and assigns, “Vulcan Parent”), and Cougar Investment Holdings LLC, a Washington limited liability company and Affiliate of Vulcan (“Vulcan Sub” and, together with Vulcan Parent, “Vulcan”).

 WHEREAS, Vulcan wishes to provide funds, through Vulcan Sub, to Omeros to assist with Omeros’ development of the
Platform (as hereinafter defined), and in consideration thereof Omeros wishes to sell, assign, convey and transfer to Vulcan Sub the Assigned Interests (as hereinafter defined). 

NOW, THEREFORE, in consideration of the mutual covenants, agreements representations and warranties set forth herein, the parties
hereto agree as follows: 
 ARTICLE I 
 DEFINITIONS 
 Section 1.01 Definitions. 

The following terms, as used herein, shall have the following meanings (any capitalized terms used herein and not defined in this
Section 1.01 shall have the meanings given to them in the UCC): 
 “Additional
Interest” shall mean, with respect to aggregate Net Proceeds in excess of the Minimum Proceeds Amount during the Proceeds Interest Period, [†] (the “Additional Interest Percentage”) of all such Net Proceeds to the extent they are derived
from the commercial exploitation of the Platform in connection with Human Orphan GPCRs or the commercial exploitation of Products directly targeting Human Orphan GPCRs; provided that to the extent that and for so long as the Discovery Fund
has not provided funding in the amount of $5,000,000 to Omeros for the development of the Platform and Products contemplated hereby on or before the date any Additional Interest is due and payable to Vulcan hereunder, the Additional Interest
Percentage shall be adjusted by dividing such percentage by X, wherein: 
 X = Funding Amount / (25,000,000 - contribution to
date by Discovery Fund). 
 “Affiliate” shall mean any Person that controls, is controlled by, or is under
common control with another Person. For purposes of this definition, “control” shall mean (i) in the case of corporate entities, (a) direct or indirect ownership of at least fifty percent (50%) of the stock or shares
having the right to vote for the election of directors, or (b) the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such 

  
  

	†	 DESIGNATES
PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

 - 1 - 

 CONFIDENTIAL TREATMENT 
  

 
entity, whether through ownership of voting securities, by contract or otherwise, and (ii) in the case of non-corporate entities, (a) direct or indirect ownership of at least fifty
percent (50%) of the equity interest of such non-corporate entity or (b) the power to direct the management and policies of such non-corporate entities, whether through ownership of voting securities, by contract or otherwise. 

“Agreement” shall have the meaning set forth in the first paragraph hereof. 

“Applicable Percentage” shall mean, with respect to aggregate Net Proceeds during the Proceeds Interest Period, the
following: 
  

	 	(a)	 with respect to aggregate Net Proceeds of up to and including [†] 

  

	 	(b)	 with respect to aggregate Net Proceeds in excess of [†] but less than and including [†] 

  

	 	(c)	 with respect to aggregate Net Proceeds in excess of [†] but less than and including [†] 

  

	 	(d)	 with respect to aggregate Net Proceeds in excess of [†] but less than and including [†]; 

  

	 	(e)	 with respect to aggregate Net Proceeds in excess of [†] but less than and including [†] and 

  

	 	(f)	 with respect to aggregate Net Proceeds in excess of [†]; 

 provided that to the extent that and for so long as the Discovery Fund has not provided funding in the amount of $5,000,000 to Omeros for the development of the Platform and Products contemplated
hereby on or before the date any Share Payment is due and payable to Vulcan hereunder, the Net Proceed amounts and Applicable Percentages set forth in subclauses (a) through (f) above shall be adjusted such that each Net Proceeds amount is
multiplied by X and each Applicable Percentage amount is divided by X, wherein: 
 X = Funding Amount / (25,000,000 -
contribution to date by Discovery Fund). 
 “Assigned Interests” shall mean Vulcan Sub’s right to receive,
pursuant to the terms and conditions of this Agreement, amounts equal to the sum of (a) the Applicable Percentage of the Net Proceeds plus (b) the Additional Interest. 

“Assignment and Assumption Transfer” shall mean a Platform and Product Transfer that Vulcan shall have elected, pursuant
to Section 5.12, to treat as an Assignment and Assumption Transfer. 

  
  

	†	 DESIGNATES
PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

 - 2 - 

 CONFIDENTIAL TREATMENT 
  

 “Bankruptcy Event” shall mean the occurrence of any of the following:

 (i) Omeros shall commence any case, proceeding or other action (A) under any existing or future law of any jurisdiction,
domestic or foreign, relating to bankruptcy, insolvency, reorganization, relief of debtors or the like, seeking to have an order for relief entered with respect to it, or seeking to adjudicate it bankrupt or insolvent, or seeking reorganization,
arrangement, adjustment, winding-up, liquidation, dissolution, composition or other relief with respect to it or its respective debts, or (B) seeking appointment of a receiver, trustee, custodian or other similar official for it or for all or
any portion of its assets, or Omeros shall make a general assignment for the benefit of its respective creditors; 
 (ii) there
shall be commenced against Omeros any case, proceeding or other action of a nature referred to in clause (i) above which remains undismissed, undischarged or unbonded for a period of sixty (60) calendar days; or 

(iii) Omeros shall take any action in furtherance of, or expressly indicating its consent to, approval of, or acquiescence in, any of the
acts set forth in clause (i) or (ii) above. 
 “Business Day” shall mean any day other than a
Saturday, a Sunday, any day which is a legal holiday under the laws of the State of Washington, or any day on which banking institutions located in the State of Washington are required by law or other governmental action to close. 

“Change of Control” shall mean: 
 (i) the acquisition by any Person or group (within the meaning of Sections 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934) of beneficial ownership of any capital stock of Omeros, if after
such acquisition, such Person or group would be the “beneficial owner” (as defined in Rule 13d-3 under the Securities Exchange Act of 1934), directly or indirectly, of securities of Omeros representing more than fifty percent (50%) of
the combined voting power of Omeros’ then outstanding securities entitled to vote generally in the election of directors; or 
 (ii) the consummation, after approval by Omeros’ shareholders, of a merger or consolidation of Omeros with any other Person, other than a merger or consolidation which would result in Omeros’
voting securities outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity) more than fifty percent (50%) of the combined voting power of
Omeros’ voting securities or such surviving entity’s voting securities outstanding immediately after such merger or consolidation; or 
 (iii) the consummation, after approval by Omeros’ shareholders, of a sale of all or substantially all of the assets of Omeros to any other Person, other than a sale wherein the holders of
Omeros’ voting securities outstanding immediately prior thereto represent (either by remaining outstanding or by being converted into voting securities of the purchasing entity) more than fifty percent (50%) of the combined voting power of
the voting securities of such purchasing entity outstanding immediately after such sale of all or substantially all of the assets of Omeros. 

  
 - 3 -

 CONFIDENTIAL TREATMENT 
  

 “Closing” shall have the meaning set forth in Section 6.01.

 “Closing Date” shall mean the date of this Agreement. 

“Collateral” shall have the meaning set forth in Section 7.01. 

“Commercially Reasonable Efforts” shall mean [†] 

“Commission” shall mean the U.S. Securities and Exchange Commission or any successor entity. 

“Commission Documents” shall mean (1) all reports, schedules, registrations, forms, statements, information and
other documents filed with or furnished to the Commission by Omeros pursuant to the reporting requirements of the Exchange Act, including all material filed or furnished pursuant to Section 13(a), 14(a) or 15(d) of the Exchange Act, which have
been filed or furnished by Omeros since December 31, 2009; and (2) all information contained in such filings and all documents and disclosures that have been incorporated by reference therein. 

“Confidential Information” shall mean, as it relates to Omeros and its Affiliates and any Products or the Platform, the
Intellectual Property and any and all information or materials, including research and development information, know-how, inventions, trade secrets, targets (genes or proteins), technical data, knock-out and knock-in mouse strains, gene expression
profiles, behavioral and physiological assays, phenotypes, cell lines, cellular, biochemical and chemical assays, chemical structures, chemical structure-activity relationships, formulae, treatment methods, clinical trial design criteria, protocols,
case report forms (blank or including patient data), investigators’ brochures, drawings, designs, models, samples, processes, chemistry, manufacturing and controls information, regulatory information, and any type of product development,
business or marketing plans or strategies, financial information, customer lists or other customer information, any data concerning the existing business or reasonably foreseeable future business of Omeros, and such other information that Omeros
identifies to Vulcan as confidential or the nature of which or the circumstances of the disclosure of which would reasonably indicate that such information is confidential. 
 “Consideration” shall mean any and all license fees, milestone fees, royalties, cross-licenses, services and any other fees, damages and payments, in whatever form, in each case to the
extent clearly constituting consideration relating directly to the Products and/or the Platform in any agreement, award or judgment. 
 “Deemed Liquid Securities” shall have meaning set forth in Section 5.02(d). 
 “Disclosure Schedule” shall have the meaning set forth in Article III. 
 “Discovery Fund” shall mean the Life Sciences Discovery Fund Authority, a granting agency of the State of Washington. 

  
  

	†	 DESIGNATES
PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

 - 4 - 

 CONFIDENTIAL TREATMENT 
  

 “Event of Default” shall have the meaning set forth in
Section 8.01. 
 “Exchange Act” shall mean the U.S. Securities Exchange Act of 1934, as amended, and the
rules and regulations promulgated thereunder. 
 “Excluded Assets” shall have the meaning set forth in
Section 2.06. 
 “Excluded Liabilities and Obligations” shall have the meaning set forth in
Section 2.05. 
 “Fair Market Value” shall mean, with respect to any Liquid Security, the average closing
price of such security for the twenty (20) trading days prior to the date of determination, and with respect to any other security or asset, the fair market value thereof. 

“Financial Statements” shall mean the consolidated balance sheets of Omeros and its Subsidiary at December 31, 2009
and the related consolidated statements of operations and cash flows and the consolidated statements of convertible preferred stock and shareholders’ equity audited for the fiscal year ended December 31, 2009 and unaudited for the six
month period ended June 30, 2010, and the accompanying footnotes thereto. 
 “Fiscal Quarter” shall mean
each calendar quarter. 
 “Fiscal Year” shall mean the calendar year. 

“Funding Amount” shall have the meaning set forth in Section 2.04(a). 

“GAAP” shall mean generally accepted accounting principles in the United States, or, to the extent adopted by Omeros
(or, if applicable, its Affiliates), the International Financial Reporting Standards, in each case as in effect from time to time. 
 “Government Funding Sources” shall mean any foreign, federal, state or local (domestic or foreign) government, government agency or institution, government-owned corporation, government
authority, quasi-governmental organization, public research center, university or other institution established by government to advance a public purpose. 
 “Governmental Authority” shall mean any government, court, regulatory or administrative agency or commission, or other governmental authority, agency or instrumentality, whether foreign,
federal, state or local (domestic or foreign), including the United States Patent and Trademark Office, the United States Food and Drug Administration, the United States National Institutes of Health, or any other government authority in any
country. 
 “GPCR” shall mean any G protein-coupled receptor. 

“GPCR Program” shall mean all research, development and commercialization activities of Omeros or its Affiliates to the
extent relating to any Product or use of the Platform. 
 “Gross Proceeds” means the sum, from the Closing Date
to the date of calculation, of all Consideration actually received by Omeros or any of its Affiliates during the Proceeds Interest Period derived from: 

  
 - 5 -

 CONFIDENTIAL TREATMENT 
  

 (a) any license, development, commercialization, collaboration,
distribution, marketing or partnering agreement entered into before or during the Proceeds Interest Period relating directly to any Products and/or the Platform and/or 

(b) otherwise any licensing, sale, transfer, use or other commercial exploitation of any Products or the Platform,
including any royalty payments, sale proceeds, or damages or settlement payments received in any infringement or similar suits brought by Omeros for alleged infringement or misappropriation of intellectual property rights developed in connection
with any Product or the Platform, 
 (excluding in all cases: (1) the Funding Amount, (2) any Consideration received by Omeros or its
Affiliates from Government Funding Sources unless such Consideration is comprised of revenue from services of a type generally offered to Third Parties by Omeros or its Affiliates, royalty payments or sale proceeds, in each case relating directly to
any Products and/or the Platform, (3) any Consideration received by Omeros or its Affiliates that is clearly identified in the underlying agreement as designated for research and development of the Platform or any Products (which research and
development funds will be tracked using Omeros’ standard methods or policies of accounting or as may be otherwise required by the applicable agreement) and related overhead from corporate partners or from other Third Parties, (4) any
Consideration received by Omeros or its Affiliates in the form of grants, (5) bona fide investments in equity of Omeros or its Affiliates, at or less than the then-current fair market value of such equity, and (6) any Consideration
received by Omeros or its Affiliates in connection with a Change of Control or an Assignment and Assumption Transfer); provided, that: 
 (i) all Gross Proceeds which consist of Liquid Securities or Deemed Liquid Securities shall be valued in accordance with Section 5.02(d)), when computing Net Proceeds; 

(ii) all Gross Proceeds which are Illiquid Proceeds shall not be included in the calculation of Net Proceeds until there has been a
Realization of such Illiquid Proceeds, in which case such Illiquid Proceeds shall be valued at the Fair Market Value of such Realization when computing Net Proceeds; 
 (iii) in calculating Gross Proceeds, any Consideration received by Omeros or any Affiliate of Omeros from any Affiliate of Omeros (for purposes of clarity, other than any stock or any other equity
interest held by Omeros in such Affiliate or any other Affiliate of Omeros and dividends or other distributions received by right of ownership of stock or other equity interest in such Affiliate of Omeros) shall be excluded pro rata, in proportion
to Omeros’ ownership interest in such Affiliate or such Affiliate’s ownership interest in Omeros, as the case may be; 

(iv) any Consideration received by Omeros in situations where the parties are not dealing at arms-length shall be valued, for purposes of
calculating Gross Proceeds under this Agreement, at no less than the current fair market value, in substantially contemporaneous arms-length transactions, of the rights, goods and services provided by Omeros in return for such Consideration; and

  
 - 6 -

 CONFIDENTIAL TREATMENT 
  

 (v) Consideration for a sale, assignment or grant of any exclusive right or exclusive
license in, to, or under the Platform or any Product or any Intellectual Property comprising or claiming all or a portion of the Platform or any Product, other than as part of a Change of Control or an Assignment and Assumption Transfer, shall be
counted in the Gross Proceeds as the same is received by Omeros or its Affiliate. 
 For purposes of determining Gross Proceeds, Consideration
received or expenditures incurred by any Affiliate of Omeros shall be included pro rata, in proportion to Omeros’ ownership interest in such Affiliate or such Affiliate’s ownership interest in Omeros, as the case may be. 

“Human Class A Orphan GPCRs” shall mean those Human Orphan GPCRs set forth in Schedule 1; provided
that, to the extent that on or after the Closing Date any GPCR set forth on Schedule 1 shall be determined to have not been a Human Orphan GPCR as of the Closing Date due to the efforts of any Third Party, such GPCR shall be deemed to be
excluded from the definition of Class A Human Orphan GPCR for all purposes of this Agreement. 
 “Human Orphan
GPCR” shall mean any human GPCR for which one or more functionally active ligand(s) have not, prior to their first identification through use of the Platform, been identified through use of technologies other than the Platform, it being
understood that such identification of one or more functionally active ligand(s) constitutes the “de-orphanization” of such GPCR. 
 “Illiquid Proceeds” shall mean any Gross Proceeds that are in a form other than cash, cash equivalents or Liquid Securities. 

“Indebtedness” shall mean (a) any liabilities for borrowed money or amounts owed in excess of
[†] (other than trade accounts payable incurred in
the ordinary course of business), (b) all guaranties, endorsements, indemnities and other contingent obligations in respect of Indebtedness of others in excess of [†], whether or not the same are or should be reflected in the Company’s balance sheet (or the notes thereto),
except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business; and (c) the present value of any lease payments in excess of [†] due under leases required to be capitalized in accordance with
GAAP. 
 “Intellectual Property” shall mean all proprietary information; trade secrets; know-how; confidential
information; inventions (whether patentable or unpatentable and whether or not reduced to practice or claimed in a pending patent application) and improvements thereto; Patents; registered or unregistered trademarks, trade names, service marks,
including all goodwill associated therewith; registered and unregistered copyrights and all applications thereof; in each case that are owned or controlled by Omeros. 

“Knowledge” shall mean the actual knowledge of [†] 

  
  

	†	 DESIGNATES
PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

 - 7 - 

 CONFIDENTIAL TREATMENT 
  

 “Liens” shall mean all liens, encumbrances, security interests,
mortgages or charges of any kind. 
 “Liquid Securities” shall mean Third Party securities,
not subject to any contractual or legal limitation on the sale thereof, with an average daily trading volume for the
[†] prior to the delivery of such securities to
Vulcan of at [†] the number of such Liquid Securities
to be allocated to Vulcan in accordance with Section 2.02(c). 
 “Loan Agreement” shall mean the Loan and
Security Agreement dated as of October 21, 2010 between Oxford and Omeros. 
 “Losses” shall mean
collectively, any and all claims, damages, losses, judgments, liabilities, costs and expenses (including reasonable expenses of investigation and reasonable attorneys’ fees and expenses in connection with any action, suit or proceeding).

 “Material Adverse Effect” shall mean [†] 

“Material Contract” shall mean the Option Agreement and, for purposes of Sections 3.08 and 3.10 only, the Loan
Agreement, and any contract, agreement or other arrangement (other than the Transaction Documents) that could reasonably be expected to result in Gross Proceeds (i) to which either Omeros or any of its Subsidiaries is a party or by which any of
Omeros’ or its Subsidiaries’ respective assets or properties are bound or committed, (ii) which is directly related to any Products or the Platform, and (iii) as to which breach, nonperformance or failure to renew would
reasonably be expected to have a Material Adverse Effect. 
 “Minimum Proceeds Amount”
shall mean [†] provided that to the extent
that and for so long as the Discovery Fund has not provided funding in the amount of $5,000,000 to Omeros for the development of the Platform and Products contemplated hereby on or before the date any Additional Interest is due and payable
hereunder, the Minimum Proceeds Amount shall be adjusted such that the Minimum Proceeds Amount is multiplied by X, wherein: 

                X = Funding Amount / (25,000,000 -
contribution to date by Discovery Fund). 
 “Net Proceeds” shall mean Gross Proceeds, less the sum, from the
Closing Date to the date of calculation, of all expenses and expenditures, in each case determined in accordance with GAAP, incurred by Omeros or its Affiliates on or after the Closing Date in excess of the Funding Amount and any amounts provided by
the Discovery Fund for the development of the Platform and Products contemplated hereby, in connection with, and to the extent attributable to the conduct of its GPCR Program, including research and development expenses and related overhead, and
milestone, royalty and similar payments to Third Parties with respect to the practicing or exploiting of the Platform or any Products, legal expenses (including legal expenses associated with applying, prosecuting, maintaining and enforcing
Intellectual Property), cost of goods sold and Product Sales Deductions (with respect to Product sold by Omeros and its Affiliates), and amounts paid to acquire relevant technologies (including payments pursuant to 

  
  

	†	 DESIGNATES
PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

 - 8 - 

 CONFIDENTIAL TREATMENT 
  

 
the Option Agreement for the acquisition of the Platform) and expenditures for the purchase of equipment and other tangible assets for the GPCR Program; 

except, in each case, not including expenses or expenditures to the extent that such expenses or expenditures are funded with
(1) any Consideration received by Omeros or its Affiliates from Government Funding Sources unless such Consideration is comprised of revenue from services of a type generally offered to Third Parties by Omeros or its Affiliates, royalty
payments or sale proceeds, in each case relating directly to any Products and/or the Platform, (2) any Consideration received by Omeros or its Affiliates that is clearly identified in the underlying agreement as designated for research and
development of the Platform or any Products (which research and development funds will be tracked using Omeros’ standard methods or policies of accounting or as may be otherwise required by the applicable agreement) and related overhead from
corporate partners or from other Third Parties and (3) any Consideration received by Omeros or its Affiliates in the form of grants, that is excluded from Gross Proceeds; provided that, while as to any particular date of calculation, the
Net Proceeds may have a negative value, such negative values will be carried forward to the next calculation period, and only positive Net Proceeds will be counted in determining the Share Payments; and provided, further, [†] For purposes of determining Net Proceeds, Consideration
received or expenditures incurred by any Affiliate of Omeros shall be included pro rata, in proportion to Omeros’ ownership interest in such Affiliate or such Affiliate’s ownership interest in Omeros, as the case may be. 

“Obligations” shall mean any and all obligations of Omeros under this Agreement. 

“Omeros” shall have the meaning set forth in the first paragraph hereof. 

“Omeros Indemnified Party” shall have the meaning set forth in Section 10.04(b). 

“Omeros Material Adverse Effect” shall mean
[†] 

“Omeros-Washington Life Sciences Initiative” shall mean a non-profit entity to be formed after the Closing by Omeros and
the Discovery Fund with a currently proposed mission of advancing the life sciences, generating economic benefits and funding scientific research in the State of Washington. 
 “Option Agreement” shall mean the Exclusive Technology Option Agreement effective as of September 4, 2009, by and among Omeros, Patobios Limited, Susan George, Brian O’Dowd and
U.S. Bank National Association as escrow agent, as amended. 
 “Oxford” means Oxford Finance Corporation.

 “Patents” shall mean (a) all national, regional and international patents and patent applications,
including provisional patent applications; (b) all patent applications filed either from a patent or patent application described in clause (a) or from an application claiming priority to a patent or patent application described in clause
(a), including divisionals, 

  
  

	†	 DESIGNATES
PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

 - 9 - 

 CONFIDENTIAL TREATMENT 
  

 
continuations, continuations-in-part, provisionals, converted provisionals, and continued prosecution applications; (c) any and all patents that have issued or in the future issue from the
foregoing patent applications (clauses (a) and (b)), including utility models, petty patents and design patents and certificates of invention; (d) any and all extensions or restorations by existing or future extension or restoration
mechanisms, including revalidations, reissues, re-examinations and extensions (including any supplementary protection certificates and the like) of the foregoing patents or patents applications (clauses (a), (b) and (c)); and (e) any
similar rights, including so-called pipeline protection, or any importation, revalidation, confirmation or introduction patent or registration patent or patent of addition as to any such foregoing patent applications and patents. 

“Permitted Liens” shall have the meaning set forth on Schedule 1.01. 

“Person” shall mean an individual, corporation, partnership, limited liability company, association, trust or other
entity or organization, but not including a government or political subdivision or any agency or instrumentality of such government or political subdivision. 
 “Platform” shall mean all of the tangible and intangible assets purchased by Omeros pursuant to the Option Agreement and any and all improvements thereto made or acquired by or for Omeros
and its Affiliates (whether before or after such purchase), together with all Intellectual Property protecting such assets or their use or application. 
 “Platform and Product Transfer” shall mean a sale or assignment, whether in one or a series of related transactions, of all or substantially all of the Platform, together with all or
substantially all of the Products not (a) previously sold or (b) subject to a license in favor of a Third Party at the time of such sale or assignment. 
 “Proceeds Interest Period” shall mean the period from and including the Closing Date until the earlier of (a) twenty-one years after the death of the last survivor of the
currently-in being (as of the Closing Date) descendants of Joseph P. Kennedy Sr. (father of President John F. Kennedy), and (b) the last to occur of (i) the thirty-fifth (35th) anniversary of the Closing Date and (ii) the date
that aggregate Net Proceeds are at least the Minimum Proceeds Amount, unless earlier terminated in accordance with the terms of this Agreement. 
 “Proceeds Interests” shall mean rights to the Gross Proceeds. 

“Products” shall mean any product and its derivatives that is in any way and to any extent identified, discovered,
developed, tested, certified, or manufactured through the use or application of the Platform, and any service relating to any such product, together with all Intellectual Property protecting such products and services. 

“Product Sales Deductions” shall mean the following expenses to the extent incurred with respect to a sale of Product:

 (a) returns, rebates, chargebacks and other allowances; 

(b) retroactive price reductions that are actually allowed or granted; 

  
 - 10 -

 CONFIDENTIAL TREATMENT 
  

 (c) sales commissions paid to Third Party distributors and/or selling agents, in amounts
customary to the trade; 
 (d) marketing, sales and distribution expenses; and 

(e) all sales or excise taxes, transportation and insurance, custom duties, and other governmental charges. 

“Quarterly Report” shall mean, with respect to the relevant Fiscal Quarter of Omeros, (i) a report, certified by
the Chief Financial Officer of Omeros, providing reasonable detail of the calculation of Net Proceeds for such Fiscal Quarter, including Gross Proceeds, a description of all deductions from Gross Proceeds pursuant to this Agreement, a description of
any Consideration received from Affiliates and Subsidiaries of Omeros that were characterized as Gross Proceeds in such prior period, a description of any expenses and expenditures recognized by Omeros from the operations of its Affiliates and
Subsidiaries that reduced Net Proceeds in such prior period, a description of pro rata calculation of such Consideration, expenses and expenditures (in accordance with the “Gross Proceeds” and “Net Proceeds” definitions set forth
above) and a description of all Third Party securities received by Omeros in such prior period that are Illiquid Proceeds, (ii) copies of each Material Contract entered into, amended, modified or terminated in such Fiscal Quarter,
provided, that such copies may be redacted by Omeros to delete any confidential information of the parties thereto, so long as the financial provisions thereof are not redacted and (iii) a report, certified by the Chief Financial Officer
of Omeros, providing reasonable detail of the expenditures made from the sum of the Funding Amount and amounts paid by the Discovery Fund to Omeros for the development of the Platform and Products contemplated hereby. 

“Realization” shall mean, for a given asset, any time that such asset is liquidated into, is exchanged for, is
specifically borrowed upon for (it being understood that a secured loan that includes such asset along with other non-similar assets shall not be “borrowed upon” for purposes of this definition), is converted into, becomes or pays a
dividend of, cash, cash equivalents or Liquid Securities. 
 “SEC Filing” shall mean any 10-K, 10-Q, 8-K or
other form (including all accompanying exhibits) filed by Omeros with the United States Securities and Exchange Commission. 

“Secured Amount” means, at a particular time, the sum of (a) 125% of the Funding Amount, less all Share Payments
then received by Vulcan pursuant to the terms of this Agreement, plus (b) all costs of collecting and disposing of its Collateral and costs of enforcement by Vulcan of its rights as a secured creditor under this Agreement. 

“Securities” shall mean stock, bonds, notes, debentures and other obligations, investment contracts and other
instruments, other evidences of indebtedness and other debt or equity-based investments of any type or form. 

“Securities Act” shall mean the U.S. Securities Act of 1933, as amended, and the rules and regulations promulgated
thereunder. 
 “Share Payment Date” shall have the meaning set forth in Section 2.02(b). 

  
 - 11 -

 CONFIDENTIAL TREATMENT 
  

 “Share Payments” shall mean (i) the Applicable Percentage in
respect of Net Proceeds and (ii) the Additional Interest. 
 “Subsidiary” or
“Subsidiaries” shall mean with respect to any Person (i) any corporation of which the outstanding capital stock having at least a majority of votes entitled to be cast in the election of directors under ordinary circumstances
shall at the time be owned, directly or indirectly, by such Person or (ii) any other Person of which at least a majority voting interest under ordinary circumstances is at the time, directly or indirectly, owned by such Person. 

“Term” shall mean the term of this Agreement, as provided in Section 9.01 hereof. 

“Third Party” shall mean any Person other than Omeros or Vulcan or their respective Affiliates. 

“Transaction Documents” shall mean, collectively, this Agreement and the Warrants. 

“Transfer” or “Transferred” shall mean any sale, conveyance, assignment, disposition or transfer.

 “UCC” shall mean the Uniform Commercial Code as from time to time in effect in the State of Washington;
provided, however, in the event that, by reason of mandatory provisions of law, the attachment, perfection, the effect of perfection and nonperfection or priority of the security interest in any Collateral is governed by the Uniform
Commercial Code as in effect in a jurisdiction other than the State of Washington, then the term “UCC” shall instead mean the Uniform Commercial Code as in effect in such other jurisdiction for purposes of the provisions of this Agreement
relating to such attachment, perfection, the effect of perfection and nonperfection or priority and for purposes of definitions related to such provisions. In the event the relevant UCC uses the term “Division” in place of
“Article” to designate subdivisions of such UCC, the references in this Agreement to “Article” shall instead be a reference to “Division” with respect to such subdivisions. 

“United States” shall mean the United States of America. 

“Vulcan” shall have the meaning set forth in the first paragraph hereof. 

“Vulcan Sub” shall have the meaning set forth in the first paragraph hereof. 

“Vulcan Indemnified Party” shall have the meaning set forth in Section 10.04(a). 

“Warrants” shall have the meaning set forth in Section 2.03. 

  
 - 12 -

 CONFIDENTIAL TREATMENT 
  

 ARTICLE II 

FUNDING AND TRANSFER OF ASSIGNED INTERESTS 
 Section 2.01 Funding and Transfer. 
 Upon the terms and subject
to the conditions set forth in this Agreement, Omeros agrees to sell, assign, transfer and convey to Vulcan Sub, and Vulcan Sub agrees to acquire from Omeros, free and clear of all Liens (except for Permitted Liens) and subject to the conditions set
forth in Article VI, all of Omeros’ rights and interests in and to the Assigned Interests on the Closing Date. Vulcan Sub’s ownership interest in each of the Assigned Interests so acquired shall vest immediately upon Omeros’ receipt
of payment for such Assigned Interests pursuant to Section 2.04. 
 Section 2.02 Payments in Respect of the
Assigned Interests. 
 (a) As partial consideration for the payment of the Funding Amount by Vulcan
Sub, Vulcan Sub shall be entitled to receive the Share Payments; provided that, notwithstanding anything to the contrary set forth in this Agreement, in the event that (i) the Discovery Fund has provided funding in the amount of no less
than $5,000,000 to Omeros for the development of the Platform and Products contemplated herein and (ii) the Omeros-Washington Life Sciences Initiative has been formed and is in existence, at Omeros’ election and in its sole discretion,
Omeros may cause up to [†] of any Additional Interest
portion of any Share Payment to be paid to the Omeros-Washington Life Sciences Initiative and not to Vulcan Sub. Upon receipt, Share Payments shall be credited against the outstanding balance, if any, of the Secured Amount until such time as the
secured indebtedness of Omeros is paid in full. 
 (b) Omeros shall make the applicable Share Payments to
Vulcan Sub within [†] after the end of each Fiscal
Quarter which begins or ends during the Proceeds Interest Period (each, a “Share Payment Date”), each such payment to be in an amount equal to the Share Payment calculated for such Fiscal Quarter based on the portion of Net Proceeds
received by Omeros during that Fiscal Quarter, with adjustment for any underpayment or overpayment for previous Fiscal Quarters if applicable and for any Share Payments made by a Third Party directly to Vulcan Sub as described in Section 5.11.

 (c) All payments to be made by Omeros to Vulcan Sub hereunder or under any other Transaction Document shall be made by wire
transfer of immediately available funds to the account designated by Vulcan Sub; provided, that for any Share Payments attributable to Net Proceeds which consist of Liquid Securities or Deemed Liquid Securities, Omeros shall have the option of
delivering the applicable portion, if any (based on Omeros’ good faith projection of the Share Payment that will be payable on the next succeeding Share Payment Date), of such Liquid Securities or Deemed Liquid Securities to Vulcan Sub as
satisfaction of the payment of such Share Payments as required by Section 2.02(b) (and such delivery may occur, at the option of Omeros, prior to the Share Payment Date with respect to the Fiscal Quarter in which such Liquid 

  
  

	†	 DESIGNATES
PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

 - 13 - 

 CONFIDENTIAL TREATMENT 
  

 
Securities or Deemed Liquid Securities were received by (or became Liquid Securities or Deemed Liquid Securities in possession of) Omeros, or, at Vulcan’s request, within ten
(10) Business Days after, with respect to Liquid Securities, the date Omeros delivers the notice provided for in Section 5.02(d) and, with respect to Deemed Liquid Securities, the date such securities were designated Deemed Liquid
Securities by Vulcan). To the extent that any portion of a Share Payment is made by delivery of Liquid Securities or Deemed Liquid Securities in accordance with this Section 2.02(c) prior to the applicable Share Payment Date, each of Vulcan and
Omeros agree that if as of such Share Payment Date any adjustment for underpayment or overpayment is required as a result of the projection of the Share Payment not being the same as the actual Share Payment, such adjustment shall be made by wire
transfer of immediately available funds to the other party. 
 Section 2.03 Warrants. 

As partial consideration for the payment of the Funding Amount by Vulcan, Omeros shall issue to Vulcan Sub, at the Closing, three
Warrants, each substantially in the form of Exhibit A, such warrants being exercisable until the fifth anniversary of the Closing Date, with the following details (collectively, the “Warrants”): 

(a) one Warrant for one hundred thirty-three thousand three hundred thirty-three (133,333) shares of common stock of Omeros with an
exercise price of twenty dollars ($20.00) per share; 
 (b) one Warrant for one hundred thirty-three thousand three hundred
thirty-three (133,333) shares of common stock of Omeros with an exercise price of thirty dollars ($30.00) per share; and 

(c) one Warrant for one hundred thirty-three thousand three hundred thirty-three (133,333) shares of common stock of Omeros with an
exercise price of forty dollars ($40.00) per share. 
 Section 2.04 Funding Amount. 

(a) In full consideration for the assignment by Omeros of the Assigned Interests and the issuance by Omeros of the Warrants, and subject
to the terms and conditions set forth herein, Vulcan Sub shall pay to Omeros or its designees, at the Closing, twenty million dollars ($20,000,000) (the “Funding Amount”). 

(b) The payments to be made by Vulcan Sub hereunder shall be paid by wire transfer of immediately available funds to the account
designated by Omeros. 
 Section 2.05 No Assumed Obligations. 

Notwithstanding any provision in this Agreement or any other writing to the contrary, Vulcan Sub is acquiring only the Assigned Interests
and neither Vulcan Parent nor Vulcan Sub is assuming any liability or obligation of Omeros or any of its Affiliates of whatever nature, whether presently in existence or arising or asserted hereafter, whether under any Transaction Document or
otherwise. All such liabilities and obligations shall be retained by and remain 

  
 - 14 -

 CONFIDENTIAL TREATMENT 
  

 
obligations and liabilities of Omeros or its Affiliates (the “Excluded Liabilities and Obligations”). 
 Section 2.06 Excluded Assets. 
 Notwithstanding any provision in
this Agreement or any other writing to the contrary, Omeros is not selling, conveying, assigning, or transferring to Vulcan any assets, properties or rights of Omeros, including any ownership interest in any Intellectual Property, the Platform or
the Products, other than (i) Omeros’ rights and interests in and to the Assigned Interests subject to and in accordance with the terms of this Agreement and (ii) the assignments for security purposes being made under
Section 7.01. All other assets, properties and rights of Omeros are not being sold, conveyed, assigned or transferred to Vulcan Sub hereunder (the “Excluded Assets”), whether or not they are related to any Products or the
Platform. 
 ARTICLE III 
 REPRESENTATIONS AND WARRANTIES OF OMEROS 
 Omeros hereby represents and
warrants to Vulcan as of the date hereof and except as disclosed in any Commission Document or on the Disclosure Schedule attached as Schedule 3 (the “Disclosure Schedule”), the following: 

Section 3.01 Organization. 
 Omeros is a corporation duly incorporated and validly existing under the laws of the State of Washington and has all corporate powers, licenses, authorizations, consents and approvals required to carry on
its business. 
 Section 3.02 Corporate Authorization. 

All corporate action on the part of Omeros necessary for the authorization, execution, delivery and performance of the Transaction
Documents by Omeros and the performance of Omeros’ obligations under the Transaction Documents, including the issuance and delivery of the Warrants and the reservation of the equity securities issuable upon exercise of the Warrants, has been
taken. The Transaction Documents, when executed and delivered by Omeros, shall constitute valid and binding obligations of Omeros enforceable against Omeros in accordance with their terms, subject to laws of general application relating to
bankruptcy, insolvency and the relief of debtors. The Warrants, and the securities to be issued upon exercise of the Warrants, when issued in compliance with the provisions of this Agreement and the Warrants, (i) will not violate any preemptive
rights or rights of first refusal, (ii) will be issued in compliance with all applicable federal and state securities laws, and (iii) will be free of any Liens or encumbrances, other than any Liens or encumbrances created by or imposed
upon Vulcan; provided, that the Warrants and such securities may be subject to restrictions on transfer under state and/or federal securities laws as required by such laws at the time the transfer is proposed. The securities of Omeros, when
issued in compliance with the provisions of the Warrants, will be validly issued, fully paid and nonassessable. 

  
 - 15 -

 CONFIDENTIAL TREATMENT 
  

 Section 3.03 Governmental Authorization. 

The execution and delivery by Omeros of the Transaction Documents, and the performance by Omeros of its obligations hereunder and
thereunder, does not require any notice to, action or consent by, or in respect of, or filing with, any Governmental Authority, except for the filing of UCC financing statements pursuant to this Agreement and the filing of United States Securities
and Exchange Commission Form D for the Warrants. 
 Section 3.04 Capitalization. 

As of the Closing Date, before giving effect to the transactions contemplated by the Transaction Documents, the authorized capital stock
of Omeros consists of (a) 150,000,000 shares of common stock, par value $0.01 per share, of which 21,520,036 shares are issued and outstanding and (b) 20,000,000 shares of preferred stock, par value $0.01 per share, of which no shares are
issued and outstanding. Except as set forth on Section 3.04 of the Disclosure Schedule, there are no outstanding or authorized options, warrants, purchase rights, subscription rights, conversion rights, exchange rights or other contracts or
commitments that could require Omeros to issue, sell or otherwise cause to become outstanding any of shares of its capital stock. There are no outstanding or authorized equity appreciation, phantom equity, or similar rights with respect to Omeros.

 Section 3.05 Ownership. 
 Omeros, immediately prior to the assignment of the Assigned Interests, owns, and is the sole holder of, all the Assigned Interests free and clear of all Liens other than Permitted Liens. Omeros has not
transferred, sold, or otherwise disposed of, or agreed to transfer, sell, or otherwise dispose of any portion of the Proceeds Interests other than as contemplated by this Agreement. Omeros has the full right to sell, transfer, convey and assign to
Vulcan all of Omeros’ rights and interests in and to the Assigned Interests being sold, transferred, conveyed and assigned to Vulcan pursuant to this Agreement without any requirement to obtain the consent of any Person, except such consents as
are obtained at or prior to the Closing. At the Closing, Vulcan shall acquire good and valid rights and interests of Omeros in and to the Assigned Interests being sold, transferred, conveyed and assigned to Vulcan pursuant to this Agreement, free
and clear of any and all Liens, except for Permitted Liens, subject to the terms and conditions of this Agreement. 

Section 3.06 Litigation. 
 There is no (i) action, suit, arbitration proceeding or other proceeding pending or, to the Knowledge of Omeros, threatened against Omeros or (ii) any governmental inquiry pending or, to the
Knowledge of Omeros, threatened against Omeros, in each case with respect to clauses (i) and (ii) above, which involves the Platform or Products, which questions the validity of any of the Transaction Documents or which would reasonably be
expected to have an Omeros Material Adverse Effect. 

  
 - 16 -

 CONFIDENTIAL TREATMENT 
  

 Section 3.07 Compliance with Laws. 

Omeros (a) is not in violation of, has not violated, or to the Knowledge of Omeros, is not under investigation with respect to, and
(b) has not been threatened to be charged with or been given notice of any violation of, any law, rule, ordinance or regulation of, or any judgment, order, writ, decree, permit or license entered by any Governmental Authority applicable to
Omeros, the Assigned Interests or the Proceeds Interests which would reasonably be expected to have an Omeros Material Adverse Effect. 
 Section 3.08 Conflicts. 
 Neither the execution and delivery of
any of the Transaction Documents nor the consummation of the transactions contemplated hereby and thereby will: (i) contravene, conflict with, result in a breach or violation of, constitute a default under, or accelerate the performance
provided by, in any material respects, any (A) law, rule, ordinance or regulation of any Governmental Authority, or any judgment, order, writ, decree, permit or license of any Governmental Authority, to which Omeros or any of its Subsidiaries
or any of their respective assets or properties may be subject or bound; or (B) Material Contract; (ii) contravene, conflict with, or result in a breach or violation of the articles of incorporation or by-laws (or other organizational or
constitutional documents) of Omeros or any of its Subsidiaries; or (iii) result in the creation or imposition of any Lien on the Assigned Interests, the Proceeds Interests, or any other Collateral, other than, with respect to clause
(iii) above, any Permitted Lien. 
 Section 3.09 Commission Documents, Financial Statements. 

(a) Omeros has timely filed (giving effect to permissible extensions in accordance with Rule 12b-25 under the Exchange Act) all Commission
Documents. Omeros has delivered or made available to Vulcan, via EDGAR or otherwise, true and complete copies of the Commission Documents filed with or furnished to the Commission prior to the Closing Date. No Subsidiary of Omeros is required to
file or furnish any report, schedule, registration, form, statement, information or other document with the Commission. As of its filing date, each Commission Document filed with or furnished to the Commission prior to the Closing Date complied in
all material respects with the requirements of the Securities Act or the Exchange Act, as applicable, and other federal, state and local laws, rules and regulations applicable to it, and, as of its filing date (or, if amended or superseded by a
filing prior to the Closing Date, on the date of such amended or superseded filing), such Commission Document did not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in
order to make the statements therein, in light of the circumstances under which they were made, not misleading. Omeros has delivered or made available to Vulcan, via EDGAR or otherwise, true and complete copies of all comment letters and substantive
correspondence received by Omeros from the Commission relating to the Commission Documents filed with or furnished to the Commission as of the Closing Date, together with all written responses of Omeros thereto in the form such responses were filed
via EDGAR. There are no outstanding or unresolved comments or undertakings in such comment letters received by Omeros from the Commission. The Commission has not issued any stop order or other order suspending the effectiveness of any registration
statement filed by Omeros under the Securities Act or the Exchange Act. 

  
 - 17 -

 CONFIDENTIAL TREATMENT 
  

 (b) The financial statements, together with the related notes and schedules, of Omeros
included in the Commission Documents comply as to form in all material respects with all applicable accounting requirements and the published rules and regulations of the Commission and all other applicable rules and regulations with respect
thereto. Such financial statements, together with the related notes and schedules, have been prepared in accordance with GAAP applied on a consistent basis during the periods involved (except (i) as may be otherwise indicated in such financial
statements or the notes thereto or (ii) in the case of unaudited interim statements, to the extent they may not include footnotes or may be condensed or summary statements), and fairly present in all material respects the financial condition of
Omeros and its consolidated Subsidiaries as of the dates thereof and the results of operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments). 

Section 3.10 Material Contracts. 
 Section 3.10 of the Disclosure Schedule sets forth all of the Material Contracts. Neither Omeros nor any of its Subsidiaries is in breach of or in default under any Material Contract, which
default, individually or in the aggregate, would result in a Material Adverse Effect. To the Knowledge of Omeros, no condition exists that would permit any other party thereto to terminate any Material Contract prior to its expiration. Neither
Omeros nor any of its Subsidiaries has received any notice or, to the Knowledge of Omeros, any threat, of early termination of any Material Contract. To the Knowledge of Omeros, no other party to a Material Contract is in breach of or in default
under such Material Contract. All Material Contracts are valid, binding and enforceable against Omeros and its Subsidiaries and, to the Knowledge of Omeros, against each other party thereto, subject to laws of general application relating to
bankruptcy, insolvency and the relief of debtors. True, complete and correct copies of the Material Contracts have been made available to Vulcan. 
 Section 3.11 Place of Business. 
 Omeros’ principal place
of business and chief executive office is located at 1420 Fifth Avenue, Suite 2600, Seattle, Washington. 
 Section 3.12
Broker’s Fees. 
 Omeros has not taken any action that would entitle any Person to any commission or
broker’s fee payable by Omeros or Vulcan in connection with the transactions contemplated by the Transaction Documents. 

Section 3.13 Human Class A Orphan GPCRs. 
 Schedule 1 sets forth, all human GPCRs that are known to Omeros and believed by Omeros to be Human Class A Orphan GPCRs. 

Section 3.14 No Material Adverse Effect. 
 Except as disclosed in any Commission Documents filed since December 31, 2009, or which may be deemed to have resulted from the Company’s continued losses from operations,

  
 - 18 -

 CONFIDENTIAL TREATMENT 
  

 
since December 31, 2009, the Company has not experienced or suffered any Material Adverse Effect or Omeros Material Adverse Effect, and there exists no current state of facts, condition or
event which would have a Material Adverse Effect or an Omeros Material Adverse Effect. 
 Section 3.15 No Undisclosed
Liabilities. 
 Neither the Company nor any of its Subsidiaries has any liabilities, obligations, claims or losses
(whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on a balance sheet of the Company or any Subsidiary (including the notes thereto) in conformity with GAAP
and are not disclosed in the Commission Documents, other than those incurred in the ordinary course of the Company’s or its Subsidiaries respective businesses since December 31, 2009 and which, individually or in the aggregate, do not or
would not have a Material Adverse Effect or an Omeros Material Adverse Effect. 
 Section 3.16 No Undisclosed Events
or Circumstances. 
 No event or circumstance has occurred or information exists with respect to the Company or any of
its Subsidiaries or its or their business, properties, liabilities, operations (including results thereof) or conditions (financial or otherwise), which, under applicable law, rule or regulation, requires public disclosure or announcement by the
Company at or before the Closing but which has not been so publicly announced or disclosed, except for events or circumstances which, individually or in the aggregate, do not or would not have a Material Adverse Effect or an Omeros Material Adverse
Effect. 
 Section 3.17 Indebtedness; Solvency. 

There is no existing or continuing default or event of default in respect of any Indebtedness of the Company or any of its Subsidiaries.
The Company has not taken any steps, and does not currently expect to take any steps, to seek protection pursuant to Title 11 of the United States Code or any similar federal or state bankruptcy law or law for the relief of debtors, nor does the
Company have any Knowledge that its creditors intend to initiate involuntary bankruptcy, insolvency, reorganization or liquidation proceedings or other proceedings for relief under Title 11 of the United States Code or any other federal or state
bankruptcy law or any law for the relief of debtors. The Company is generally able to pay its debts as they become due. 

Section 3.18 Intellectual Property. 
 To Omeros’ Knowledge, assuming the acquisition of the Platform pursuant to the Option Agreement, Omeros or its Subsidiaries owns or possesses sufficient legal rights to all Intellectual Property that
is necessary to the conduct of the GPCR Program as now conducted and, solely with respect to the Platform (and not with respect to any specific GPCR or Product), as presently proposed to be conducted, without any violation, infringement, or
misappropriation of the rights of others. Omeros has not received any written communications alleging that Omeros or its Affiliates have violated, infringed or misappropriated, or, by conducting their businesses, would violate, infringe or
misappropriate, any of the Intellectual Property or any privacy or publicity right of any Third Person. 

  
 - 19 -

 CONFIDENTIAL TREATMENT 
  

 Section 3.19 Investment Company Act Status. 

Omeros is not, and as a result of the consummation of the transactions contemplated by the Transaction Documents and the payment of the
Funding Amount described herein shall not be required to be registered as, an “investment company” or a company “controlled” by an “investment company,” within the meaning of the Investment Company Act of 1940, as
amended. 
 Section 3.20 Disclosure. 
 All disclosure provided to Vulcan regarding the transactions contemplated by the Transaction Documents (including, without limitation, the representations and warranties of Omeros contained in the
Transaction Documents to which it is a party (as modified by the Disclosure Schedule)) and the Platform and the Products furnished by or on behalf of Omeros or any of its Subsidiaries is true and correct and does not contain any untrue statement of
a material fact or omit to state any material fact necessary in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading. 

ARTICLE IV 

REPRESENTATIONS AND WARRANTIES OF VULCAN 
 Vulcan represents and warrants to Omeros as of the date hereof, the following: 

Section 4.01 Organization. 
 Vulcan Parent is a corporation duly formed and validly existing under the laws of the State of Washington. Vulcan Sub is a limited liability company duly formed and validly existing under the laws of the
State of Washington 
 Section 4.02 Authorization. 

Each of Vulcan Parent and Vulcan Sub has all necessary power and authority to enter into, execute and deliver the Transaction Documents
and to perform all of the obligations to be performed by it hereunder and thereunder and to consummate the transactions contemplated hereunder and thereunder. The Transaction Documents have been duly authorized, executed and delivered by Vulcan
Parent and Vulcan Sub and each Transaction Document constitutes the valid and binding obligation of Vulcan Parent and Vulcan Sub, as the case may be, enforceable against such party in accordance with its respective terms, subject to laws of general
application relating to bankruptcy, insolvency and the relief of debtors. 
 Section 4.03 Broker’s Fees.

 Neither Vulcan Parent nor Vulcan Sub has taken any action that would entitle any Person to any commission or broker’s
fee payable by Omeros in connection with the transactions contemplated by this Agreement. 

  
 - 20 -

 CONFIDENTIAL TREATMENT 
  

 Section 4.04 Conflicts. 

Neither the execution and delivery of this Agreement or any other Transaction Document nor the consummation of the transactions
contemplated hereby or thereby will: (i) contravene, conflict with, result in a breach or violation of, constitute a default under, or accelerate the performance provided by, in any material respects any provisions of: (A) any law, rule or
regulation of any Governmental Authority, or any judgment, order, writ, decree, permit or license of any Governmental Authority, to which Vulcan Parent, Vulcan Sub or any of their respective assets or properties may be subject or bound; or
(B) any contract, agreement, commitment or instrument to which Vulcan Parent or Vulcan Sub is a party or by which Vulcan Parent or Vulcan Sub or any of their respective assets or properties is bound or committed; or (ii) contravene,
conflict with, or result in a breach or violation of, any provisions of the organizational or constitutional documents of Vulcan Parent or Vulcan Sub. 
 Section 4.05 Consents. 
 The execution and delivery by Vulcan
Parent and Vulcan Sub of this Agreement and the other Transaction Documents to which each such Person is a party, and the performance by Vulcan Parent and Vulcan Sub of their respective obligations hereunder and thereunder, do not require any notice
to, action or consent by, or in respect of, or filing with, any Governmental Authority or Person. 
 Section 4.06
Accredited Investor. 
 Vulcan Sub is an accredited investor as defined in Rule 501(a) of Regulation D promulgated
under the Securities Act. 
 ARTICLE V 
 COVENANTS 
 During the Term, the following covenants shall apply:

 Section 5.01 Platform; Development. 

(a) Omeros shall within seventy-five (75) days of the Closing Date purchase the Platform free and clear of Liens other than Permitted
Liens. Omeros will deliver an Exercise Notice (as defined in the Option Agreement) to Patobios for the acquisition of the Platform within forty-eight (48) hours of the execution of this Agreement by Omeros and Vulcan; 

(b) Omeros shall, prior to the expiration of nineteen (19) months after the Closing Date: 

(i) screen using the Platform at least seventy-five percent (75%) of all Human Class A Orphan GPCRs using its standard method
of GPCR screening, utilizing, in Omeros’ reasonable judgment, a substantial portion of its applicable and appropriate compound libraries for each such GPCR, which level of effort shall, for each such GPCR screened (other than where the same is
not required, due to any easier method of compound identification for a particular 

  
 - 21 -

 CONFIDENTIAL TREATMENT 
  

 
Human Class A Orphan GPCR), be at least commensurate with the activities, resources, facilities or personnel conducted or devoted by Omeros to the screening of GPCRs within the set of five
Human Class A Orphan GPCRs screened prior to the Closing Date; and 
 (ii) commence a medicinal chemistry development
program focused on, and use Commercially Reasonable Efforts in, advancing toward compound optimization for the purpose of developing a clinical candidate with respect to at least one orphan GPCR for which compounds were identified using the
Platform; 
 provided, however, that such nineteen (19) month period shall be extended to [†] in the event that Omeros has screened (as described above) at
least [†] of all such Human Class A Orphan GPCRs
within nineteen (19) months following the Closing Date, and provided, further, however, that the covenants set forth in this Section 5.01(b) shall expire and be of no further force and effect automatically upon the date on
which Vulcan has received aggregate Share Payments of at least [†]. Within [†] after completing performance of the obligations set forth in this Section 5.01(b) (the “Screening Obligations”), Omeros shall provide Vulcan with written notice of such completion
(the “Screening Completion Notice”). Vulcan shall have [†] following its receipt of the Screening Completion Notice to identify in writing any dispute regarding the satisfaction by Omeros of the Screening Obligations (a “Dispute Notice”). If no
Dispute Notice is timely delivered by Vulcan, this Section 5.01(b) shall be deemed satisfied for any and all purposes of this Agreement. To the extent any Dispute Notice is delivered by Vulcan, Omeros shall automatically, and without any
further action by Omeros or Vulcan, be granted an additional ninety (90) Business Days (beyond the expiration of the twenty-one (21) month period described above) to perform the Screening Obligations. 

(c) Omeros shall cause no fewer than [†] to dedicate a substantial portion of their time to the compound optimization activities described in
Section 5.01(b)(ii) until Omeros has expended the Funding Amount or until such earlier time, if any, as Omeros shall reasonably decide to abandon the GPCR Program. 
 (d) Omeros shall use Commercially Reasonable Efforts to exploit the Platform in a manner consistent with the maximization of Omeros shareholder value. 

Section 5.02 Information; Access; Audits. 
 (a) In addition to the information required to be prepared and delivered to Vulcan under Section 10.06 herein, after the end of each Fiscal Quarter, Omeros shall produce and deliver to Vulcan, on or
before each Share Payment Date, a Quarterly Report for such Fiscal Quarter; provided that, unless Omeros or its Affiliates receive Gross Proceeds prior to June 30, 2011 (in which case a Quarterly Report shall be delivered in accordance
with this Section 5.02(a) with respect to the Fiscal Quarter in which such Gross Proceeds were received), no Quarterly Report shall be deliverable under this Section 5.02(a) until the Share Payment Date relating to the Fiscal Quarter
ending June 30, 2011 (which Quarterly Report shall relate to the period from the Closing Date up to and including June 30, 2011). 

  
  

	†	 DESIGNATES
PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

 - 22 - 

 CONFIDENTIAL TREATMENT 
  

 (b) Vulcan and any of Vulcan’s representatives shall have the right, upon
reasonable written request from Vulcan, from time to time, to meet with Omeros’ senior officers, at a mutually agreed upon time and place, to discuss the clinical development plans, business plans, budgets, expansion activities, financial
results and then-existing projections, if any, as they relate to the Platform, the Products, and the Net Proceeds, and to provide to Vulcan any other information reasonably requested by Vulcan related to any licensees of any part of the Platform or
any rights in any Products. 
 (c) Omeros agrees to keep until the termination of this Agreement separate
books of account and records that provide a true and accurate record of Gross Proceeds, all related costs and expenses related to the Platform or any of the Products, and all associated exclusions thereof. Once per Fiscal Year, Vulcan shall have the
right to appoint a reputable and impartial independent certified public accounting firm who is not and has not within the prior one year been otherwise engaged by Vulcan and/or its Subsidiaries, that is reasonably acceptable to Omeros (the
“Auditor”), to inspect and audit such books and records and any documents of Omeros relating to the Platform, the Products, the Gross Proceeds, the Net Proceeds, the expenditures related to the Funding Amount and amounts funded by
other parties and the calculation of the Share Payments for any prior periods that were not previously audited under this Section 5.02(c) during the immediately preceding five-year period. Upon written request from Vulcan with reasonable
notice, but no more than once per Fiscal Year, Omeros shall make the separate books and records required by this section available for inspection by the Auditor and/or Vulcan at reasonable times and during normal business hours at such place or
places where such records are customarily kept solely to verify the accuracy and methodology of the calculation of Gross Proceeds, Net Proceeds and Share Payments and Omeros’ compliance or non-compliance with its covenants under this Agreement
for any such unaudited prior periods. Vulcan agrees to hold in strict confidence and to cause the Auditor to hold in strict confidence all information concerning the Gross Proceeds and the determination of Net Proceeds and Share Payments and all
information learned in the course of any audit or inspection, except to the extent necessary for Vulcan to reveal such information in order to enforce its rights under this Agreement or if disclosure is required by law, regulation or judicial order
after Vulcan has notified Omeros of its receipt of any notice, claim or order for disclosure and given Omeros a reasonable opportunity to prevent such disclosure pursuant to such law, regulation or judicial order. The parties shall instruct the
Auditor to conclude the audit within a reasonable time, which shall not exceed [†]. Vulcan shall pay the fees and expenses of the Auditor; provided, however, if the Share Payments amount as determined by the Auditor is more than [†] greater than the Share Payments amount reported in the
Quarterly Reports being audited, taken as a whole (a “Reported Amount”), Omeros shall pay the fees and expenses of the Auditor. In the event the Auditor determines that the Share Payments for one or more Fiscal Quarters have been
either under-reported and underpaid or over-reported and overpaid by Omeros, within [†] thereafter, Omeros shall deliver to Vulcan payment in full of the amount of such underpayment or Vulcan shall deliver to Omeros payment in full of the amount of such overpayment, as applicable.

  
  

	†	 DESIGNATES
PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

 - 23 - 

 CONFIDENTIAL TREATMENT 
  

 (d) Promptly following, and in no event more than [†], receipt
by Omeros as Consideration of Liquid Securities or other Third Party securities that are publicly traded and that do not meet the criteria set forth in the definition of “Liquid Securities” herein (such other securities, “Other
Securities”), Omeros shall provide written notice to Vulcan of Omeros’ possession of such Liquid Securities or Other Securities and a detailed description of the issuer of such securities, the number of securities so received by
Omeros, the Fair Market Value ascribed by Omeros to such securities and any Known contractual or legal limitations on the transfer thereof. Within [†] following delivery of such notice to Vulcan, Vulcan may, by written notice to Omeros, deem certain Other
Securities (but solely to the extent that there is no contractual or legal limitation on Omeros’ ability to transfer such Other Securities to Vulcan) to be Liquid Securities (“Deemed Liquid Securities), in which case the Fair Market
Value of such Deemed Liquid Securities shall be the greater of (i) the Fair Market Value thereof [†] and (ii) the Fair Market Value of the securities [†]. Any Liquid Security shall be valued at its Fair Market Value, at
[†]. 

Section 5.03 Capitalization. 
 Omeros shall maintain sufficient authorized common stock for issuance upon the exercise of the Warrants. 
 Section 5.04 Compliance with Law. 
 Omeros shall comply in all
material respects with all laws relevant to the development and commercialization of the Platform and the Products. 

Section 5.05 Confidentiality; Public Announcement. 

(a) All information furnished by Omeros to Vulcan, including the Confidential Information, in connection with this Agreement and any other
Transaction Document and the transactions contemplated hereby and thereby, as well as the terms, conditions and provisions of this Agreement and any other Transaction Document, shall be kept confidential by Vulcan, and shall be used by Vulcan and
its Affiliates only in connection with this Agreement and any other Transaction Document and the transactions contemplated hereby and thereby. Notwithstanding the foregoing, (i) Vulcan may disclose such information to its partners, directors,
employees, managers, officers and Affiliates, and to its actual or potential auditors, assignees, investors, bankers, advisors, trustees and other financing parties and participants and its respective representatives and counsel; provided,
that such Persons shall be informed of the confidential nature of such information and shall be obligated to keep such information confidential in a manner consistent with the terms of this Section 5.05(a) and that Vulcan shall take, and shall
require such Persons to take, reasonable steps to prevent any unauthorized use or disclosure of any such information, and (ii) the foregoing restrictions shall not apply to information that (A) is already in the public domain at the time
the information is disclosed (other than as a result of its improper disclosure by Vulcan, its Affiliates or representatives), (B) thereafter becomes lawfully obtainable from other sources who are not under an obligation of confidentiality and
are not 

  
  

	†	 DESIGNATES
PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

 - 24 - 

 CONFIDENTIAL TREATMENT 
  

 
otherwise prohibited from disclosing such information by a contractual, legal or fiduciary obligation, or (C) is required to be disclosed in any document filed with any Governmental
Authority. 
 (b) Except as required by law or the rules and regulations of any Governmental Authority, or except with the prior
written consent of Omeros (which consent shall not be unreasonably withheld or delayed), Vulcan shall not issue any press release or make any other public disclosure with respect to the transactions contemplated by this Agreement or any other
Transaction Document, the Products or the Platform. There shall be no restrictions on the ability of Omeros to issue any press release or make any other public disclosure with respect to the transactions contemplated by this Agreement or any other
Transaction Document or otherwise; provided, however, that Omeros shall obtain the prior written consent of Vulcan to the press release announcing the transactions contemplated by this Agreement intended for dissemination promptly
following the Closing, which consent shall not be unreasonably withheld; provided, further, that except as required by law or the rules and regulations of any Governmental Authority, Omeros will not issue any press release or make any
public disclosure (other than that referenced in the immediately prior proviso) with respect to Vulcan without the consent of Vulcan. 
 Section 5.06 Further Assurance. 
 Vulcan and Omeros shall
execute and deliver such additional documents, certificates and instruments, and perform such additional acts, as may be reasonably requested and necessary or appropriate to carry out and effectuate all of the provisions of this Agreement and any
other Transaction Document and to consummate all of the transactions contemplated by this Agreement and any other Transaction Document; provided, that Omeros shall not be required to take any actions to perfect the security interest granted
in favor of Vulcan pursuant to this Agreement, other than those set forth in Article VII. 
 Section 5.07
Intellectual Property. 
 Omeros shall use commercially reasonable efforts to take, or to cause its licensees or
agents to take, all actions that Omeros considers, in its reasonable business judgment, necessary or desirable to prosecute and maintain the Patents owned or controlled by Omeros that cover or claim the Platform or its uses, or the Products or their
manufacture or uses. 
 Section 5.08 Negative Pledge. 

Omeros shall not, without the prior written consent of Vulcan, create, incur, assume or suffer to exist any Lien over the Intellectual
Property comprising the Platform, except for Permitted Liens; provided that no such consent shall be required in the event that Omeros grants to Oxford or, only after all indebtedness owing Oxford has been satisfied in full and Oxford has no
more commitment to lend to Omeros, any other secured lender (or agent therefor) in connection with indebtedness for borrowed money, any Lien over the Intellectual Property. 

  
 - 25 -

 CONFIDENTIAL TREATMENT 
  

 Section 5.09 Insurance. 

Omeros shall maintain insurance policies that are customary for a business of similar size and development stage. 

Section 5.10 Notice. 
 Omeros shall provide Vulcan with prompt written notice after becoming aware of any of the following: 
 (a) the occurrence of a Material Adverse Effect; 
 (b) in the event that, and so
long as, Omeros is not subject to the reporting obligations of the Securities Exchange Act of 1934, as amended, the occurrence of an Omeros Material Adverse Effect; 
 (c) the occurrence of an Event of Default; 
 (d) the occurrence of a Change of
Control or the sale of all or substantially all of the assets of Omeros; or 
 (e) the commencement of any litigation against
Omeros relating to the Platform, the Products or Net Proceeds. 
 Section 5.11 Third Party Agreements.

 In any agreement that Omeros shall enter into with a Third Party pursuant to which Gross Proceeds are to be paid to
Omeros, Omeros shall include a provision permitting the applicable Share Payments attributable to such agreement to be paid directly to Vulcan at Vulcan’s election, during the continuance of an Event of Default; provided, however,
that Omeros may request on a case-by-case basis that Vulcan waive this requirement, which waiver Vulcan shall not unreasonably withhold or delay; provided, further, that after such time as the security interest described in
Section 7.01 is automatically released, Omeros shall only be required to use commercially reasonable efforts to negotiate such a provision in such agreements. 
 Section 5.12 Platform and Product Transfer. 

Until the date that Vulcan has received, in the aggregate, Share Payments equal to at least three times the Funding
Amount (the “Minimum Return”), Omeros shall not make, suffer to be made, or assist to be made any Platform and Product Transfer, unless Omeros provides Vulcan with written notice of the material terms and conditions of any such
Platform and Product Transfer delivered not less than
[†] prior to the anticipated closing of such
transaction (a “Transfer Notice”), in which case Vulcan will be entitled to elect to treat the Platform and Product Transfer as an Assignment and Assumption Transfer, by providing written notice to 

  
  

	†	 DESIGNATES
PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

 - 26 - 

 CONFIDENTIAL TREATMENT 
  

 
Omeros of such election within [†] after its receipt of the Transfer Notice. If Vulcan elects to treat a Platform and Product Transfer as an Assignment and Assumption Transfer, then upon the closing of such Platform and Product Transfer,
if such closing occurs, Omeros shall be required to assign this Agreement and its obligations and rights hereunder to the transferee, and the transferee shall be required to accept such rights and assume such obligations, in connection therewith.
Any failure by Vulcan to respond within such [†]
period shall be deemed an election by Vulcan that the Platform and Product Transfer not be an Assignment and Assumption Transfer. For purposes of this Section 5.12, the Minimum Return shall be calculated taking into account the Net Proceeds
that would be payable to Omeros under the proposed Platform and Product Transfer, assuming for such purpose that the Product and Platform Transfer is not an Assignment and Assumption Transfer. 

ARTICLE VI 

THE CLOSING; CONDITIONS TO CLOSING 
 Section 6.01 Closing. 
 Subject to the closing conditions set
forth in Section 6.02 and Section 6.03, the closing of the purchase and sale of the Assigned Interests (the “Closing”) shall take place at the offices of Omeros at 1420 Fifth Avenue, Suite 2600, Seattle, Washington on the
Closing Date. 
 Section 6.02 Conditions Applicable to Vulcan. 

The obligation of Vulcan Parent and Vulcan Sub to effect the Closing shall be subject to the satisfaction of each of the following
conditions, any of which may be waived by Vulcan in its sole discretion: 
 (a) Accuracy of Representations and
Warranties. The representations and warranties of Omeros set forth in the Transaction Documents shall be true, correct and complete in all material respects as of the Closing Date. 

(b) Litigation. No action, suit, litigation, proceeding or investigation shall have been instituted, be pending or threatened
(i) challenging or seeking to make illegal, to delay or otherwise directly or indirectly to restrain or prohibit the consummation of the transactions contemplated by this Agreement, or seeking to obtain damages in connection with the
transactions contemplated by this Agreement, or (ii) seeking to restrain or prohibit Vulcan Sub’s acquisition or future receipt of the Assigned Interests. 
 (c) Officer’s Certificate. Vulcan Parent shall have received a certificate of an executive officer of Omeros pursuant to which such officer certifies that the conditions set forth in Sections
6.02(a), (b) and (e) have been satisfied in all respects. 

  
  

	†	 DESIGNATES
PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

 - 27 - 

 CONFIDENTIAL TREATMENT 
  

 (d) Corporate Documents of Omeros. Vulcan Parent shall have received on the
Closing Date, certificates, dated as of the Closing Date, of an executive officer of Omeros (the statements made in which shall be true and correct on and as of the Closing Date); (i) attaching copies, certified by such officer as true and
complete, of Omeros’ articles of incorporation or other organizational documents (together with any and all amendments thereto) certified by the appropriate Governmental Authority as being true, correct and complete copies; and
(ii) attaching copies, certified by such officer as true and complete, of resolutions of the board of directors of Omeros authorizing and approving the execution, delivery and performance by Omeros of the Transaction Documents and the
transactions contemplated herein and therein. 
 (e) Covenants. Omeros shall have complied in all material respects with
its covenants in Article V required to be performed prior to the Closing Date. 
 Section 6.03 Conditions Applicable
to Omeros. 
 The obligation of Omeros to effect the Closing shall be subject to the satisfaction of each of the
following conditions, any of which may be waived by Omeros in its sole discretion: 
 (a) Accuracy of Representations and
Warranties. The representations and warranties of Vulcan Parent and Vulcan Sub set forth in this Agreement shall be true, correct and complete in all material respects as of the Closing Date. 

(b) Litigation. No action, suit, litigation, proceeding or investigation shall have been instituted, be pending or threatened
(i) challenging or seeking to make illegal, to delay or otherwise directly or indirectly to restrain or prohibit the consummation of the transactions contemplated by this Agreement, or seeking to obtain damages in connection with the
transactions contemplated by this Agreement, or (ii) seeking to restrain or prohibit Vulcan Sub’s acquisition or future receipt of the Assigned Interests. 
 (c) Subordination Agreement. Vulcan Parent and Vulcan Sub shall have entered into all subordination agreements reasonably requested by any sources of secured financing to Omeros. 

(d) Closing Certificate. Omeros shall have received at the Closing a certificate of an authorized representative of Vulcan Parent
and Vulcan Sub certifying that the conditions set forth in Section 6.03(a) and Section 6.03(b) have been satisfied in all material respects as of the Closing Date. 
 (e) Full Payment. The amounts to be paid by Vulcan Sub directly to Omeros and/or its designees pursuant to Section 2.04(a) shall have been tendered by wire transfer of immediately available
funds to the accounts designated by Omeros. 

  
 - 28 -

 CONFIDENTIAL TREATMENT 
  

 ARTICLE VII 

COLLATERAL 
 Section 7.01 Grant of Security Interest. 
 (a) To secure the
prompt payment and performance of the Obligations in an amount equal to the Secured Amount, Omeros hereto hereby grants to Vulcan a continuing security interest in and Lien upon all personal property described on Schedule 7.01, as such terms
are defined in Article 9 of the UCC unless defined in Section 1.01 or Schedule 1.01, whether now owned or hereafter arising, wherever located, and in all proceeds (including Illiquid Proceeds) and products thereof (together, the
“Collateral”); provided, however, that such security interest shall be automatically released (and Vulcan shall promptly file the appropriate UCC termination statement(s) recording such release) upon the first to occur
of (1) the time the Obligations are paid and performed in full and (2) the time Omeros has paid to Vulcan the entire Secured Amount. 
 (b) All security interests granted to Vulcan pursuant to this Agreement shall be junior and subordinate (as a “silent” junior lien) to any security interests that may now or in the future be
granted to any sources of secured financing to Omeros (including security interests granted to providers of equipment financing, term loans, revolving lines of credit and equity lines of credit) but shall be senior to all unsecured creditors
(including for unsecured trade payables), to the extent of its perfected security interest in the Collateral, after giving effect to the claims of senior creditors to such Collateral. Vulcan shall enter into any subordination agreements that may be
reasonably requested from time to time by Third Parties to effect such subordination. 
 Section 7.02 No Assumption
of Liability. 
 The Lien on Collateral granted hereunder is given as security only and shall not subject Vulcan to, or
in any way modify, any obligation or liability of Omeros relating to any Collateral. 
 Section 7.03 Further
Assurances. 
 Omeros authorizes Vulcan to file any UCC financing statements with all appropriate jurisdictions or
agencies, and agrees to take other actions reasonably requested by Vulcan, to perfect or protect Vulcan’s interest or rights hereunder. Such financing statements shall indicate that the scope of Vulcan’s interest is limited to the
Collateral as defined in this Agreement. 
 Section 7.04 Exclusions from the Collateral. 

Notwithstanding Section 7.01 or anything else herein to the contrary, in no event shall the Lien granted hereunder attach to
(a) any Intellectual Property, (b) share capital in excess of 65% of the voting power of all classes of capital stock or other equity interests entitled to vote of any Subsidiary of Omeros organized under the laws of any jurisdiction other
than the United States, any State thereof or the District of Columbia, or (c) any rights or interests in any lease, license, contract, agreement, or asset if under the terms of any lease, license, contract, or agreement, or applicable law, the
valid grant of a Lien therein or in such assets to Vulcan is prohibited or would result in a default thereunder (other than to the extent that any such term would be 

  
 - 29 -

 CONFIDENTIAL TREATMENT 
  

 
rendered ineffective pursuant to Sections 9-406, 9-407, 9-408 or 9-409 of the uniform commercial code of any relevant jurisdiction or any other applicable law). 

Section 7.05 Release of Liens. 
 (a) Upon the Transfer of any Collateral by Omeros or its Subsidiaries to any Third Party, such Collateral shall automatically be released from the Liens created by this Agreement without delivery of any
instrument or performance of any act by any Person; provided, however, that neither a Change of Control nor a Transfer in an Assignment and Assumption Transfer shall constitute a Transfer for purposes of this Subsection 7.05(a).

 (b) Upon the expiration of the Term, all Collateral shall automatically be released from the Liens created by this Agreement
without delivery of any instrument or performance of any act by any Person. With respect to any such release, Vulcan shall, upon the request of Omeros, execute and deliver to Omeros such documents as Omeros shall reasonably request to evidence such
release. 
 (c) With respect to any release of Collateral under this Agreement, Vulcan shall, upon the request of Omeros,
execute and deliver to Omeros such documents as Omeros shall reasonably request to evidence such release. 
 ARTICLE VIII

 EVENTS OF DEFAULT 
 Section 8.01 Events of Default. 
 Each of the following events
or occurrences described in this Section 8.01 shall constitute an “Event of Default”: 

(a) Failure by Omeros to make a Share Payment as required by Section 2.02(b); provided, that before such
failure is deemed to be an Event of Default, Vulcan must first send written notice to Omeros of such failure to pay, and Omeros shall have [†] following receipt of such written notice to make the required Share Payment. 

(b) Failure of any representation or warranty made by Omeros in Article III to be true and correct as of the Closing
Date (without giving effect to any limitation as to “materiality,” “Material Adverse Affect” or “Omeros Material Adverse Affect” set forth therein), where such failure to be true and correct results in a Material
Adverse Effect; provided, that if such breach is curable, such breach shall not be deemed to be an Event of Default unless Omeros fails to cure such breach within [†] following receipt of written notice from Vulcan notifying Omeros of such breach. 

  
  

	†	 DESIGNATES
PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

 - 30 - 

 CONFIDENTIAL TREATMENT 
  

 (c) Breach by Omeros of any of its covenants in Section 5.01(a),
Section 5.01(b) or Section 5.12, whether or not such breach results in a Material Adverse Effect; 
 (d) Breach by
Omeros of any of its covenants in Article V (other than Section 5.01(a), Section 5.01(b) or Section 5.12), where such breach results in a Material Adverse Effect; provided, that if such breach is curable, such breach shall not
be deemed to be an Event of Default unless Omeros fails to cure such breach within [†] Business Days following receipt of written notice from Vulcan notifying Omeros of such breach. 

(e) The occurrence of a Bankruptcy Event. 
 (f) Omeros is in material default under any agreement related to secured indebtedness in an aggregate outstanding amount in excess of the greater of (i) [†] and (ii) [†] of Omeros’ then-current market capitalization (or, if it
is not then a public corporation, the fair market value of all of its issued and outstanding equity), such default is not cured within the applicable time period provided in such agreement, and the obligations of Omeros under such agreement are
accelerated as a result thereof. 
 (g) The board of directors and/or the shareholders of Omeros approve any resolution
authorizing the liquidation, winding up or dissolution of Omeros. 
 Section 8.02 Remedies Upon Event of Default.

 If (a) an Event of Default occurs under [†] for any reason, whether voluntary or involuntary, and be continuing, the entire balance of the Secured Amount
shall become immediately due and payable without any further action by Vulcan and (b) if an Event of Default occurs (including under [†] for any reason, whether voluntary or involuntary, and be continuing, Vulcan may exercise any of its rights under
the UCC with respect to its security interest in the Collateral pursuant to Section 7.01. 
 ARTICLE IX 

TERMINATION 
 Section 9.01 Termination Date. 
 Except as otherwise provided in
this Section 9.01 and in Section 9.02, the term of this Agreement (the “Term”) shall commence on the Closing Date and shall terminate upon expiration of the Proceeds Interest Period. If any payments are required to be made
by one of the parties hereunder after such date, this Agreement shall remain in full force and effect until any and all such payments have been made in full and (except as provided in Section 9.02) solely for that purpose. 

  
  

	†	 DESIGNATES
PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

 - 31 - 

 CONFIDENTIAL TREATMENT 
  

 Section 9.02 Effect of Termination. 

In the event of the termination of this Agreement pursuant to Section 9.01, this Agreement shall terminate and shall forthwith become
void and have no effect without any liability on the part of any party hereto or its Affiliates, directors, officers, shareholders, partners, managers or members other than the provisions of this Section 9.02 and Section 5.02,
Section 5.05, Section 10.01, Section 10.02, Section 10.03, Section 10.04 and Section 10.14 hereof, which shall survive any termination. Nothing contained in this Section 9.02 shall relieve any party from liability
for any breach of this Agreement. 
 ARTICLE X 
 MISCELLANEOUS 
 Section 10.01 Specific Performance.

 Each of the parties hereto acknowledges that the other parties will have no adequate remedy at law if it fails to perform
any of its obligations under any of the Transaction Documents. In such event, each of the parties agrees that the other parties shall have the right, in addition to any other rights it may have (whether at law or equity), to specify performance of
this Agreement. 
 Section 10.02 Notices. 

All notices, consents, waivers and communications hereunder given by any party to the other shall be in writing (including facsimile
transmission) and delivered personally, by telegraph, telecopy, telex or facsimile, or by a recognized overnight courier, in each case addressed: 
 If to Vulcan Parent or Vulcan Sub to: 
 Vulcan Inc. 

505 Fifth Avenue, Suite 900 
 Seattle, WA 98104 
 Attention: General Counsel 

Facsimile No.: (206) 342-3000 
 with a copy to: 
 Fenwick & West LLP 

1191 Second Avenue, 10th Floor 
 Seattle, WA 98101 
 Attention: William H. Bromfield 

Facsimile No.: (206) 389-4511 
 If to Omeros to: 
 Omeros Corporation 

  
 - 32 -

 CONFIDENTIAL TREATMENT 
  

 1420 Fifth Avenue, Suite 2600 

Seattle, WA 98101 

Attention: Chief Executive Officer and General Counsel 
 Facsimile No.: (206) 676-5005 
 with a copy to: 

Covington & Burling LLP 
 One Front Street 
 San Francisco, CA 94111 

Attention: James C. Snipes 
 Facsimile No.: (415) 591-6091 
 or to such other address or addresses as Vulcan or Omeros may
from time to time designate by notice as provided herein, except that notices of changes of address shall be effective only upon receipt. All such notices, consents, waivers and communications shall: (a) when telegraphed, telecopied, telexed or
facsimiled, be effective upon receipt by the transmitting party of confirmation of complete transmission, or (b) when delivered by a recognized overnight courier or in person, be effective upon receipt when hand delivered. 

Section 10.03 Successors and Assigns. 
 The provisions of this Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns. Omeros shall not be entitled to assign any of its
obligations and rights under this Agreement without the prior written consent of Vulcan; provided, that Omeros may, without restriction or the requirement of any consent by Vulcan, assign any of its rights and obligations under this Agreement
to an Affiliate; provided, further, that, subject to Section 5.12, Omeros shall be required to assign this Agreement and its obligations and rights hereunder to the transferee, and the transferee shall be required to accept such
rights and assume such obligations, without any consent of Vulcan, in connection with any assignment to an Affiliate, any assignment in connection with a Change of Control, or any Assignment and Assumption Transfer; provided, further,
that from and after the date of any assignment to an Affiliate, Change of Control, or Assignment and Assumption Transfer, the calculation of Gross Proceeds and Net Proceeds hereunder shall provide (through definitions and other provisions similar to
those in this Agreement, mutatis mutandis, applicable to the assignee and its Affiliates, along with assumed calculations of Gross Proceeds and Net Proceeds to date) that the assignee will owe directly to Vulcan all actions, performance,
covenants, and amounts that would have been owed by Omeros to Vulcan, were the assignment not to have occurred and Omeros (rather than such assignee) were to have performed any act or suffered any omission or condition to occur by such assignee
following such assignment. Vulcan may assign any of its rights or obligations under this Agreement without restriction or the requirement of any consent from Omeros; provided that Vulcan may not, without the prior written consent of Omeros
(determined in Omeros’ sole discretion), assign any of its rights or obligations under this 

  
 - 33 -

 CONFIDENTIAL TREATMENT 
  

 
Agreement to any Person engaged in the [†] (each, a “Competitor”); and provided, further, that without the prior written consent of Omeros (which consent shall
not be unreasonably withheld), Vulcan may not assign any of its rights or obligations under this Agreement to any Person that holds directly or indirectly more than [†] of the outstanding capital stock of any Competitor. For clarity, the provision of [†] will not by itself mean that a Person is engaged in [†]. 

Section 10.04 Indemnification. 
 (a) Omeros hereby indemnifies and holds Vulcan Parent, Vulcan Sub, their respective Affiliates and any of their respective partners, directors, managers, members, officers, employees and agents (each a
“Vulcan Indemnified Party”) harmless from and against any and all Losses incurred or suffered by any Vulcan Indemnified Party arising out of (i) any breach of any representation or warranty made by Omeros in any of the
Transaction Documents; (ii) any breach of or default under any covenant or agreement by Omeros pursuant to any Transaction Document; (iii) any failure by Omeros to satisfy any of the Excluded Liabilities and Obligations; or
(iv) Omeros’ conduct of the GPCR Program, use or application of the Platform, research, development, manufacture, testing, or commercialization of any Product or of any service involving the Platform or any Product, except, in each case,
and to the extent that such Losses are indemnifiable by Vulcan in accordance with Section 10.04(b). 
 (b) Vulcan hereby
indemnifies and holds Omeros, its Affiliates and any of their respective partners, directors, managers, officers, employees and agents (each, an “Omeros Indemnified Party”) harmless from and against any and all Losses incurred or
suffered by an Omeros Indemnified Party arising out of any breach of any representation or warranty or made by Vulcan in any of the Transaction Documents or any breach of or default under any covenant or agreement by Vulcan pursuant to any
Transaction Document, except and to the extent that such Losses are indemnifiable by Omeros in accordance with Section 10.04(a). 
 (c) If any claim, demand, action or proceeding (including any investigation by any Governmental Authority) shall be brought or alleged against an indemnified party in respect of which indemnity is to be
sought against an indemnifying party pursuant to the preceding paragraphs, the indemnified party shall, promptly after receipt of notice of the commencement of any such claim, demand, action or proceeding, notify the indemnifying party in writing of
the commencement of such claim, demand, action or proceeding, enclosing a copy of all papers served, if any; provided, that the omission to so notify such indemnifying party will not relieve the indemnifying party from any liability that it
may have to any indemnified party under the foregoing provisions of this Section 10.04 unless, and only to the extent that, such omission results in the forfeiture of, or has an adverse effect on the exercise or prosecution of, substantive
rights or defenses by the indemnifying party. In case any such action is brought against an indemnified party and it notifies the indemnifying party of the commencement thereof, the indemnifying party will be entitled to participate therein and, to
the extent that it may wish, jointly with any other indemnifying party similarly notified, to assume the defense thereof, with counsel reasonably satisfactory to such indemnified party, and after notice from the 

  
  

	†	 DESIGNATES
PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

 - 34 - 

 CONFIDENTIAL TREATMENT 
  

 
indemnifying party to such indemnified party of its election to assume the defense thereof, the indemnifying party will not be liable to such indemnified party under this Section 10.04 for
any legal or other expenses subsequently incurred by such indemnified party in connection with the defense thereof other than reasonable costs of investigation. In any such proceeding, an indemnified party shall have the right to retain its own
counsel, but the reasonable fees and expenses of such counsel shall be at the expense of such indemnified party unless the named parties to any such proceeding (including any impleaded parties) include both the indemnifying party and the indemnified
party and assumption of defense by the indemnifying party would be inappropriate due to actual or potential conflicts of interests between them. It is agreed that the indemnifying party shall not, in connection with any proceeding or related
proceedings in the same jurisdiction, be liable for the reasonable fees and expenses of more than one law firm (in addition to local counsel where necessary) for all such indemnified parties. The indemnifying party shall not be liable for any
settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party from and against any loss or
liability by reason of such settlement or judgment. No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement of any pending or threatened proceeding in respect of which any indemnified party is a
party and indemnity could have been sought hereunder by such indemnified party, unless such settlement includes an unconditional release of such indemnified party from all liability on claims that are the subject matter of such proceeding.

 (d) In no event shall any indemnifying party be responsible or liable for any Losses under this Section 10.04 that are
consequential, in the nature of lost profits, special or punitive or otherwise not actual damages (except to the extent same are owing pursuant to a third party claim). The amount of Losses recoverable by an indemnified party under this
Section 10.04 with respect to an indemnity claim shall be reduced by the amount of any payment received by such indemnified party (or any Affiliate thereof), with respect to the Losses to which such indemnity claim relates, from an insurance
carrier. 
 Section 10.05 Nature of Relationship. 

The relationship between Omeros and Vulcan is solely as set forth in this Agreement, and neither Vulcan nor Omeros has any fiduciary or
other special relationship with the other or any of their respective Affiliates, except as provided herein. Omeros and Vulcan intend that solely for purposes of this Agreement, the rights and obligations of each party, as they are defined in this
Agreement, create an unincorporated joint venture taxable as a partnership under Subchapter K of the Internal Revenue Code of 1986, as amended (“the Code”). 
 Section 10.06 Tax. 
 (a) Intended Tax Treatment. Both
Omeros and Vulcan shall treat the relationship created between them under this Agreement (“the Venture”) as a partnership for United States federal, state and local income tax purposes. The parties further agree not to report or
take any tax position (on a tax return or otherwise) for United States federal, state and local income tax purposes that is inconsistent with the treatment of the Venture as a partnership. To the extent that Omeros obtains additional funding for the
Platform from Discovery Fund or any other third party on terms substantially similar to the terms provided for in this Agreement (other than 

  
 - 35 -

 CONFIDENTIAL TREATMENT 
  

 
necessary differences in the Funding Amount, the number of Warrants or the Applicable Percentage), Omeros agrees that it will require Discovery Fund or any other third party to consent to the
same partnership treatment for United States federal, state and local income tax purposes for each such party’s interests in the Platform or the Products. 

(b) Capital Accounts. For purposes of complying with the rules and regulations promulgated under Subchapter K
of the Code, capital accounts will be maintained for each of the parties in the Venture. Vulcan shall have an initial capital account in the Venture equal to [†]. Omeros shall have an initial capital account that the parties hereby agree shall
equal [†]. Any additional Funding Amounts provided by
Vulcan or Omeros shall increase their respective capital accounts and the amount of the Venture’s expenses specially allocated to Vulcan pursuant to the first sentence of Section 10.06(c)(i) shall reduce Vulcan’s capital account.

 (c) Allocations of Profits and Losses. 

(i) All expenses of the Venture (other than cost recovery deductions related to assets contributed by Omeros) shall be
[†], the Net Proceeds shall be allocated between
Omeros, Vulcan and any other party participating in the Venture in accordance with each such party’s Applicable Percentage(s) of Net Proceeds for the year in which the allocation is made. If the Net Proceeds for any year are negative, the net
negative amount shall be allocated in accordance with each such party’s Applicable Percentage(s) of Net Proceeds for the year in which the allocation is made. For avoidance of doubt, the items allocated under this section shall include only
those items of income that constitute Gross Proceeds and only those items of expense that would be taken into account in the calculation of Net Proceeds. 
 (ii) Except as provided in subsection (iii) below, all items of income, gain, loss, deduction and any other tax items for each taxable year (“Tax Items”) shall be allocated for tax
purposes in accordance with the allocations of expense and Net Proceeds set forth in subsection (i) above. 
 (iii) Gain or
loss upon the sale or other disposition of any asset of the Venture contributed to the Venture or any depreciation, amortization, or other cost recovery deduction allowable with respect to the basis of any such asset shall be allocated for tax
purposes so as to take into account the difference between the adjusted tax basis and the fair market value of such asset on the date of contribution using the “traditional method” set forth in Treasury Regulation Section 1.704-3(b)
promulgated under Section 704(c) of the Code. In addition, any “reverse Section 704(c)” allocations shall also be made using the “traditional method” set forth in Treasury Regulation Section 1.704-3(b). 

(d) Tax Matters Partner. Omeros is specially authorized to act as the “Tax Matters Partner” under the Code and in any
similar capacity under state or local law, and to the extent provided in Code Sections 6221 through 6231 and similar provisions of federal, state, local, or foreign law, to represent the Venture, Vulcan and any other party to the Venture before
taxing authorities and in courts of competent jurisdiction in tax matters affecting the Venture or Vulcan 

  
  

	†	 DESIGNATES
PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

 - 36 - 

 CONFIDENTIAL TREATMENT 
  

 
in its capacity as a partner of the Venture, and to file any tax returns and execute any agreements or other documents relating to or affecting such tax matters. Notwithstanding Omeros’
right to act as the agent of the Venture in tax disputes, Omeros agrees to allow Vulcan to participate in any such dispute with its own separate counsel (at Vulcan’s expense), provided that such right of participation shall not interfere with
Omeros’ right to defend, settle, agree to or otherwise resolve any such dispute on terms that it, in its reasonable discretion, deems advisable. 
 (e) Tax Returns. Omeros shall be responsible for the preparation and filing of all tax returns on behalf of the Venture. At least [†] prior to the due date, as extended, of the Venture’s
partnership tax returns, or any tax election or tax agreement, Omeros shall provide a copy of a draft of any such tax return to Vulcan for its review and approval (which shall not be unreasonably withheld). Omeros shall also consult with Vulcan
concerning any tax proceedings relating to the Venture, and obtain Vulcan’s prior consent (which shall not be unreasonably withheld) before taking any action in its capacity as Tax Matters Partner which could materially affect Vulcan’s
items of income, deduction, loss, credit or other items derived from or related to the Venture. 
 (f)
Tax Information. A good faith estimate of all tax information reasonably required by Vulcan (including Vulcan’s share of any Code section 41 tax credit for research and experimental expenses) shall be delivered to Vulcan within [†] after the end of each fiscal year of the Venture, and a final
K-1 with all relevant information included shall be delivered to Vulcan not later than [†] months after the end of each fiscal year. 
 Section 10.07 Entire Agreement. 
 This Agreement, together with
the Exhibits and Schedules hereto (which are incorporated herein by reference) and the other Transaction Documents, constitute the entire agreement between the parties with respect to the subject matter hereof and supersede all prior agreements,
understandings and negotiations, both written and oral, between the parties with respect to the subject matter of this Agreement. No representation, inducement, promise, understanding, condition or warranty not set forth herein (or in the Exhibits,
Schedules or other Transaction Documents) has been made or relied upon by either party hereto. Neither this Agreement nor any provision hereof is intended to confer upon any Person other than the parties hereto any rights or remedies hereunder.

 Section 10.08 Amendments; No Waivers. 

(a) This Agreement or any term or provision hereof may not be amended, changed or modified except with the written consent of the parties
hereto. No waiver of any right hereunder shall be effective unless such waiver is signed in writing by the party against whom such waiver is sought to be enforced. 
 (b) No failure or delay by either party in exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof 

  
  

	†	 DESIGNATES
PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

 - 37 - 

 CONFIDENTIAL TREATMENT 
  

 
preclude any other or further exercise thereof or the exercise of any other right, power or privilege. The rights and remedies herein provided shall be cumulative and not exclusive of any rights
or remedies provided by law. 
 Section 10.09 Interpretation. 

When a reference is made in this Agreement to Articles, Sections, Schedules or Exhibits, such reference shall be to an Article, Section,
Schedule or Exhibit to this Agreement unless otherwise indicated. The words “include”, “includes” and “including” when used herein shall be deemed in each case to be followed by the words “without limitation”.
Neither party hereto shall be or be deemed to be the drafter of this Agreement for the purposes of construing this Agreement against one party or the other. 
 Section 10.10 Headings and Captions. 
 The headings and captions
in this Agreement are for convenience and reference purposes only and shall not be considered a part of or affect the construction or interpretation of any provision of this Agreement. 

Section 10.11 Counterparts; Effectiveness. 
 This Agreement may be executed in two or more counterparts, each of which shall be an original, but all of which together shall constitute one and the same instrument. This Agreement shall become
effective when each party hereto shall have received a counterpart hereof signed by the other parties hereto. Any counterpart may be executed by facsimile or pdf signature and such facsimile or pdf signature shall be deemed an original. 

Section 10.12 Severability. 
 If any provision of this Agreement is held to be invalid or unenforceable, the remaining provisions shall nevertheless be given full force and effect unless the invalid provisions are of such essential
importance to this Agreement that it is to be reasonably assumed that the parties would not have entered into this Agreement without the invalid provisions. In such event, the parties shall substitute such invalid provisions with valid ones, which
in their economic effect come so close to the invalid provisions that it can be reasonably assumed that the parties would have entered into this Agreement also with those substituted provisions. 

Section 10.13 Expenses. 
 Each party hereto will pay all of its own fees and expenses in connection with entering into and consummating the transactions contemplated by this Agreement. 

Section 10.14 Governing Law; Jurisdiction. 
 (a) This Agreement shall be governed by, and construed, interpreted and enforced in accordance with, the laws of the state of Washington, without giving effect to the principles of conflicts of law
thereof. 

  
 - 38 -

 CONFIDENTIAL TREATMENT 
  

 (b) Any legal action or proceeding with respect to this Agreement or any other
Transaction Document may be brought in any state or federal court of competent jurisdiction in the State of Washington. By execution and delivery of this Agreement, each party hereto hereby irrevocably consents to and accepts, for itself and in
respect of its property, generally and unconditionally the non-exclusive jurisdiction of such courts. Each party hereto hereby further irrevocably waives any objection, including any objection to the laying of venue or based on the grounds of
forum non conveniens, which it may now or hereafter have to the bringing of any action or proceeding in such jurisdiction in respect of any Transaction Document. 
 (c) Each party hereto hereby irrevocably consents to the service of process out of any of the courts referred to in subsection (b) above of this Section 10.14 in any such suit, action or
proceeding by the mailing of copies thereof by registered or certified mail, postage prepaid, to it at its address set forth in this Agreement. Each party hereto hereby irrevocably waives any objection to such service of process and further
irrevocably waives and agrees not to plead or claim in any suit, action or proceeding commenced hereunder or under any other Transaction Document that service of process was in any way invalid or ineffective. Nothing herein shall affect the right of
a party to serve process on the other party in any other manner permitted by law. 
 Section 10.15 Force Majeure.

 Neither party shall lose any rights hereunder or be liable to the other party for Losses on account of failure of
performance by the defaulting party if the failure is occasioned by war, act of God, terrorism or embargo, and the non-performing party has exerted commercially reasonable efforts to overcome such force majeure. 

Section 10.16 Waiver of Jury Trial. 
 Each party hereto hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any action, proceeding, claim or counterclaim arising out of or
relating to any Transaction Document or the transactions contemplated under any Transaction Document. This waiver shall apply to any subsequent amendments, renewals, supplements or modifications to any Transaction Document. 

[SIGNATURE PAGE FOLLOWS] 

  
 - 39 -

 CONFIDENTIAL TREATMENT 
  

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly
executed by their respective authorized officers as of the date first above written. 
  

	
	OMEROS CORPORATION
	
	By: /s/ Gregory A. Demopulos
	Name: Gregory A. Demopulos, M.D.
	Title: Chairman & CEO
	
	VULCAN INC.
	
	By: /s/ William McGrath
	Name: William McGrath
	Title: Executive Vice President
	
	COUGAR INVESTMENT HOLDINGS LLC
	
	By: /s/ William McGrath
	Name: William McGrath
	Title: Executive Vice President

 [Signature
Page to Platform Development Funding Agreement] 

  

 CONFIDENTIAL TREATMENT 
  

 Exhibit A 
 Form of Warrant 

 CONFIDENTIAL TREATMENT 
  

 THE SECURITIES REPRESENTED BY THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN
OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933. 
  

					
	Warrant No. [CS]-[number]	  		  	Number of Shares: 133,333
	Date of Issuance: October 21, 2010	  		  	(subject to adjustment)

OMEROS CORPORATION 
 Common Stock Purchase Warrant 
 Omeros Corporation (the
“Company”), for value received, hereby certifies that Cougar Investment Holdings LLC, or its registered assigns (the “Registered Holder”), is entitled, subject to the terms set forth below, to purchase from the
Company, at any time after the date hereof and on or before the Expiration Date (as defined in Section 6 below), up to 133,333 shares of Common Stock of the Company (“Common Stock”), at a purchase price of $[20.00/30.00/40.00]
per share. The shares purchasable upon exercise of this Warrant and the purchase price per share, as adjusted from time to time pursuant to the provisions of this Warrant, are hereinafter referred to as the “Warrant Stock” and the
“Purchase Price,” respectively. 
 1. Exercise. 

(a) Manner of Exercise. This Warrant may be exercised by the Registered Holder, in whole or in part, by surrendering this
Warrant, with the purchase form appended hereto as Exhibit A duly executed by such Registered Holder or by such Registered Holder’s duly authorized attorney, at the principal office of the Company, or at such other office or agency
as the Company may designate, accompanied by payment in full of the Purchase Price payable in respect of the number of shares of Warrant Stock purchased upon such exercise. The Purchase Price may be paid by cash, certified check or wire transfer.

 (b) Effective Time of Exercise. Each exercise of this Warrant shall be deemed to have been effected immediately
prior to the close of business on the day on which this Warrant shall have been surrendered to the Company as provided in Section 1(a) above. At such time, the person or persons in whose name or names any shares for Warrant Stock shall be
issuable upon such exercise as provided in Section 1(d) below shall be deemed to have become the holder or holders of record of the Warrant Stock. 
 (c) Net Issue Exercise. 
 (i) In lieu of exercising this Warrant in
the manner provided above in Section 1(a), the Registered Holder may elect to receive shares equal to the value of this Warrant (or the portion thereof being canceled) by surrender of this Warrant at the principal office of the

  
 - 2 -

 CONFIDENTIAL TREATMENT 
  

 
Company together with notice of such election in which event the Company shall issue to such Holder a number of shares of Warrant Stock computed using the following formula: 

 

							
		 	X =	  	Y (A - B)	  	
		 		  	A	  	

  

			
	Where	 	X = The number of shares of Warrant Stock to be issued to the Registered Holder.
		
		 	Y = The number of shares of Warrant Stock purchasable under this Warrant (at the date of such calculation).
		
		 	A = The arithmetic average of the Closing Sale Prices of the Common Stock for the five consecutive Trading Days ending on the Trading Day immediately preceding the date of the
Exercise Notice (the “Fair Market Value”).
		
		 	B = The Purchase Price (as adjusted to the date of such calculation).

 (ii) For purposes of this Section 1(c): 
 “Bloomberg” means
Bloomberg Financial Markets. 
 “Closing Sale Price” means, for any security as of any date, the last closing
trade price for such security on the Principal Market, as reported by Bloomberg, or, if the Principal Market begins to operate on an extended hours basis and does not designate the closing trade price, then the last trade price, respectively, of
such security prior to 4:00:00 p.m., New York time, as reported by Bloomberg, or, if the Principal Market is not the principal securities exchange or trading market for such security, the last closing trade price of such security on the principal
securities exchange or trading market where such security is listed or traded as reported by Bloomberg, or if the foregoing do not apply, the last closing trade price of such security in the over-the-counter market on the electronic bulletin board
for such security as reported by Bloomberg, or, if no closing trade price is reported for such security by Bloomberg, the average of the bid prices, or the ask prices, respectively, of any market makers for such security as reported in the
“pink sheets” by Pink OTC Markets Inc. If the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair market value
thereof as determined by the Board of Directors of the Company in the exercise of its good faith judgment. All such foregoing determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination or other similar
transaction during the applicable calculation period. 
 “Principal Market” means The NASDAQ Stock Market, LLC.

 “Trading Day” means any day on which the Common Stock is traded on the Principal Market, or, if the
Principal Market is not the principal trading market for the Common Stock, then on the principal securities exchange or securities market on which the Common Stock are then traded; provided that “Trading Day” shall not include any
day on which the Common Stock is scheduled to trade on such exchange or market for less than 4.5 hours or any day that the Common Stock is suspended from trading during the final hour of trading on such exchange or market (or if such exchange or
market does not designate in advance the closing 

  
 - 3 -

 CONFIDENTIAL TREATMENT 
  

 
time of trading on such exchange or market, then during the hour ending at 4:00 p.m., New York time). 
 (d) Delivery to Holder. As soon as practicable after the exercise of this Warrant in whole or in part, and in any event within 10 days thereafter, the Company at its expense will cause to be
issued in the name of, and delivered to, the Registered Holder, or as such Registered Holder (upon payment by such Registered Holder of any applicable transfer taxes) may direct: 

(i) the number of shares of Warrant Stock to which such Registered Holder shall be entitled, which shall be delivered, at the
Company’s option, either electronically by crediting the Registered Holder’s account at DTC through its Deposit/Withdrawal at Custodian (DWAC) system, or by physical certificate or certificates, and 

(ii) in case such exercise is in part only, a new warrant or warrants (dated the date hereof) of like tenor, calling in the aggregate on
the face or faces thereof for the number of shares of Warrant Stock equal (without giving effect to any adjustment therein) to the number of such shares called for on the face of this Warrant minus the number of such shares purchased and, as
applicable, surrendered, by the Registered Holder upon such exercise as provided in Section 1(a) or 1(c) above. 
 2.
Adjustments. 
 (a) Stock Splits and Dividends. If outstanding shares of the Company’s Common Stock
shall be subdivided into a greater number of shares or a dividend in Common Stock shall be paid in respect of Common Stock, the Purchase Price in effect immediately prior to such subdivision or at the record date of such dividend shall
simultaneously with the effectiveness of such subdivision or immediately after the record date of such dividend be proportionately reduced. If outstanding shares of Common Stock shall be combined into a smaller number of shares, the Purchase Price
in effect immediately prior to such combination shall, simultaneously with the effectiveness of such combination, be proportionately increased. When any adjustment is required to be made in the Purchase Price, the number of shares of Warrant Stock
purchasable upon the exercise of this Warrant shall be changed to the number determined by dividing (i) an amount equal to the number of shares issuable upon the exercise of this Warrant immediately prior to such adjustment, multiplied by the
Purchase Price in effect immediately prior to such adjustment, by (ii) the Purchase Price in effect immediately after such adjustment. 
 (b) Reclassification, Etc. In case there occurs any reclassification or change of the outstanding securities of the Company or any reorganization of the Company (or any other corporation the
stock or securities of which are at the time receivable upon the exercise of this Warrant) or any similar corporate reorganization on or after the date hereof, then and in each such case the Registered Holder, upon the exercise hereof at any
time after the consummation of such reclassification, change, or reorganization shall be entitled to receive, in lieu of the stock or other securities and property receivable upon the exercise hereof prior to such consummation, the stock or other
securities or property to which such Holder would have been entitled upon such 

  
 - 4 -

 CONFIDENTIAL TREATMENT 
  

 
consummation if such Holder had exercised this Warrant immediately prior thereto, all subject to further adjustment pursuant to the provisions of this Section 2. 

(c) Adjustment Certificate. When any adjustment is required to be made in the Warrant Stock or the Purchase Price pursuant
to this Section 2, the Company shall promptly mail to the Registered Holder a certificate setting forth (i) a brief statement of the facts requiring such adjustment, (ii) the Purchase Price after such adjustment and (iii) the
kind and amount of stock or other securities or property into which this Warrant shall be exercisable after such adjustment. 

3. Transfers. 
 (a) Unregistered Security. Each holder of this Warrant acknowledges that this Warrant and the Warrant Stock have not been registered under the Securities Act of 1933, as amended (the
“Securities Act”), and agrees not to sell, pledge, distribute, offer for sale, transfer or otherwise dispose of this Warrant or any Warrant Stock issued upon its exercise of the Warrant in the absence of (i) an effective
registration statement under the Securities Act as to this Warrant or such Warrant Stock and registration or qualification of this Warrant or such Warrant Stock under any applicable U.S. federal or state securities law then in effect, or
(ii) an opinion of counsel, satisfactory to the Company, that such registration and qualification are not required. Each certificate or other instrument for Warrant Stock issued upon the exercise of this Warrant shall bear a legend
substantially to the foregoing effect. 
 (b) Transferability. Subject to the provisions of
Section 3(a), this Warrant and all rights hereunder are transferable, in whole or in part, upon surrender of the Warrant with a properly executed assignment (in the form of Exhibit B hereto) at the principal office of the Company.

 (c) Warrant Register. The Company will maintain a register containing the names and addresses of the Registered
Holders of this Warrant. Until any transfer of this Warrant is made in the warrant register, the Company may treat the Registered Holder of this Warrant as the absolute owner hereof for all purposes; provided, however, that if this
Warrant is properly assigned in blank, the Company may (but shall not be required to) treat the bearer hereof as the absolute owner hereof for all purposes, notwithstanding any notice to the contrary. Any Registered Holder may change such Registered
Holder’s address as shown on the warrant register by written notice to the Company requesting such change. 
 4.
Representations and Warranties of the Registered Holders. Each Registered Holder hereby represents and warrants to the Company that: 
 (a) Purchase Entirely for Own Account. This Warrant is issued to the Registered Holder in reliance upon the Registered Holder’s representation to the Company, which by the Registered
Holder’s acceptance of this Agreement, the Registered Holder hereby confirms, that any Warrant Stock to be acquired by the Registered Holder upon exercise of this Warrant will be acquired for investment for the Registered Holder’s own
account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, and that the Registered Holder has no present intention of selling, granting any participation in, or

  
 - 5 -

 CONFIDENTIAL TREATMENT 
  

 
otherwise distributing the same. By accepting this Warrant, the Registered Holder further represents that the Registered Holder does not presently have any contract, undertaking, agreement or
arrangement with any person to sell, transfer or grant participations to such person or to any third person, with respect to any of the Warrant Stock. The Registered Holder has not been formed for the specific purpose of acquiring the Warrant Stock.

 (b) Disclosure of Information. The Registered Holder has had an opportunity to discuss the Company’s
business, management, financial affairs and the terms and conditions of the Warrant with the Company’s management and has had an opportunity to review the Company’s facilities. 

(c) Restricted Securities. The Registered Holder understands that the Warrant Stock has not been, and will not be,
registered under the Securities Act, by reason of a specific exemption from the registration provisions of the Securities Act which depends upon, among other things, the bona fide nature of the investment intent and the accuracy of the Registered
Holder’s representations as expressed herein. The Registered Holder understands that the shares of Warrant Stock are “restricted securities” under applicable U.S. federal and state securities laws and that, pursuant to these laws, the
Registered Holder must hold the Warrant Stock indefinitely unless such shares are registered with the Securities and Exchange Commission and qualified by state authorities, or an exemption from such registration and qualification requirements is
available. The Registered Holder acknowledges that, except as set forth herein, the Company has no obligation to the Registered Holder to register or qualify the Warrant Stock for resale. The Registered Holder further acknowledges that if an
exemption from registration or qualification is available, it may be conditioned on various requirements including, but not limited to, the time and manner of sale, the holding period for the Warrant Stock, and on requirements relating to the
Company which are outside of the Registered Holder’s control, and which the Company is under no obligation and may not be able to satisfy. 
 (d) Legends. The Registered Holder understands that the Warrant Stock and any securities issued in respect of or exchange for the Warrant Stock, may bear one or all of the following legends:

 (i) “THESE SHARES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND
NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT
SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933.” 
 (ii) Any legend required by the Blue Sky laws of
any state to the extent such laws are applicable to the shares. 
 (e) Accredited Investor. The Registered Holder
is an accredited investor as defined in Rule 501(a) of Regulation D promulgated under the Securities Act. 

  
 - 6 -

 CONFIDENTIAL TREATMENT 
  

 5. No Impairment. The Company will not, by amendment of its charter or
through reorganization, consolidation, merger, dissolution, sale of assets or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will (subject to Section 15 below) at all
times in good faith assist in the carrying out of all such terms and in the taking of all such action as may be necessary or appropriate in order to protect the rights of the holder of this Warrant against impairment. 

6. Termination. This Warrant (and the right to purchase securities upon exercise hereof) shall terminate on
October 21, 2015 (the “Expiration Date”). 
 7. Notices of Certain Transactions. In case:

 (a) the Company shall take a record of the holders of its Common Stock (or other stock or securities at the time deliverable
upon the exercise of this Warrant) for the purpose of entitling or enabling them to receive any dividend or other distribution, or to receive any right to subscribe for or purchase any shares of stock of any class or any other securities, or to
receive any other right, to subscribe for or purchase any shares of stock of any class or any other securities, or to receive any other right, or 
 (b) of any capital reorganization of the Company, any reclassification of the capital stock of the Company, any consolidation or merger of the Company, any consolidation or merger of the Company with or
into another corporation (other than a consolidation or merger in which the Company is the surviving entity), or any transfer of all or substantially all of the assets of the Company, or 

(c) of the voluntary or involuntary dissolution, liquidation or winding-up of the Company, or 

(d) of any redemption of the Common Stock, 
 then, and in each such case, the Company will mail or cause to be mailed to the Registered Holder of this Warrant a notice specifying, as the case may be, (i) the date on which a record is to be
taken for the purpose of such dividend, distribution or right, and stating the amount and character of such dividend, distribution or right, or (ii) the effective date on which such reorganization, reclassification, consolidation, merger,
transfer, dissolution, liquidation, winding-up, redemption or conversion is to take place, and the time, if any is to be fixed, as of which the holders of record of Common Stock (or such other stock or securities at the time deliverable upon such
reorganization, reclassification, consolidation, merger, transfer, dissolution, liquidation, winding-up, redemption or conversion) are to be determined. Such notice shall be mailed at least 10 days prior to the record date or effective date for the
event specified in such notice. 
 8. Reservation of Stock. The Company will at all times reserve and keep
available, solely for the issuance and delivery upon the exercise of this Warrant, such shares of Warrant Stock and other stock, securities and property, as from time to time shall be issuable upon the exercise of this Warrant. 

  
 - 7 -

 CONFIDENTIAL TREATMENT 
  

 9. Exchange of Warrants. Upon the surrender by the Registered Holder of
any Warrant or Warrants, properly endorsed, to the Company at the principal office of the Company, the Company will, subject to the provisions of Section 3 hereof, issue and deliver to or upon the order of such Holder, at the Company’s
expense, a new Warrant or Warrants of like tenor, in the name of such Registered Holder or as such Registered Holder (upon payment by such Registered Holder of any applicable transfer taxes) may direct, calling in the aggregate on the face or faces
thereof for the number of shares of Common Stock called for on the face or faces of the Warrant or Warrants so surrendered. 

10. Replacement of Warrants. Upon receipt of evidence reasonably satisfactory to the Company of the loss, theft,
destruction or mutilation of this Warrant and (in the case of loss, theft or destruction) upon delivery of an indemnity agreement (with surety if reasonably required) in an amount reasonably satisfactory to the Company, or (in the case of
mutilation) upon surrender and cancellation of this Warrant, the Company will issue, in lieu thereof, a new Warrant of like tenor. 
 11. Mailing of Notices. Any notice required or permitted pursuant to this Warrant shall be in writing and shall be deemed sufficient upon receipt, when delivered personally or sent by
courier, overnight delivery service or confirmed facsimile, or 48 hours after being deposited in the regular mail, as certified or registered mail (airmail if sent internationally), with postage prepaid, addressed (a) if to the Registered
Holder, to the address of the Registered Holder most recently furnished in writing to the Company and (b) if to the Company, to the address set forth below or subsequently modified by written notice to the Registered Holder. 

12. No Rights as Shareholder. Until the exercise of this Warrant, the Registered Holder of this Warrant shall not have or
exercise any rights by virtue hereof as a shareholder of the Company. 
 13. No Fractional Shares. No fractional
shares of Common Stock will be issued in connection with any exercise hereunder. In lieu of any fractional shares which would otherwise be issuable, the Company shall pay cash equal to the product of such fraction multiplied by the Fair Market Value
of one share of Common Stock on the date of exercise. 
 14. Amendment or Waiver. Any term of this Warrant
may be amended or waived only by an instrument in writing signed by the party against which enforcement of the amendment or waiver is sought. 
 15. Headings. The headings in this Warrant are for purposes of reference only and shall not limit or otherwise affect the meaning of any provision of this Warrant. 

16. Governing Law. This Warrant shall be governed, construed and interpreted in accordance with the laws of the State of
Washington, without giving effect to principles of conflicts of law. 
 [signature page follows] 

  
 - 9 -

 CONFIDENTIAL TREATMENT 
  

 IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer
thereunto duly authorized. 
  

			
	OMEROS CORPORATION
		
	By	 	
 

			
		
	Address:	 	1420 Fifth Avenue, Suite 2600
		 	Seattle, Washington 98101
		
	Fax Number:	 	(206) 264-7856

 CONFIDENTIAL TREATMENT 
  

 EXHIBIT A 
 PURCHASE FORM 
  

							
	To:	  	Omeros Corporation	  		  	Dated:
				
		  	 ̈  Cash Exercise	  	 ̈  Net Issue Exercise	  	

 (1) [Cash Exercise: The undersigned, pursuant to the provisions set forth in the attached Warrant
No. CS-[number], hereby irrevocably elects to purchase          shares of the Common Stock covered by such Warrant and herewith makes payment of
$            , representing the full purchase price for such shares at the price per share provided for in such Warrant.] [Net Issue Exercise: The undersigned pursuant to the
provisions set forth in the attached Warrant No. CS-[number], hereby irrevocably elects to Net Issue Exercise with respect to          shares of the Common Stock covered by such Warrant.] 

The undersigned acknowledges that it has reviewed the representations and warranties contained in Section 4 of the Warrant and by
its signature below hereby makes such representations and warranties to the Company. Capitalized terms contained herein and in such representations and warranties shall have the meanings assigned to them in the Warrant. 

 

			
	Signature:	 	  

		
	Name (print):	 	  

		
	Title (if applicable):	 	  

		
	Company (if applicable):	 	  

 CONFIDENTIAL TREATMENT 
  

 EXHIBIT B 
 ASSIGNMENT FORM 
 FOR VALUE RECEIVED,
                                         
                    hereby sells, assigns and transfers all of the rights of the undersigned under the attached Warrant with respect to the number of
shares of Common Stock covered thereby set forth below, unto: 
  

					
	 Name of Assignee
	 	 Address/Fax Number
	 	 No. of Shares

		 		 	
		 		 	
		 		 	

  

									
	Dated:	 	  
	 		  	Signature:	  	  

					
		 		 		  		  	  

					
		 		 		  	Witness:	  	  

 CONFIDENTIAL TREATMENT 
  

 Schedule 1 
 List of Human Class A Orphan GPCRs 
  

					
	[†]	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	 
	 	 	 	 	
	 	 	 
	 	 	 	 	

  
  

	†	 DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 CONFIDENTIAL TREATMENT 
  

 Schedule 1.01 

Selected Definitions 
 “Account” is any “account” as defined in the UCC with such additions to such term as may hereafter be made, and includes, without limitation, all accounts receivable and other
sums owing to Borrower. 
 “Books” are all Omeros’ books and records including ledgers, federal and state
tax returns, records regarding Omeros’ assets or liabilities, the Collateral, business operations or financial condition, and all computer programs or storage or any equipment containing such information. 

“Equipment” is all “equipment” as defined in the UCC with such additions to such term as may hereafter be
made, and includes without limitation all machinery, fixtures, goods, vehicles (including motor vehicles and trailers), and any interest in any of the foregoing. 
 “ERISA” is the Employee Retirement Income Security Act of 1974, and its regulations. 
 “General Intangibles” is all “general intangibles” as defined in the UCC in effect on the date hereof with such additions to such term as may hereafter be made, and includes
without limitation, all Intellectual Property, claims, income and other tax refunds, security and other deposits, payment intangibles, contract rights, options to purchase or sell real or personal property, rights in all litigation presently or
hereafter pending (whether in contract, tort or otherwise), insurance policies (including without limitation key man, property damage, and business interruption insurance), payments of insurance and rights to payment of any kind. 

“Inventory” is all “inventory” as defined in the UCC in effect on the date hereof with such additions to such
term as may hereafter be made, and includes without limitation all merchandise, raw materials, parts, supplies, packing and shipping materials, work in process and finished products, including without limitation such inventory as is temporarily out
of Omeros’ custody or possession or in transit and including any returned goods and any documents of title representing any of the above. 
 “Permitted Intellectual Property Licenses” are: (i) non-exclusive licenses of Intellectual Property granted to third parties in the ordinary course of business,
(ii) licenses of Intellectual Property that could not result in a legal transfer of title of the licensed property but that may be exclusive or non-exclusive with respect to territory, field(s) of use, rights to research, develop,
commercialize, manufacture, market and/or distribute, and (iii) exclusive or non-exclusive licenses, assignments or other conveyance of rights to Intellectual Property directly related to specific G protein-coupled receptor(s) and/or compounds
interacting with such G protein-coupled receptor(s). 
 “Permitted Liens” are: 

 CONFIDENTIAL TREATMENT 
  

 (a) Liens securing (i) any Indebtedness that does not exceed
[†] in principal amount existing on the Closing Date, and (ii) any Indebtedness in excess of
[†] in principal amount existing on the Closing Date
and shown on the Disclosure Schedule; 
 (b) or Liens arising under the Loan Agreement or other Loan Documents (as defined in
the Loan Agreement); 
 (c) Liens for taxes, fees, assessments or other government charges or levies, either not delinquent or
being contested in good faith and for which Omeros maintains adequate reserves on its Books, provided that no notice of any such Lien has been filed or recorded under the Internal Revenue Code of 1986, as amended, and the Treasury Regulations
adopted thereunder; 
 (d) Liens (including with respect to capital leases) (i) on property (including accessions,
additions, parts, replacements, fixtures, improvements and attachments thereto, and the proceeds thereof) acquired or held by Omeros or its Subsidiaries incurred for financing such property (including accessions, additions, parts, replacements,
fixtures, improvements and attachments thereto, and the proceeds thereof) other than Accounts, Inventory, and financed Equipment, or (ii) existing on property (and accessions, additions, parts, replacements, fixtures, improvements and
attachments thereto, and the proceeds thereof) when acquired other than Accounts, Inventory, and financed Equipment, if the Lien is confined to such property (including accessions, additions, parts, replacements, fixtures, improvements and
attachments thereto, and the proceeds thereof); 
 (e) Liens incurred in the extension, renewal or refinancing of the
indebtedness secured by Liens described in (a) through (c), but any extension, renewal or replacement Lien must be limited to the property encumbered by the existing Lien and the principal amount of the indebtedness it secures may not increase;

 (f) leases or subleases of real property granted in the ordinary course of Omeros’ business, and leases, subleases,
non-exclusive licenses or sublicenses of personal property (other than Intellectual Property) granted in the ordinary course of Omeros’ business, if the leases, subleases, licenses and sublicenses do not prohibit granting Lender a
security interest therein; 
 (g) Permitted Intellectual Property Licenses; 

(h) leases or subleases granted in the ordinary course of Omeros’ business, including in connection with Omeros’ leased
premises or leased property; 
 (i) Liens in favor of financial institutions arising in connection with Omeros’ deposit or
securities accounts held at such institutions; 

  
  

	†	 DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 - 2 - 

 CONFIDENTIAL TREATMENT 
  

 (j) Liens of carriers, warehousemen, suppliers, or other Persons that are possessory in
nature arising in the ordinary course of business and which are not delinquent or remain payable without penalty or which are being contested in good faith and by appropriate proceedings which proceedings have the effect of preventing the forfeiture
or sale of the property subject thereto; 
 (k) Liens to secure payment of workers’ compensation, employment insurance,
old-age pensions, social security and other like obligations incurred in the ordinary course of business (other than Liens imposed by ERISA); 
 (k) Liens in favor of custom and revenue authorities arising as a matter of law to secure the payment of custom duties in connection with the importation of goods; 

(l) Liens arising from attachments or judgments, orders, or decrees in circumstances not constituting an Event of Default; 

(m) Liens on insurance proceeds in favor of insurance companies granted solely to secure financed insurance premiums; and 

(n) deposits to secure the performance of bids, trade contracts (other than for borrowed money), contracts for the purchase of property,
leases, statutory obligations, surety and appeal bonds, performance bonds and other obligations of a like nature, in each case, incurred in the ordinary course of business and not representing an obligation for borrowed money. 

  
 - 3 -

 CONFIDENTIAL TREATMENT 
  

 Schedule 3 
 Disclosure Schedule 
 [†] 

    [†] 

			
	 	 
	 	 	 
	 	 
	 	 	 
	 	 
	 	 	 
	 	 
	 	 	 
	 	 
	 	 	 
	 	 
	 	 	 
	 	 
	 	 	 
	 	 
	 	 	 
	 	 
	 	 	 
	 	 
	 	 	 
	 	 
	 	 	 
	 	 
	 	 	 

    [†] 

    [†] 

  
  

	†	 DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 CONFIDENTIAL TREATMENT 
  

 Schedule 7.01 

Collateral 
 The
Collateral consists of all of Omeros’ right, title and interest in and to the following personal property (capitalized terms used herein but not defined herein shall have the meanings set forth on Schedule 1.01), to the extent it comprises all
or any portion of the Platform or Products: 
 All goods, Accounts (including health-care receivables), Equipment, Inventory, contract rights or
rights to payment of money, leases, license agreements, franchise agreements, General Intangibles, commercial tort claims, documents, instruments (including any promissory notes), chattel paper (whether tangible or electronic), fixtures, letters of
credit rights (whether or not the letter of credit is evidenced by a writing), securities, and all other investment property, supporting obligations, and financial assets, whether now owned or hereafter acquired, wherever located; and All Books
relating to the foregoing, and any and all claims, rights and interests in any of the above and all substitutions for, additions, attachments, accessories, accessions and improvements to and replacements, products, proceeds and insurance proceeds of
any or all of the foregoing. 

  
 - 2 -GRANT AWARD AGREEMENT

			
		  	Exhibit 10.45
		
	 LSDF Grant No.: 4580719

Principal Investigator: Gregory A. Demopulos, M.D.

Organization: Omeros Corporation
	  	CONFIDENTIAL TREATMENT

  

 Life Sciences Discovery Fund 

LSDF 10-05 Opportunity Grant 
 Grant Award Agreement 
 This agreement (“Agreement”), is entered into by
the Life Sciences Discovery Fund Authority, (“Grantor”), a granting agency of the state of Washington, with offices at 2324 Eastlake Avenue East, Suite 501, Seattle, WA 98102, and Omeros Corporation (“Grantee”),
having an administrative office at 1420 Fifth Avenue, Suite 2600, Seattle WA 98101. Capitalized terms used herein but not defined shall have the meanings set forth on Schedule 1. 
 Grantor is authorized by statute of the state of Washington to make grants for the fundamental government purpose of promoting life sciences research to improve health and health care, foster economic
development, and strengthen the competitiveness of the life sciences sector within Washington state; 
 Grantor is further authorized by statute
of the state of Washington to leverage public moneys with amounts received from other public and private sources in accordance with contribution agreements, to promote life sciences research; 
 Grantor is further authorized by statute of the state of Washington to enter into contribution agreements with private entities and public entities other than the state to receive moneys in consideration
of the authority’s promise to leverage those moneys with amounts received through appropriations from the legislature and contributions from other public entities and private entities, in order to use those moneys to promote life sciences
research; 
 Grantee has established a program of life sciences G protein-coupled receptor (“GPCR”) research, development and
commercialization activities under the direction of the Principal Investigator (as defined below); 
 Grantee intends to allocate space, monies,
personnel and other resources to facilitate the execution and growth of the GPCR research, development and commercialization activities and Grantor desires to assist Grantee in this effort; and 

Grantor intends to provide funding for the GPCR activities as set forth in Article 2, and to award Grantee funds not to exceed $5,000,000 to conduct
these activities; 
 NOW, THEREFORE, in consideration of the above and the mutual terms and conditions set forth below, Grantor and Grantee
agree as follows: 

  
 Page 1

			
	 LSDF Grant No.: 4580719

Principal Investigator: Gregory A. Demopulos, M.D.

Organization: Omeros Corporation
	  	CONFIDENTIAL TREATMENT

  

 ARTICLE 1. EFFECTIVE DATE AND AVAILABILITY OF GRANT MONEY 

This Agreement shall be effective on October 21, 2010 (“Effective Date”). Disbursement of funds shall be subject to Grantee
compliance with all terms and conditions set forth in this Agreement. 
 ARTICLE 2. DESCRIPTION OF GPCR PROGRAM 

2.1 The grant provided herein funds in part the GPCR Program as described in that certain proposal entitled, “Drug Discovery for Orphan G
Protein-Coupled Receptors”, electronically received by Grantor from Grantee on September 1, 2010, and having Grantor’s reference number 4580719, which is attached hereto as Exhibit F. Such proposal is not incorporated by reference
herein, and except as otherwise expressly provided in this Agreement, nothing in such proposal shall be binding on Grantee hereunder. 
 2.2
Milestones and Timeline. Grantee shall use Commercially Reasonable Efforts to achieve the milestones and timeline (“Milestones and Timeline”) set forth in Exhibit A. Material changes in the Milestones and Timeline require the
advance written approval of Grantor. In performing the activities set forth in the Milestones and Timeline, Grantee shall comply with all relevant federal, state, or local laws and regulations, and executive orders applicable to such activities.
Without limiting the preceding sentence, Grantee shall comply with all federal and state laws relating to discrimination by employers or in public accommodations, receipt and disbursement of state and federal funds, tax reporting and withholding
requirements, workers’ compensation, and wage and hour laws, in each case as they relate to Grantee’s activities to meet the Milestones and Timeline. 
 2.3 Key Personnel. The activities set forth in the Milestones and Timeline shall be directed by Gregory Alexander Demopulos, M.D. (the “Principal Investigator”), who shall select
and supervise other participants as needed. The Principal Investigator shall be responsible for administering the grant in accordance with the terms and conditions of this Agreement, submitting progress reports required hereunder to Grantor in a
timely manner, overseeing personnel matters and disbursement of grant funds and responding to any inquiries from Grantor related to progress or financial reports or to an audit of grant expenses pursuant to this Agreement. The Principal Investigator
shall sign or otherwise authorize all progress reports and requests made pursuant to this Agreement. 
 In the event that prior
to the completion of the activities described in the Milestones and Timeline the Principal Investigator changes his or her employment status with the Grantee, relocates outside of Washington, or otherwise is unable to

  
 Page 2

			
	 LSDF Grant No.: 4580719

Principal Investigator: Gregory A. Demopulos, M.D.

Organization: Omeros Corporation
	  	CONFIDENTIAL TREATMENT

  

 
fulfill the role of Principal Investigator, Grantee shall notify Grantor in writing within [†] of such an event and identify in writing an alternate Principal Investigator, reasonably
acceptable to Grantor. Failure by Grantee to have an approved Principal Investigator (other than as the result of any act or omission by Grantor) constitutes an Event of Default (as defined in Article 15), subject to the applicable Cure Period, and
is grounds for Grantor’s exercise of its rights under Article 16. 
 In the event that during the Term, Principal
Investigator or any Investigator (as defined in Article 10) involved in completing the Milestones and Timeline are debarred or become subject to debarment under the provisions of the Generic Drug Enforcement Act of 1992, 21 U.S.C. or have otherwise
been disqualified or suspended from work on the Milestones and Timeline, in each case by the U.S. Food and Drug Administration (“FDA”) or any other governmental agency or professional body with respect to the performance of
scientific or clinical investigations, Grantee shall immediately notify Grantor in writing. Debarment of the Principal Investigator or any Investigator involved in work on the Milestones and Timeline constitutes an Event of Default (as defined in
Article 15), subject to the applicable Cure Period, and is grounds for Grantor’s exercise of its rights under Article 16. 
 2.4 Control
of GPCR Program. Control of the GPCR Program shall rest with Grantee. Subject to the terms of this Agreement, Grantee may engage third party collaborators in the conduct of the GPCR Program. 

2.5 Collaborators. In the event that completion of the Milestones and Timeline involves third party collaborators of Grantee, Grantee shall be
responsible for the performance of such collaborators and for ensuring that the work performed by such collaborators is consistent with the terms and conditions of this Agreement. Grantee warrants that it shall enter into written agreement(s) with
all such collaborators in accordance with the Milestones and Timeline. Among other provisions, such agreement(s) shall allow for the allocation of the rights that the Grantee and collaborators shall have in any intellectual property developed during
the course of meeting the Milestones and Timeline and shall identify which of the parties shall be responsible for commercialization of such intellectual property. Grantee’s collaborators as of the Effective Date are listed in Exhibit B.

 2.6 Title to Equipment and Computers. Title to equipment and computers purchased with funds awarded under this Agreement shall be
vested in the Grantee. Failure to keep equipment and computers available for the GPCR Program during the Term constitutes an Event of Default (as defined in Article 15), subject to the applicable Cure Period, and is grounds for Grantor’s
exercise of its rights under Article 16. Grantee may make equipment and computers available for use in other research studies as long as such use does not unduly interfere with the work on the GPCR Program. 

  
  

	†	 DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 Page 3 

			
	 LSDF Grant No.: 4580719

Principal Investigator: Gregory A. Demopulos, M.D.

Organization: Omeros Corporation
	  	CONFIDENTIAL TREATMENT

  

 2.7 Employees. Grantee shall cause no fewer than [†] to dedicate a substantial portion of their time to the compound
optimization activities described in Milestone 2 set forth in Exhibit A until Grantee has expended the Grant Award. 
 2.8 Shareholder
Value. Grantee shall use Commercially Reasonable Efforts to exploit the Platform in a manner consistent with the maximization of Grantee’s shareholder value. 
 ARTICLE 3. FUNDING AND PAYMENT 
 3.1 Funding. Grantor shall award funding to Grantee
in the amount of $5,000,000 (the “Grant Award”). Grantee shall allocate the Grant Award toward completing the Milestones and Timeline according to the budget (“Budget”) shown in Exhibit C. The obligation of Grantor
to disburse funds to Grantee under this Article 3 is contingent upon Grantor having sufficient funds and expenditure authorization and authority under state or federal laws, regulations or guidelines to do so, as determined by Grantor. 

3.2 Pre-Award Costs. Grantor shall not reimburse Grantee for expenditures made prior to the Effective Date of this Agreement without advance
written approval of Grantor; provided that Grantor hereby agrees to reimburse Grantee for those expenditures made prior to the Effective Date that are specified on Exhibit A (the “Pre-Award Costs”). 

3.3 Allowable Costs. Costs allowable under the Grant Award are based on the Budget and shall be consistent with Grantee’s policies. Except as
set forth in Section 3.2, reimbursable expenditures shall include costs incurred by Grantee from the Effective Date until completion of the Milestones and Timeline, failure by Grantor to cure any event of default prior to the expiration of the
applicable Cure Period or Grantor’s exercise of its rights under Article 16, whichever is earliest; in no event shall allowable costs exceed the amount of the Grant Award. 

Expenditures for the following are not allowable: costs not within the Budget, costs associated with patient care beyond what are
required for completing the Milestones and Timeline, and computers not essential for completing the Milestones and Timeline. Facilities and administration support for completing the Milestones and Timeline is not allowable. 

The following direct costs for completing the Milestones and Timeline (or the LSI Milestones and Timeline, as applicable) are allowable:
costs of research tools; consulting fees where such fees contribute directly to the Milestones and Timeline; 

  
  

	†	 DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 Page 4 

			
	 LSDF Grant No.: 4580719

Principal Investigator: Gregory A. Demopulos, M.D.

Organization: Omeros Corporation
	  	CONFIDENTIAL TREATMENT

  

 
personnel costs (including wages, benefits and stipends); costs of equipment (at a unit cost above $5,000), supplies and travel; subcontracts; fees and expenses associated with the formation of
LSI; fees and expenses associated with seeking 501(c)(3) tax-exempt status for LSI; and other costs as itemized by Grantee and approved by Grantor. 
 3.4 Budget Modifications. Grantee shall seek the advance written approval from Grantor for expenditures that are not within the Budget or any changes to the Budget that directly impact the nature
or design of the Milestones and Timeline. Such requests shall be submitted in writing by Grantee’s Authorized Official (identified in Article 28). 
 3.5 Payments. Grantor shall make payments to Grantee for work on the Milestones and Timeline on a cost-reimbursement basis upon receipt of invoices (or other payment verification as set forth in
the Milestones and Timeline) submitted to and approved by Grantor, such approval not to be unreasonably withheld; provided that [†]. All payments shall be subject to Grantee’s timely progress in achieving the goals set forth in the
Milestones and Timeline, as reasonably determined by Grantor, and to Grantor’s receipt of Grantee’s semi-annual progress reports as described in Article 4. Invoices shall be submitted by Grantee using Grantor’s electronic submission
system, with a signed copy sent by mail or other means as specified in Article 28. Commencing on the Effective Date of this Agreement, invoices shall be submitted for continuous expenditure periods of not less than 30 days and not greater than 90
days, and shall be submitted no later than 60 days from the end of the invoice period. Invoices shall include expenditures within a single year of the Budget only. Invoices shall state the milestone(s) within the Milestones and Timeline against
which costs have been incurred within the invoice period, shall itemize all allowable costs according to the categories within the Budget, and shall be signed by Grantee’s Authorized Official certifying that all expenditures are directly
related to the Milestones and Timeline and the Budget. Grantor may require expenditure documentation as part of the reimbursement process, if reasonably necessary to ensure consistency with the Milestones and Timeline and the Budget. Grantor shall
pay to Grantee all allowable costs incurred until completion of the Milestones and Timeline or Grantor’s exercise of its rights under Article 16, whichever is earliest, insofar as those allowable costs do not exceed the Grant Award. All
payments of the Grant Award shall be sent to Grantee via electronic funds transfer. Grantee shall complete and send a Direct Deposit Authorization form and signed W-9 form to Grantor for payments to commence. 

3.6 Annual Financial Reports. Grantee shall summarize expenditures during each annual period within the Budget in an annual
financial report (“AFR”) submitted to Grantor. The first AFR shall be due no later than
[†] after the first anniversary of the Effective Date
of this Agreement; subsequent reports shall be due no later than [†] after each yearly anniversary thereafter until completion of the Milestones and Timeline or 

  
  

	†	 DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 Page 5 

			
	 LSDF Grant No.: 4580719

Principal Investigator: Gregory A. Demopulos, M.D.

Organization: Omeros Corporation
	  	CONFIDENTIAL TREATMENT

  

 
Grantor’s exercise of its rights under Article 16, whichever is earliest. AFRs shall include all expenditures made since the end of the previous annual reporting period. AFRs shall be signed
by Grantee’s Authorized Official certifying that all expenditures are directly related to activities within the Milestones and Timeline and the Budget. Grantee’s expenditures within the subsequent annual period within the Budget shall not
be reimbursed by Grantor until the previous year’s AFR has been submitted and approved by Grantor, such approval not to be unreasonably withheld or delayed. 
 3.7 Unexpended Funds Within an Annual Budget. Should any unexpended funds remain at the end of a year within the Budget, Grantee may request that such unexpended funds be re-allocated into
subsequent years within the Budget. Such requests shall be submitted in writing by Grantee’s Authorized Official at least [†] prior to the end of the then-current period within the Budget and shall include projected expenditures through
such period, the projected balance of funds remaining at end of such period, and shall further detail how the unexpended funds are to be re-allocated within the Budget. Authorization to re-allocate unexpended funds is subject to the sole discretion
of Grantor. The final amount of the unexpended funds shall be determined by Grantor upon Grantee’s timely submission of invoices and the applicable AFR. Revision of the Milestones and Timeline may be required, depending on the nature of the
re-allocation. 
 3.8 No-Cost Extensions. In the event that unexpended funds remain at the end of the timeline within
the Milestones and Timeline, and there are remaining milestones to be accomplished, Grantee may request an extension of the timeline to allow Grantee to accomplish such milestones. Such requests shall include an amended budget and Milestones and
Timeline and shall be submitted in writing by Grantee’s Authorized Official. The decision to grant an extension is subject to the sole discretion of the Grantor, with such extension granted in annual increments, for a maximum of two years. At
least [†] of the time within the Milestones and
Timeline shall be completed prior to Grantee requesting a no-cost extension. 
 3.9 Budget Surpluses. Should any unexpended funds remain
within the Budget after Grantee has met the Milestones and Timeline (“Budget Surplus”), as solely determined by Grantor, Grantee may request that such Budget Surplus be allocated to support new work. Such new work shall be
consistent with the nature and goals of the GPCR Program and authority to spend a Budget Surplus on such new work shall require advance written approval of Grantor. Budget Surplus allocation requests shall be submitted in writing by Grantee’s
Authorized Official prior to expiration of the timeline within the Milestones and Timeline, and shall include a detailed description of the research activities to be performed utilizing the Budget Surplus, a new set of milestones and a timeline for
their accomplishment, and shall detail how the Budget Surplus will be allocated within the Budget. The final amount of such Budget Surplus 

  
  

	†	 DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 Page 6 

			
	 LSDF Grant No.: 4580719

Principal Investigator: Gregory A. Demopulos, M.D.

Organization: Omeros Corporation
	  	CONFIDENTIAL TREATMENT

  

 
shall be determined by Grantor upon Grantee’s timely submission of invoices. Grantor reserves the right to refer Budget Surplus allocation requests for outside expert review, the cost of
which shall be deducted from the Budget Surplus. 
 3.10 Supplemental Funding. Prior to completing the Milestones and Timeline and under
certain circumstances as described below, Grantee may request funding in excess of what has been previously authorized under this Agreement (“Budget Supplement”). Grantee may request a Budget Supplement: 

3.10.A. when a disruptive event, that could not be foreseen or predicted at the Effective Date threatens completion of the Milestones and
Timeline within the Budget; or 
 3.10.B. when findings, that were not anticipated within the Proposal, result from work within
the GPCR Program and promise significant health or economic benefits to Washington state. 
 Requests for a Budget Supplement shall be submitted
in writing by Grantee’s Authorized Official within a reasonable time of the occurrence of the precipitating event. Provision of a Budget Supplement is subject to the sole discretion of Grantor and the availability of funds. Grantor reserves the
right to refer Budget Supplement requests for outside expert review. 
 3.11 Final Request(s) for Payment. Grantee
shall submit final requests for reimbursement no later than [†] after completion of the Milestones and Timeline or Grantor’s exercise of its rights under Article 16, whichever is earliest. Failure to comply with this Section 3.11 may result in
Grantor’s refusal or inability to reimburse. Grantor shall not make the final payment until the proper invoice, marked “Final,” has been approved by Grantor and a report regarding progress against the Milestones and Timeline has been
received and approved by Grantor, which approvals shall not be unreasonably withheld or delayed. 
 ARTICLE 4. RESEARCH PROGRESS REPORTS

 4.1 Submission Schedule. Grantee shall submit written research progress reports to Grantor in accordance with this Article 4
describing Grantee’s progress in completing the Milestones and Timeline. All such progress reports shall be submitted by the Principal Investigator and shall detail the activities of Grantee and Grantee’s collaborators in completing the
Milestones and Timeline during the period covered by the report; provided that in no event shall Grantee be required to disclose trade secrets, compound structures, phenotypes, targets, assay details, third-party confidential information or
details about prospective partners (including the identity thereof) in 

  
  

	†	 DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 Page 7 

			
	 LSDF Grant No.: 4580719

Principal Investigator: Gregory A. Demopulos, M.D.

Organization: Omeros Corporation
	  	CONFIDENTIAL TREATMENT

  

 
such reports. The first progress report shall be due
[†] after the Effective Date of this Agreement;
subsequent reports shall be due at [†] intervals
thereafter. Grantee shall submit to Grantor a final research progress report to Grantor no later than [†] after the completion of the Milestones and Timeline or Grantor’s exercise of its rights under Article 16, whichever is earliest. Payment of Grantee’s invoices shall be predicated on
Grantor’s receipt and approval, such approval not to be unreasonably withheld, of Grantee’s progress report for the most recent required period. 
 4.2 Submission Method and Content. Progress reports shall be submitted electronically through Grantor’s online progress report system semi-annually until the first to occur of (a) Grantee
having submitted reimbursement requests for the full amount of the Grant Award or (b) completion of the Milestones and Timeline. Thereafter, during the Term, progress reports shall be made upon Grantor’s reasonable request, through an
in-person interview with the Principal Investigator, such interview to be conducted using the report content template found in Exhibit D. Grantor reserves the right to periodically change the content of progress reports and Grantee shall make
subsequent progress reports according to the template then in use by Grantor. Progress reports shall be of sufficient detail to allow Grantor to assess progress made on the Milestones and Timeline since the prior report. In the event that a progress
report lacks such detail, Grantee shall provide Grantor with additional detail in a timely manner as reasonably requested by Grantor. Grantee shall also disclose in writing to Grantor any problems, delays or adverse conditions which may materially
affect its ability to meet the Milestones and Timeline. This disclosure shall be accompanied by a statement of the action taken or proposed and any assistance needed from Grantor to resolve the situation. Grantor shall hold all progress reports
confidential, subject to the public disclosure laws of the state of Washington (See e.g., RCW 42.56.270(14)). 
 Upon the reasonable
prior written request of Grantor, prior to completion of the Milestones and Timeline, Grantee shall arrange site visits or in-person briefings at a mutually agreed upon time and place to enable Grantor to assess the impact of its funding;
provided that in no event shall Grantee be required to disclose trade secrets, compound structures, phenotypes, targets, assay details, third-party confidential information or details about prospective partners (including the identity
thereof) in such visits or briefings. 
 4.3 Post-Award Progress Reports. After submission of the final research progress report, Grantee
shall provide Grantor with periodic oral post-award research progress reports regarding the GPCR Program according to a mutually agreeable format and schedule, through the fifth anniversary of the submission of such final report; provided
that in no event shall Grantee be required to disclose trade secrets, compound structures, phenotypes, targets, assay details, third-party confidential information or 

  
  

	†	 DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 Page 8 

			
	 LSDF Grant No.: 4580719

Principal Investigator: Gregory A. Demopulos, M.D.

Organization: Omeros Corporation
	  	CONFIDENTIAL TREATMENT

  

 
details about prospective partners (including the identity thereof) in such progress reports. 
 ARTICLE 5. ACCOUNTING AND AUDITING 
 Grantee shall record the receipt of
the grant funds and any expenditures related to completing the Milestones and Timeline in such a form as to enable Grantor to verify that the funds were expended for the stated purposes of the grant and in accordance with generally accepted
accounting principles. All pertinent records, including, but not limited to, invoices, purchase orders, packing lists, warranties, rebates and worksheets supporting allocations shall be retained in Grantee files for at least [†], or as otherwise required by state and federal law, or as
requested by Grantor, after Grantor’s final payment to Grantee under this Agreement. If there are unresolved audit questions at the end of the retention period, Grantee shall retain such records until the questions are resolved. Grantor
reserves the right at reasonable times and during normal business hours to audit such records for any prior periods that have not been previously audited subject to the terms of this Agreement during the immediately preceding [†] period, or have them audited, during the Term (as defined in
Article 14) of this Agreement or thereafter; provided that no more than one such audit shall be conducted during any calendar year. If as a result of an audit Grantor reasonably concludes that funds were spent for purposes not related to
completing the Milestones and Timeline, as set forth in the Budget and subject to this Agreement, Grantor shall be entitled to a refund of such funds, including interest on the amount refunded. Grantee shall return such funds, including interest at
the then current prime rate, to Grantor within [†] of
Grantor’s written demand. 
 ARTICLE 6. INTELLECTUAL PROPERTY 
 6.1 Policies and Management. Grantor’s grant awards are intended to support research that enhances competitiveness, improves health and health care and fosters economic development in
Washington state. Grantor and Grantee recognize that discoveries and developments having public health, scientific, business, or commercial application or value may be made in the course of performing the GPCR Program. Grantor and Grantee desire
that such discoveries and developments be administered in such a manner that they are brought into commercial use at the earliest reasonably practicable time, in a manner consistent with Commercially Reasonable Efforts and the maximization of
Grantee’s shareholder value. Grantor and Grantee recognize that this may be best accomplished through patenting, copyrighting, trademarking and/or licensing such discoveries and developments. In accepting an award from Grantor, Grantee warrants
that it has policies in place regarding ownership and management of intellectual property. Grantee further warrants that it has expertise in 

  
  

	†	 DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 Page 9 

			
	 LSDF Grant No.: 4580719

Principal Investigator: Gregory A. Demopulos, M.D.

Organization: Omeros Corporation
	  	CONFIDENTIAL TREATMENT

  

 
commercialization of intellectual property, including evaluating invention disclosures, patenting and licensing, and commercial drug development including drug discovery and lead optimization,
pre-clinical and clinical testing, and regulatory approval. 
 6.2 Ownership and Disposition. Grantor claims no ownership rights in any
Intellectual Property conceived, reduced to practice or otherwise made in the course of performing the GPCR Program. Grantee agrees to use Commercially Reasonable Efforts to commercialize such Intellectual Property. 

ARTICLE 7. SHARE PAYMENTS AND ADDITIONAL INTEREST 
 7.1 Share Payments. Subject to Grantor’s election in accordance with Article 19 to receive any amounts payable hereunder to LSI, each of Grantor and LSI shall be entitled to receive the Share
Payments as partial consideration for the payment of the Grant Award by Grantor; provided that (subject to any election by Grantor in accordance with Article 19), any and all payments of Additional Interest shall be paid by Grantee to LSI.
The initial [†] (in the aggregate) of any Share
Payments (excluding Additional Interest) shall be paid by Grantee to Grantor. Thereafter, any additional Share Payments (excluding Additional Interest), up to a maximum aggregate amount of [†], shall be paid by Grantee to LSI. As soon as Grantee has made Share Payments to Grantor and LSI equal to [†] in the aggregate, Grantee shall have no further obligations
hereunder to make any Share Payments to Grantee or LSI; provided that Grantee agrees to continue to make payments of Additional Interest, if any, to LSI. 
 7.2 Timing of Payments. Subject to Section 7.3, Grantee shall make the applicable Share Payments to Grantor or LSI, as applicable, within [†] after the end of each Fiscal Quarter which begins or ends
during the Proceeds Interest Period (each, a “Share Payment Date”), each such payment to be in an amount equal to the Share Payment calculated for such Fiscal Quarter based on the portion of Net Proceeds received by Grantee during
that Fiscal Quarter, with adjustment for any underpayment or overpayment for previous Fiscal Quarters if applicable. 
 7.3 Payment
Method. All payments to be made by Grantee to Grantor (or LSI, as applicable) hereunder shall be made by wire transfer of immediately available funds to the account designated by Grantor (or LSI, as applicable); provided, that for any
Share Payments attributable to Net Proceeds which consist of Liquid Securities or Deemed Liquid Securities, Grantor shall have the option of (a) accepting delivery by Grantee of the applicable portion, if any (based on Grantee’s good faith
projection of the Share Payment that will be payable on the next succeeding Share Payment Date), of such Liquid Securities or Deemed Liquid Securities as satisfaction of the payment of such Share Payments as required by Section 7.2 (and such
delivery may occur, at the option of Grantee, prior to the Share Payment Date with respect to the Fiscal Quarter in which 

  
  

	†	 DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 Page 10 

			
	 LSDF Grant No.: 4580719

Principal Investigator: Gregory A. Demopulos, M.D.

Organization: Omeros Corporation
	  	CONFIDENTIAL TREATMENT

  

 
such Liquid Securities or Deemed Liquid Securities were received by (or became Liquid Securities or Deemed Liquid Securities in possession of) Grantee) or (b) directing Grantee to use
commercially reasonable efforts to sell, liquidate or otherwise convert such applicable portion of Liquid Securities or Deemed Liquid Securities into cash or cash equivalents on Grantor’s behalf as promptly as practicable (a “Directed
Sale”), which cash or cash equivalents shall thereafter be delivered by Grantee to Grantor before or after the related Share Payment Date; provided that any fees, costs or expenses (including brokerage fees) incurred by Grantee in
seeking such a sale, liquidation or conversion shall be deducted by Grantee from such cash or cash equivalents before payment of the balance thereof to Grantor; and provided, further, that for purposes of calculating any amounts under
this Agreement, the Fair Market Value of any Liquid Security or Deemed Liquid Security that is subject to a Directed Sale shall be determined solely in accordance with Section 7.5 without regard to the amount of cash or cash equivalents
received in such Directed Sale (or any deductions therefrom pursuant to the preceding proviso). To the extent that any portion of a Share Payment is made in accordance with this Section 7.3 prior to the applicable Share Payment Date, each of
Grantor and Grantee agree that if as of such Share Payment Date any adjustment for underpayment or overpayment is required as a result of the projection of the Share Payment not being the same as the actual Share Payment, such adjustment shall be
made by wire transfer of immediately available funds to the other party. 
 7.4 Product and Platform Transfer. Grantee shall be entitled
to elect to treat any Platform and Product Transfer as an Assignment and Assumption Transfer, by providing prior written notice to Grantor of such election. If Grantee elects to treat a Platform and Product Transfer as an Assignment and Assumption
Transfer, then upon the closing of such Platform and Product Transfer, if such closing occurs, Grantee shall be required to assign this Agreement and its obligations and rights hereunder to the transferee, and the transferee shall be required to
accept such rights and assume such obligations, in connection therewith. 
 7.5 Liquid Securities; Deemed Liquid
Securities. Promptly following, and in no event more than [†] after, receipt by Grantee as Consideration of Liquid Securities or other Third Party securities that are publicly traded and that do not meet the criteria set forth in the definition of “Liquid
Securities” herein (such other securities, “Other Securities”), Grantee shall provide written notice to Grantor of Grantee’s possession of such Liquid Securities or Other Securities and a detailed description of the issuer
of such securities, the number of securities so received by Grantee, the Fair Market Value of such securities and any known contractual or legal limitations on the transfer thereof. In the event that any such Other Securities are deemed to be Liquid
Securities by Vulcan in accordance with the Platform Development Agreement (“Deemed Liquid Securities”), Grantee shall so notify Grantor in writing. The Fair Market Value of any 

  
  

	†	 DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 Page 11 

			
	 LSDF Grant No.: 4580719

Principal Investigator: Gregory A. Demopulos, M.D.

Organization: Omeros Corporation
	  	CONFIDENTIAL TREATMENT

  

 
Deemed Liquid Security hereunder shall be the Fair Market Value attributed to such Deemed Liquid Security under the Platform Development Agreement. The date of determination of Fair Market Value
of any Liquid Security shall be the later of [†]. 
 ARTICLE 8. LIFE SCIENCES INITIATIVE 

8.1 Mission and Shared Purpose. As partial consideration for the Grant Award, Grantee shall establish a non-profit entity (the “Life
Sciences Initiative” or “LSI”), the name of which shall be agreed by the parties, and shall allocate Share Payments to such entity in accordance with Article 7. 
 The intention of the parties is that LSI: 
 1) be a non-profit, tax-exempt
organization, governed by a board of trustees, with 50% of the board members appointed by Grantor and 50% appointed by Grantee; 

2) be a source of both philanthropic support and, to the extent legally permissible, investment capital; 

3) have a stated mission of advancing the life sciences in Washington by accelerating scientific discovery and enhancing translation of
that discovery to improving health and health care in Washington state and across the world, generating economic benefits to Washington state, and enhancing the competitiveness of Washington state’s life sciences sector; 

4) have the ability to benefit financially from investments and re-deploy that benefit to the mission; 

5) have shared goals and a close working relationship with other entities promoting the life sciences sector in Washington state,
including Grantor, such goals to include, but not be limited to, promoting high quality research and development, improving health outcomes, lowering health care costs, creating less costly diagnostic or treatment modalities, creating breakthrough
treatments for a particular disease or condition, leveraging its funding against that from other sources, stimulating health care delivery, biomedical manufacturing, and life sciences related employment in Washington state, and enhancing
public-private collaboration in Washington state; and 
 6) approach its mission based on a deep understanding of the life
sciences sector and a rigorous approach to decision making, that includes grant-making programs, establishment of unique facilities of broad impact, and investment strategies targeted at critical phases of translation from discovery to broader
benefit, including early stage companies. 

  
  

	†	 DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 Page 12 

			
	 LSDF Grant No.: 4580719

Principal Investigator: Gregory A. Demopulos, M.D.

Organization: Omeros Corporation
	  	CONFIDENTIAL TREATMENT

  

 8.2 Formation. Grantee shall form LSI in accordance with the LSI Milestones and
Timeline attached as Exhibit A-2 (the “LSI Milestones and Timeline”) and the Budget, and in consultation with Grantor; provided that, fees and expenses associated with completing Milestone 5, as set forth in Exhibit A-2,
shall be allowable costs hereunder, reimbursable by Grantor; provided, further, that before seeking reimbursement from Grantor for any such costs and expenses associated with Milestone 5, Grantee shall use reasonable efforts to engage
a legal provider to perform at least a portion of the work required for the completion of Milestone 5 on a pro bono basis. Failure of Grantee to form LSI in accordance with the LSI Milestones and Timeline (other than as the result of any act or
omission by Grantor) constitutes an Event of Default (as defined in Article 15), subject to the applicable Cure Period, and is grounds for Grantor’s exercise of its rights under Article 16. In no event shall Grantee have any obligation to fund,
staff or otherwise support LSI, except as expressly set forth in Article 7 and this Section 8.2. 
 ARTICLE 9. SHARE PAYMENTS REPORTS;
NOTICES 
 9.1 Quarterly Report. After the end of each Fiscal Quarter, Grantee shall produce and deliver to Grantor,
on or before each Share Payment Date, a Quarterly Report for such Fiscal Quarter; provided that, unless Grantee or its Affiliates receive Gross Proceeds prior to June 30, 2011 (in which case a Quarterly Report shall be delivered in
accordance with this Section 9.1 with respect to the Fiscal Quarter in which such Gross Proceeds were received), no Quarterly Report shall be deliverable under this Section 9.1 until the Share Payment Date relating to the Fiscal Quarter
ending June 30, 2011 (which Quarterly Report shall relate to the period from the Effective Date up to and including June 30, 2011). Grantor shall hold all such reports and agreements confidential, subject to the public disclosure laws of
the state of Washington (See e.g., RCW 42.56.270(14)) 
 9.2 Meetings. Grantor and any of Grantor’s representatives
shall have the right, upon reasonable prior written request from Grantor from time to time, to meet with Grantee’s senior officers, at a mutually agreed upon time and place, to discuss the GPCR Program; provided that in no event shall
Grantee be required to disclose t trade secrets, compound structures, phenotypes, targets, assay details, third-party confidential information or details about prospective partners (including the identity thereof) at any such meetings. 

9.3 Notices. Grantee shall notify Grantor promptly and in writing of the occurrence of a Material Adverse Effect or the
occurrence of a Change of Control or the sale of all or substantially all of the assets of Grantee. 

  
 Page 13

			
	 LSDF Grant No.: 4580719

Principal Investigator: Gregory A. Demopulos, M.D.

Organization: Omeros Corporation
	  	CONFIDENTIAL TREATMENT

  

 ARTICLE 10. CONFLICT OF INTEREST 
 Grantee represents and warrants that it has a financial conflict of interest policy (the “Policy”) in place applicable to performing research funded by the United States Public Health
Service (the “USPHS”) that it will apply to completing the Milestones and Timeline in the same manner as if completing the Milestones and Timeline were funded by a USPHS grant. Grantee further represents and warrants that Grantee
has taken reasonable steps to inform the Principal Investigator and any Investigator (as defined in the Policy) working on the Milestones and Timeline of the Policy and requirements for complying with its terms. In accepting this award, Grantee
represents that Grantee has advised the Principal Investigator and any Investigator working on the Milestones and Timeline that they are required to disclose, in accordance with the foregoing policy, any potential financial conflicts of interest
associated with their work on the Milestones and Timeline to Grantee and that Grantee has received such disclosures or received an affirmative statement that there are no conflicts to disclose. Grantee further represents that it has eliminated or
mitigated all disclosed financial conflicts consistent with the terms of its policy. Grantee also agrees to take reasonable measures to assure that its subcontractors who are Investigators working on the Milestones and Timeline are aware of and have
agreed to comply with the provisions of this Article. 
 At execution of this Agreement, Grantee shall submit to Grantor the completed and
executed statement found in Exhibit E of any potential financial conflicts of interest associated with personnel working on the Milestones and Timeline; attesting to its receipt of disclosures from such personnel that, at a minimum, confirm any
understandings of Grantor stated in Exhibit E; and assuring that all disclosed potential conflicts of interest have been eliminated or mitigated. 
 In the event that new financial conflicts of interest are disclosed during the course of working on the Milestones and Timeline, Grantee shall report such disclosures in writing to Grantor in a timely
manner using the procedure specified within this Article 10. 
 Upon the request of Grantor, Grantee shall provide, in writing, information
about any financial conflicts of interest that have been disclosed subject to this Article 10, or that have been identified by Grantor in Exhibit E, and about how such disclosed or identified conflicts have been eliminated or mitigated. 

ARTICLE 11. PRESENTATIONS AND PUBLICATIONS BY GRANTEE 
 Grantee shall have the right to publish the results of the GPCR Program. Following any such publication, copies of published papers describing work under the Milestones and Timeline shall be submitted by
Grantee to Grantor. Grantee agrees to acknowledge the support of Grantor in all scientific publications by Grantee related to the Milestones and Timeline. 

  
 Page 14

			
	 LSDF Grant No.: 4580719

Principal Investigator: Gregory A. Demopulos, M.D.

Organization: Omeros Corporation
	  	CONFIDENTIAL TREATMENT

  

 ARTICLE 12. REPRESENTATIONS OF GRANTEE AUTHORITY 

Grantee represents and warrants that it has authority to enter into this Agreement and to incur and perform the obligations herein and further warrants
that the signatories to this Agreement are authorized to execute this Agreement on behalf of Grantee. 
 ARTICLE 13. USE OF HUMAN SUBJECTS
AND VERTEBRATE ANIMALS 
 13.1 Human Subjects. In the event that completion of the Milestones and Timeline involve the use of human
subjects, Grantee shall ensure that the research site operates under an appropriate Office of Human Research Protections (OHRP)-approved assurance for the protection of human subjects and complies with all Department of Health and Human Services
human-subjects-related policies and any other applicable laws or regulations. In accepting an award involving human subjects use in completing the Milestones and Timeline, Grantee warrants that it has a system that complies with federal, state, and
local government regulations to protect the rights, well-being, and personal privacy of human subjects in research and that the work to be performed in completing the Milestones and Timeline has been reviewed and approved by the applicable human
subjects oversight bodies. Grantee shall provide documentation of review and approval by the applicable oversight bodies of all human subjects work performed in completing the Milestones and Timeline in a timely fashion upon request of Grantor.

 13.2 Vertebrate Animals. In the event that completion of the Milestones and Timeline involve the use of vertebrate animals, Grantee
shall ensure that all performance sites hold Office of Laboratory Animal Welfare (OLAW)-approved assurances. In accepting an award involving vertebrate animal use in completing the Milestones and Timeline, Grantee warrants that it has a system that
complies with federal, state, and local government regulations to humanely, efficiently, effectively and legally use live vertebrate animals in research and that the work to be performed in completing the Milestones and Timeline has been reviewed
and approved by the applicable animal use and care oversight bodies. Grantee shall provide documentation of review and approval by the applicable oversight bodies of all vertebrate animal work performed in completing the Milestones and Timeline in a
timely fashion upon request of Grantor. 
 ARTICLE 14. TERM 
 The term of this Agreement (“Term”) shall begin on the Effective Date and shall end on the six-month anniversary of the date Grantee submits a final research progress report to Grantor
pursuant to Section 4.1, subject to the continuation of certain provisions under Section 20.1. 

  
 Page 15

			
	 LSDF Grant No.: 4580719

Principal Investigator: Gregory A. Demopulos, M.D.

Organization: Omeros Corporation
	  	CONFIDENTIAL TREATMENT

  

 ARTICLE 15. DEFAULT 
 15.1 Events of Default by Grantee. In addition to any other Events of Default as noted throughout this Agreement, the occurrence of the following events of default (other than as the result of any
act or omission by Grantor) shall each be considered an “Event of Default” by Grantee under this Agreement; provided, that if any such event of default is curable, such event of default shall not be deemed to be an Event of
Default unless Grantee fails to cure such event of default within the time period specified below following receipt of written notice from Grantor notifying Grantee of such default (each, a “Cure Period”): 

 

	 	(a)	 failure of Grantee to meet the goals set out within the Milestones and Timeline in a timely manner, subject to a [†] Cure Period; 

 

	 	(b)	 failure of Grantee to render research progress reports, Share Payments reports, or financial reports to Grantor as required by this Agreement, subject
to a [†] Cure Period; 

 

	 	(c)	 Principal Investigator or any Investigator involved in completing the Milestones and Timeline have been debarred or been subject to debarment under the
provisions of the Generic Drug Enforcement Act of 1992, 21 U.S.C. or have otherwise been disqualified or suspended from work on the Milestones and Timeline by the FDA or any other governmental agency or professional body, subject to a [†] Cure Period, provided that removal from the GPCR Program
or replacement of the Principal Investigator or subject Investigator shall constitute a cure for purposes of this Section 15.1(c); 

  

	 	(d)	 in the case of the replacement of the Principal Investigator for any reason other than as described in Section 15.1(c), failure of Grantee to
identify an alternate Principal Investigator reasonably acceptable to Grantor, subject to a [†] Cure Period; 

  

	 	(e)	the occurrence of any Bankruptcy Event; 

  

	 	(f)	 failure of Grantee to form LSI in accordance with Article 8, subject to a [†] Cure Period; 

  

	 	(g)	 failure of Grantee to provide Share Payments to Grantor or LSI in accordance with Article 7, subject to a [†] Cure Period; 

 

	 	(h)	 failure of Grantee to comply with applicable federal or state law applicable to completing the Milestones and Timeline, subject to a [†] Cure Period; 

 

	 	(i)	 failure of Grantee to make equipment purchased or leased with funds disbursed pursuant to this Agreement available for GPCR Program purposes, subject
to a [†] Cure Period; 

  
  

	†	 DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 Page 16 

			
	 LSDF Grant No.: 4580719

Principal Investigator: Gregory A. Demopulos, M.D.

Organization: Omeros Corporation
	  	CONFIDENTIAL TREATMENT

  

	 	(j)	 the breach of any other material term or condition of this Agreement, subject to a [†] Cure Period. 

 Upon notice by Grantor to Grantee of any event of default, no request for reimbursement shall be made hereunder for any expenses incurred by Grantee on or after the date of such notice until such event of
default has been cured; provided that nothing herein shall be construed to release Grantor from any obligation to reimburse Grantee for allowable costs incurred prior to the date of such notice even if reimbursement is not sought until after
the date of such notice. In the event that Grantee fails to cure an event of default within the applicable Cure Period, Grantor shall not be required to reimburse Grantee for expenses incurred by Grantee during such Cure Period. 

ARTICLE 16. GRANTOR’S RIGHTS FOLLOWING EVENTS OF DEFAULT 
 Grantor shall have the right to exercise, individually or in combination, any and all of the following rights following an Event of Default by Grantee: termination of the funding provided to Grantee by
Grantor under this Agreement; Termination of Agreement for Events of Default under Article 17; Specific Performance for Events of Default under Article 18; or Election of Receipt of Share Payments for Events of Default under Article 19. 

ARTICLE 17. TERMINATION OF AGREEMENT FOR EVENTS OF DEFAULT 
 17.1 Termination of Agreement by Grantor. After the occurrence of an event of default, upon the expiration of the applicable Cure Period, if any, Grantor may effect termination of this Agreement by
providing Grantee written notice of termination unless Grantee has cured such event of default. Subject to this Section 17.1 and Section 17.2, upon exercise of its right to terminate, Grantor reserves the right to withhold further payments
of the Grant Award. 
 17.2 Effect of Termination under Section 17.1. Upon termination of this Agreement pursuant to
Section 17.1, Grantor shall have no further obligation to disburse grant funds to Grantee, whether or not the entire amount of award has been disbursed to Grantee. In the event that this Agreement is terminated by Grantor pursuant to
Section 17.1, no later than [†] after the effective date of termination: 
  

	 	(a)	Grantee shall refund to Grantor any Grant Award funds spent for purposes other than completing the Milestones and Timeline as set forth in the Budget; and

  

	 	(b)	Grantee shall invoice Grantor for outstanding reimbursable expenditures and/or any reasonable non-cancellable obligations incurred by Grantee 

  
  

	†	 DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 Page 17 

			
	 LSDF Grant No.: 4580719

Principal Investigator: Gregory A. Demopulos, M.D.

Organization: Omeros Corporation
	  	CONFIDENTIAL TREATMENT

  

	 	 
related to completion of the Milestones and Timeline prior to the date of notice of the event of default as applicable and Grantor shall promptly reimburse Grantee for such amounts; and

  

	 	(c)	Grantee shall provide Grantor, in writing, with a final report of Grantee’s progress in advancing the Milestones and Timeline (provided that Grantee shall
not be required to disclose trade secrets, compound structures, phenotypes, targets, assay details, third-party confidential information or details about prospective partners (including the identity thereof), and a final financial report.

 Nothing herein shall be construed to release Grantee from any obligation which matured prior to the effective date of such
termination or to release Grantor from any obligation to reimburse Grantee for any allowable costs incurred by Grantee prior to the date of notice of the event of default for which Grantee has sought reimbursements pursuant to Section 3.5 or to
waive any rights Grantor may have to recover damages incurred by it as a result of Grantee’s breach of the Agreement; provided that in no event shall Grantee be responsible or liable for any damages that are consequential, in the nature
of lost profits, special or punitive or otherwise not actual direct damages. 
 17.3 Termination of Agreement by Grantee;
Effect. In the event that Grantor fails to reimburse Grantee for any reimbursable expenditures hereunder within [†] after Grantee submits any invoice (or other payment verification as set forth in the Milestones and Timeline) in accordance
with the terms and conditions of this Agreement (unless Grantor reasonably withholds approval thereof in accordance with Section 3.5), Grantee shall have the right to terminate this Agreement upon [†] written notice to Grantor; provided that if Grantor
reimburses Grantee for such reimbursable expenses within such [†] period, Grantee shall not have the right to terminate this Agreement. In the event of any such termination, at Grantee’s election, Grantee may either reimburse Grantor (without interest) for any
amounts of the Grant Award received by Grantee on or prior to the effective date of termination, in which case, notwithstanding Section 20.1 of this Agreement, this Agreement shall be of no further force and effect in any respect, or Grantee
may retain such amounts of the Grant Award, and terminate this Agreement subject to the provisions of Section 20.1. 
 ARTICLE 18.
SPECIFIC PERFORMANCE FOR EVENTS OF DEFAULT 
 Grantor shall have the right to enforce this Agreement, or any provision herein, upon the
occurrence of any one or more Event of Default by Grantee. Upon the expiration of the applicable Cure Period, if any, Grantor may seek judicial enforcement of this agreement unless Grantee has cured the event of default. Upon exercise of its right
to enforce this agreement, Grantor reserves the right to withhold further payments of the Grant Award. 

  
  

	†	 DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 Page 18 

			
	 LSDF Grant No.: 4580719

Principal Investigator: Gregory A. Demopulos, M.D.

Organization: Omeros Corporation
	  	CONFIDENTIAL TREATMENT

  

 ARTICLE 19. ELECTION OF RECEIPT OF SHARE PAYMENTS FOR EVENT OF DEFAULT 

Solely in the event that Grantee fails to form LSI in accordance with Section 8.2 or make Share Payments, if any, to LSI in
accordance with Article 7, and such failure constitutes an Event of Default under Section 15.1(f) or (g), Grantor shall have the right to elect that those portions of the Share Payments payable to LSI under Article 7 be paid instead to Grantor.
Grantor may elect receipt of the Share Payments by giving Grantee [†] advance written notice. Upon effect of such election, Grantee shall make all subsequent Share Payments to Grantor instead of to LSI. 
 Article 20. SURVIVAL 
 Subject to Section 17.3, the following provisions of this
Agreement shall survive any expiration or termination of this Agreement: Article 4, Progress Reports; Article 5, Accounting and Auditing; Article 6, Intellectual Property; Article 7, Share Payments and Additional Interest; Article 8, Washington
Omeros Life Sciences Initiative; Article 9, Share Payments Reports; Article 15, Default (only with respect to provisions surviving pursuant to this Article 20); Article 16, Grantor’s Rights Following Events of Default (only with respect to
provisions surviving pursuant to this Article 20); Article 17, Termination of Agreement for Events of Default; Article 18, Specific Performance for Events of Default (only with respect to provisions surviving pursuant to this Article 20); Article
19, Election of Receipt of Share Payments for Event of Default; Article 20, Survival; Article 22, Indemnification; Article 23, Failure to Enforce; Article 24, Relationship of the Parties; Tax Treatment; Article 25, Governing Law; Article 26,
Assignment; Article 27, No Oral Modifications (only with respect to provisions surviving pursuant to this Article 20); Article 28, Notices; Article 29, Entire Agreement; Article 31, Severability; Article 32, Disputes and Article 33, No Third Party
Beneficiaries. 
 ARTICLE 21. COMMUNICATIONS AND PUBLIC DISCLOSURES BY GRANTOR 
 Grantor may publicly disseminate information about its granting activities, including in connection with the Grant Award hereunder; provided that in no event shall Grantor disclose any trade
secrets or other proprietary or confidential information of Grantee or its collaborators. From time to time Grantor may request Grantee or Principal Investigator to assist Grantor with such communications and public disclosures. Such assistance
provided by Grantee or Principal Investigator shall be at reasonable times and locales and at Grantor’s expense. 

  
  

	†	 DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 Page 19 

			
	 LSDF Grant No.: 4580719

Principal Investigator: Gregory A. Demopulos, M.D.

Organization: Omeros Corporation
	  	CONFIDENTIAL TREATMENT

  

 ARTICLE 22. INDEMNIFICATION 
 To the fullest extent permitted by law, Grantee shall indemnify, defend, and hold harmless Grantor and all officials, agents and employees of Grantor, from and against all claims for injuries or death
arising out of or resulting from the performance of the Milestones and Timeline, except to the extent such Claims result from or arise out of the negligence, willful misconduct or violation of applicable law by Grantor, its employees, subcontractors
or agents; provided that in no event shall Grantee be responsible or liable for any damages that are consequential, in the nature of lost profits, special or punitive or otherwise not actual direct damages. 

“Claim,” as used in this Agreement, means any financial loss, claim, suit, action, damage or expense, including but not limited to
attorney’s fees, attributable for bodily injury, sickness, disease, or death, or injury to or destruction of tangible property including loss of use resulting therefrom. Grantee’s obligations to indemnify, defend, and hold harmless include
any claim by Grantee’s agents, employees, representatives, or any sub-contractor or its employees. 
 If Grantor determines that it is
entitled to defense and indemnification under this Article 22, Grantor shall promptly notify Grantee in writing of the indemnity claim, and provide all reasonably necessary or useful information in connection with such claim. 

ARTICLE 23. FAILURE TO ENFORCE 
 The
failure of Grantor at any time, or for any period of time, to enforce any of the provisions of this Agreement shall not be construed as a waiver of such provisions or as a waiver of the right of Grantor thereafter to enforce each and every such
provision. 
 ARTICLE 24. NATURE OF RELATIONSHIP 
 The relationship between Grantor and Grantee is solely as set forth in this Agreement, and neither Grantor nor Grantee has any fiduciary or other special relationship with the other or any of their
respective Affiliates, except as provided herein. Grantor acknowledges that Grantee intends that solely for purposes of this Agreement, the rights and obligations of each party, as they are defined in this Agreement, create an unincorporated joint
venture taxable as a partnership under Subchapter K of the Internal Revenue Code of 1986, as amended. Grantee recognizes that Grantor is a tax-exempt entity under the United States federal, state and local laws, has never been subject to, and is
unlikely to be subject to, any tax liability or withholding requirements under U.S. federal, state or local laws. Before withholding and paying over to any U.S. federal state or local taxing authority any amount purportedly representing a tax
liability of the pursuant to the provision of the Agreement, Grantee shall provide Grantor written notice of the claim of any such U.S. taxing authority that such 

  
 Page 20

			
	 LSDF Grant No.: 4580719

Principal Investigator: Gregory A. Demopulos, M.D.

Organization: Omeros Corporation
	  	CONFIDENTIAL TREATMENT

  

 
withholding and payment is required by law and provide Grantor the opportunity to contest such claim. 
 ARTICLE 25. GOVERNING LAW 
 This Agreement shall be governed and construed in accordance
with the laws of the state of Washington. 
 ARTICLE 26. ASSIGNMENT 

The provisions of this Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors
and assigns. Grantee shall not be entitled to assign any of its obligations and rights under this Agreement without the prior written consent of Grantor; provided, that Grantee may, without restriction or the requirement of any consent by
Grantor, assign any of its rights and obligations under this Agreement to an Affiliate; provided, further, that, subject to Section 7.4, Grantee shall be required to assign this Agreement and its obligations and rights hereunder
to the transferee, and the transferee shall be required to accept such rights and assume such obligations, without any consent of Grantor, in connection with any assignment to an Affiliate, a Change of Control or any Assignment and Assumption
Transfer; provided, further, that from and after the date of any assignment to an Affiliate, Change of Control, or Assignment and Assumption Transfer, the calculation of Gross Proceeds and Net Proceeds hereunder shall provide (through
definitions and other provisions similar to those in this Agreement, mutatis mutandis, applicable to the assignee and its Affiliates, along with assumed calculations of Gross Proceeds and Net Proceeds to date) that the assignee will owe directly to
Grantor all actions, performance, covenants, and amounts that would have been owed by Grantee to Grantor, were the assignment not to have occurred and were Grantee (rather than such assignee) to have performed any act or suffered any omission or
condition to occur by such assignee following such assignment. Grantor may assign any of its rights or obligations under this Agreement to LSI or any other entity, including any State of Washington agency, without restriction or the requirement of
any consent from Grantee; provided, that, without the prior written consent of Grantee (which consent shall not be unreasonably withheld), Grantor may not assign its rights or obligations under this Agreement to any [†] or any Affiliate thereof or any other actual or potential
competitor of Grantee (each, a “Competitor”); and provided, further, that without the prior written consent of Grantee (which consent shall not be unreasonably withheld), Grantor may not assign any of its rights or
obligations under this Agreement to any entity that directly or indirectly holds more than [†] of the outstanding capital stock of any Competitor. 

  
  

	†	 DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 Page 21 

			
	 LSDF Grant No.: 4580719

Principal Investigator: Gregory A. Demopulos, M.D.

Organization: Omeros Corporation
	  	CONFIDENTIAL TREATMENT

  

 ARTICLE 27. NO ORAL MODIFICATIONS 
 This Agreement may not be changed, modified or amended except by express written agreement of the parties executed by their authorized representatives. 

ARTICLE 28. NOTICES 
 Except as otherwise
expressly provided in this Agreement, any communications between the parties hereto or notices to be given hereunder shall be given in writing by personal delivery, electronic transmission using electronic mail or Grantor’s online systems,
facsimile, or mailing the same, postage prepaid to Grantee or Grantor at the address or number set forth below, or to such other addresses or numbers as either party may indicate pursuant to this section. Any communication or notice so addressed and
mailed shall be effective five days after mailing. Any communication or notice delivered by facsimile shall be effective on the day the transmitting machine generates a receipt of the successful transmission, if transmission was during normal
business hours of the recipient, or the next Business Day, if transmission was outside normal business hours of the recipient. Any communication or notice given by personal delivery shall be effective when actually delivered. Communications by
Grantee to Grantor using Grantor’s online systems as required under this Agreement shall be effective upon Grantee’s receipt of confirmation that such communications have been received by Grantor. Communications by electronic mail shall be
effective upon receipt of automatic receipt confirmation. 
 Notices to Grantor 

Grants Administrator 
 Life Sciences Discovery Fund 
 2324 Eastlake Avenue East, Suite 501 

Seattle, WA 98102 

Tel: 206-732-6788 

Fax: 206-732-6778 

Email: grantsadmin@lsdfa.org 

Notices to Principal Investigator 
 Gregory Demopulos, M.D. 
 c/o Omeros Corporation 

1420 Fifth Avenue, Suite 2600 
 Seattle, WA 98101 
 Attention: Chief Executive Officer 

Facsimile No.: (206) 676-5005 

  
 Page 22

			
	 LSDF Grant No.: 4580719

Principal Investigator: Gregory A. Demopulos, M.D.

Organization: Omeros Corporation
	  	CONFIDENTIAL TREATMENT

  

 Notices to Grantee: Authorized Official 

Omeros Corporation 
 1420 Fifth Avenue, Suite 2600 
 Seattle, WA 98101 

Attention: General Counsel or Senior Director of Finance 
 Facsimile No.: (206) 676-5005 
 Notices to Grantee: Financial Official 

Omeros Corporation 
 1420 Fifth Avenue, Suite 2600 
 Seattle, WA 98101 

Attention: Senior Director of Finance 
 Facsimile No.: (206) 676-5005 
 ARTICLE 29. ENTIRE AGREEMENT 

This Agreement and, subject to Section 2.1, which provides that the proposal attached as Exhibit F is not incorporated by reference, and except as
otherwise expressly provided for in this Agreement, nothing in such proposal shall be binding on Grantee in any respect hereunder, the Exhibits attached hereto express the entire understanding of the parties with reference to the subject matter
hereof, and supersede any prior or contemporaneous representations, understandings and agreements, whether oral or written. The parties agree and acknowledge that the rule of construction that ambiguities in a written agreement be construed against
its drafter shall not be applicable to this Agreement. 
 ARTICLE 30. FORCE MAJEURE 

Neither Grantor nor Grantee shall be held responsible for delay or default caused by fire, civil unrest, natural causes and war which is beyond,
respectively, Grantor’s or Grantee’s reasonable control. Each party shall, however, make all reasonable efforts to remove or eliminate such cause of delay or default and shall, upon cessation of the cause, diligently pursue performance of
its obligations under this Agreement. 
 ARTICLE 31. SEVERABILITY 
 The provisions of this Agreement are intended to be severable. If any term or provision is illegal or invalid for any reason whatsoever, such illegality or invalidity shall not affect the validity of the
remainder of the Agreement. 

  
 Page 23

			
	 LSDF Grant No.: 4580719

Principal Investigator: Gregory A. Demopulos, M.D.

Organization: Omeros Corporation
	  	CONFIDENTIAL TREATMENT

  

 ARTICLE 32. DISPUTES 
 The parties agree that, in the event of any dispute, controversy or claim (each, a “Dispute”) arising out of or relating to this Agreement or any breach or alleged breach hereof, they
shall undertake good faith efforts to resolve the matter amicably. Upon the agreement of the parties, any such Dispute may thereafter be submitted to mediation. Should the parties agree to mediate the Dispute, said mediation shall be conducted in
Seattle, Washington and in accordance with the then prevailing rules of the Commercial Mediation Rules of the American Arbitration Association. In the event that the Dispute is not resolved pursuant to mediation or, in the event the parties do not
agree upon submission of the Dispute to mediation, each party may pursue any rights and remedies as each may have, whether in law or at equity. 

ARTICLE 33. NO THIRD PARTY BENEFICIARIES 

Grantor and Grantee are the only parties to this Agreement and the only parties entitled to enforce its terms. The parties agree that Grantee’s
performance under this Agreement is solely for the benefit of Grantor to enable it to accomplish its fundamental governmental purpose. Nothing in this Agreement is intended to give, or shall give, whether directly or indirectly, any third party
standing to sue to enforce this agreement. 
 NOW, THEREFORE, agreement to the terms stated above is indicated by signatures affixed below.

  

			
	Grantee	  	Grantor
		
	By: /s/ Gregory A. Demopulos	  	By: /s/ Lee Huntsman
	Name: Gregory M. Demopulos, M.D.	  	Name: Lee Huntsman
	Title: Chairman and CEO	  	Title: Executive Director, LSDF
	Date: October 21, 2010	  	Date: October 21, 2010

 Principal Investigator 

I have read and understand the terms of this Agreement. 
 By: /s/ Gregory A. Demopulos 
 Name: Gregory M. Demopulos, M.D 

Date: October 21, 2010 

  
 Page 24

			
	 LSDF Grant No.: 4580719

Principal Investigator: Gregory A. Demopulos, M.D.

Organization: Omeros Corporation
	  	CONFIDENTIAL TREATMENT

  

 Schedule 1: Definitions 

“Additional Interest” shall mean, with respect to aggregate Net Proceeds in excess of the Minimum Proceeds Amount
during the Proceeds Interest Period, [†] (the
“Additional Interest Percentage”) of all such Net Proceeds to the extent they are derived from the commercial exploitation of the Platform in connection with Human Orphan GPCRs or the commercial exploitation of Products directly
targeting Human Orphan GPCRs; provided that to the extent that and for so long as the Grantor has not provided the maximum amount of the Grant Award to Grantee on or before the date any Additional Interest is due and payable to Grantor (or
LSI, as applicable) hereunder, the Additional Interest Percentage shall be adjusted by multiplying such percentage by X, wherein: 
 X = Grant Award paid to date / $5,000,000 
 “Affiliate” shall mean any Person
that controls, is controlled by, or is under common control with another Person. For purposes of this definition, “control” shall mean (i) in the case of corporate entities, (a) direct or indirect ownership of at least 50% of the
stock or shares having the right to vote for the election of directors, or (b) the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such entity, whether through ownership of
voting securities, by contract or otherwise, and (ii) in the case of non-corporate entities, (a) direct or indirect ownership of at least 50% of the equity interest of such non-corporate entity or (b) the power to direct the
management and policies of such non-corporate entities, whether through ownership of voting securities, by contract or otherwise. 

“Applicable Percentage” shall mean, with respect to aggregate Net Proceeds during the Proceeds Interest Period, the following:

 (a) with respect to aggregate Net Proceeds of up to and including [†]; 

(b) with respect to aggregate Net Proceeds in excess of [†] but less than and including [†]; 
 (c) with respect to aggregate Net Proceeds in excess of [†] but less than and including [†]; 
 (d) with respect to aggregate Net Proceeds in excess of [†] but less than and including [†]; 

  
  

	†	 DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 Page 25 

			
	 LSDF Grant No.: 4580719

Principal Investigator: Gregory A. Demopulos, M.D.

Organization: Omeros Corporation
	  	CONFIDENTIAL TREATMENT

  

 (e) with respect to aggregate Net Proceeds in excess of [†] but less than and
including [†]; and 

(f) with respect to aggregate Net Proceeds in excess of [†]; 

provided that to the extent that and for so long as Grantor has not provided the maximum amount of the Grant Award on or before the date any Share
Payment is due and payable to Grantor (or LSI, as applicable) hereunder, the Net Proceed amounts and Applicable Percentages set forth in subclauses (a) through (f) above shall be adjusted such that each Net Proceeds amount is multiplied by
X and each Applicable Percentage amount is multiplied by Y, wherein: 
 X = 20,000,000 / (25,000,000 - Grant Award paid to
date). 
 Y = Grant Award paid to date / $5,000,000 
 “Assignment and Assumption Transfer” shall mean a Platform and Product Transfer that Grantee shall have elected, pursuant to Section 7.4, to treat as an Assignment and Assumption
Transfer. 
 “Bankruptcy Event” shall mean the occurrence of any of the following: 

(i) Grantee shall commence any case, proceeding or other action (A) under any existing or future law of any jurisdiction, domestic or foreign,
relating to bankruptcy, insolvency, reorganization, relief of debtors or the like, seeking to have an order for relief entered with respect to it, or seeking to adjudicate it bankrupt or insolvent, or seeking reorganization, arrangement, adjustment,
winding-up, liquidation, dissolution, composition or other relief with respect to it or its respective debts, or (B) seeking appointment of a receiver, trustee, custodian or other similar official for it or for all or any portion of its assets,
or Grantee shall make a general assignment for the benefit of its respective creditors; 
 (ii) there shall be commenced against Grantee any
case, proceeding or other action of a nature referred to in clause (i) above which remains undismissed, undischarged or unbonded for a period of sixty (60) calendar days; or 
 (iii) Grantee shall take any action in furtherance of, or expressly indicating its consent to, approval of, or acquiescence in, any of the acts set forth in clause (i) or (ii) above. 

“Business Day” shall mean any day other than a Saturday, a Sunday, any day which is a legal holiday under the laws of the State of
Washington, or any day on which banking 

  
  

	†	 DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 Page 26 

			
	 LSDF Grant No.: 4580719

Principal Investigator: Gregory A. Demopulos, M.D.

Organization: Omeros Corporation
	  	CONFIDENTIAL TREATMENT

  

 
institutions located in the State of Washington are required by law or other governmental action to close. 
 “Change of Control” shall mean: 
 (i) the acquisition by any Person or group
(within the meaning of Sections 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934) of beneficial ownership of any capital stock of Grantee, if after such acquisition, such Person or group would be the “beneficial owner” (as
defined in Rule 13d-3 under the Securities Exchange Act of 1934), directly or indirectly, of securities of Grantee representing more than fifty percent (50%) of the combined voting power of Grantee’s then outstanding securities entitled to
vote generally in the election of directors; or 
 (ii) the consummation, after approval by Grantee’s shareholders, of a merger or
consolidation of Grantee with any other Person, other than a merger or consolidation which would result in Grantee’s voting securities outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being
converted into voting securities of the surviving entity) more than fifty percent (50%) of the combined voting power of Grantee’s voting securities or such surviving entity’s voting securities outstanding immediately after such merger
or consolidation; or 
 (iii) the consummation, after approval by Grantee’s shareholders, of a sale of all or substantially all of the
assets of Grantee to any other Person, other than a sale wherein the holders of Grantee’s voting securities outstanding immediately prior thereto represent (either by remaining outstanding or by being converted into voting securities of the
purchasing entity) more than fifty percent (50%) of the combined voting power of the voting securities of such purchasing entity outstanding immediately after such sale of all or substantially all of the assets of Grantee. 

“Commercially Reasonable Efforts” shall mean, [†]. 

“Consideration” shall mean any and all license fees, milestone fees, royalties, cross-licenses, services and any other fees, damages and
payments, in whatever form, in each case to the extent clearly constituting consideration relating directly to the Products and/or the Platform in any agreement, award or judgment. 
 “Deemed Liquid Securities” shall have meaning set forth in Section 7.5. 
 “Fair Market Value” shall mean, with respect to any Liquid Security, the average closing price of such security for the [†] to the date of determination, and with respect to any other security or asset, the fair market value thereof.

  
  

	†	 DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 Page 27 

			
	 LSDF Grant No.: 4580719

Principal Investigator: Gregory A. Demopulos, M.D.

Organization: Omeros Corporation
	  	CONFIDENTIAL TREATMENT

  

 “Fiscal Quarter” shall mean each calendar quarter. 

“Funding Amount” means the $20,000,000 received by Grantee from Vulcan or any Affiliate thereof pursuant to the Platform Development
Agreement. 
 “GAAP” shall mean generally accepted accounting principles in the United States, or, to the extent adopted by
Grantee (or, if applicable, its Affiliates), the International Financial Reporting Standards, in each case as in effect from time to time. 

“Government Funding Sources” shall mean any foreign, federal, state or local (domestic or foreign) government, government agency or
institution, government-owned corporation, government authority, quasi-governmental organization, public research center, university or other institution established by government to advance a public purpose. 

“GPCR Program” shall mean all research, development and commercialization activities of Grantee or its Affiliates to the extent relating
to any Product or use of the Platform. 
 “Gross Proceeds” means the sum, from the Effective Date to the date of calculation,
of all Consideration actually received by Grantee or any of its Affiliates during the Proceeds Interest Period derived from: 
 (a) any license,
development, commercialization, collaboration, distribution, marketing or partnering agreement entered into before or during the Proceeds Interest Period relating directly to any Products and/or the Platform and/or 

(b) otherwise any licensing, sale, transfer, use or other commercial exploitation of any Products or the Platform, including any royalty payments, sale
proceeds, or damages or settlement payments received in any infringement or similar suits brought by Grantee for alleged infringement or misappropriation of intellectual property rights developed in connection with any Product or the Platform,

 (excluding in all cases: (1) the Funding Amount, (2) any Consideration received by Grantee or its Affiliates from Government
Funding Sources unless such Consideration is comprised of revenue from services of a type generally offered to Third Parties by Grantee or its Affiliates, royalty payments or sale proceeds, in each case relating directly to any Products and/or the
Platform, (3) any Consideration received by Grantee or its Affiliates that is clearly identified in the underlying agreement as designated for research and development of the Platform or any Products (which research and development funds will
be tracked using Grantee’s standard methods or policies of accounting or as may be otherwise required by the applicable agreement) and related overhead from corporate partners or from other Third Parties, (4) any Consideration received by
Grantee or its Affiliates in the form of grants, (5) bona fide investments in equity of Grantee or its Affiliates, at or less than the then-current fair market value of 

  
 Page 28

			
	 LSDF Grant No.: 4580719

Principal Investigator: Gregory A. Demopulos, M.D.

Organization: Omeros Corporation
	  	CONFIDENTIAL TREATMENT

  

 
such equity, and (6) any Consideration received by Grantee or its Affiliates in connection with a Change of Control or an Assignment and Assumption Transfer); provided, that:

 (i) all Gross Proceeds which consist of Liquid Securities or Deemed Liquid Securities shall be valued in accordance with
Section 7.5, when computing Net Proceeds; 
 (ii) all Gross Proceeds which are Illiquid Proceeds shall not be included in
the calculation of Net Proceeds until there has been a Realization of such Illiquid Proceeds, in which case such Illiquid Proceeds shall be valued at the Fair Market Value of such Realization when computing Net Proceeds; 

(iii) in calculating Gross Proceeds, any Consideration received by Grantee or any Affiliate of Grantee from any Affiliate of Grantee (for purposes of
clarity, other than any stock or any other equity interest held by Grantee in such Affiliate or any other Affiliate of Grantee and dividends or other distributions received by right of ownership of stock or other equity interest in such Affiliate of
Grantee) shall be excluded pro rata, in proportion to Grantee’s ownership interest in such Affiliate or such Affiliate’s ownership interest in Grantee, as the case may be; 
 (iv) any Consideration received by Grantee in situations where the parties are not dealing at arms-length shall be valued, for purposes of calculating Gross Proceeds under this Agreement, at no less than
the current fair market value, in substantially contemporaneous arms-length transactions, of the rights, goods and services provided by Grantee in return for such Consideration; and 
 (v) Consideration for a sale, assignment or grant of any exclusive right or exclusive license in, to, or under the Platform or any Product or any Intellectual Property comprising or claiming all or a
portion of the Platform or any Product, other than as part of a Change of Control or an Assignment and Assumption Transfer, shall be counted in the Gross Proceeds as the same is received by Grantee or its Affiliate. 

For purposes of determining Gross Proceeds, Consideration received or expenditures incurred by any Affiliate of Grantee shall be included pro rata, in
proportion to Grantee’s ownership interest in such Affiliate or such Affiliate’s ownership interest in Grantee, as the case may be. 

“Human Class A Orphan GPCRs” shall mean those Human Orphan GPCRs set forth in Schedule 1A; provided that, to the extent that
on or after the Effective Date any GPCR set forth on Schedule 1A shall be determined to have not been a Human Orphan GPCR as of the Effective Date due to the efforts of any Third Party, such GPCR shall be deemed to be excluded from the definition of
Class A Human Orphan GPCR for all purposes of this Agreement. 

  
 Page 29

			
	 LSDF Grant No.: 4580719

Principal Investigator: Gregory A. Demopulos, M.D.

Organization: Omeros Corporation
	  	CONFIDENTIAL TREATMENT

  

 “Human Orphan GPCR” shall mean any human GPCR for which one or more functionally active
ligand(s) have not, prior to their first identification through use of the Platform, been identified through use of technologies other than the Platform, it being understood that such identification of one or more functionally active ligand(s)
constitutes the “de-orphanization” of such GPCR. 
 “Illiquid Proceeds” shall mean any Gross Proceeds that are in a
form other than cash, cash equivalents or Liquid Securities. 
 “Intellectual Property” shall mean all proprietary information;
trade secrets; know-how; confidential information; inventions (whether patentable or unpatentable and whether or not reduced to practice or claimed in a pending patent application) and improvements thereto; Patents; registered or unregistered
trademarks, trade names, service marks, including all goodwill associated therewith; registered and unregistered copyrights and all applications thereof; in each case that are owned or controlled by Grantee. 

“Liquid Securities” shall mean Third Party securities, not subject to any contractual or legal limitation on the
sale thereof, with an average daily trading volume for the [†] prior to the delivery to Grantor or LSI of at least
[†] the number of such Liquid Securities to be
allocated to Grantor or LSI, if any, in accordance with Section 7.5. 
 “Material Adverse Effect”
shall mean [†] 

“Material Contract” shall mean the Option Agreement, and any contract, agreement or other arrangement (other than this Agreement and the
Platform Development Agreement) that could reasonably be expected to result in Gross Proceeds (i) to which either Grantee or any of its Affiliates is a party or by which any of Grantee’s or its Affiliates’ respective assets or
properties are bound or committed, (ii) which is directly related to any Products or the Platform, and (iii) as to which breach, nonperformance or failure to renew would reasonably be expected to have a Material Adverse Effect. 

“Minimum Proceeds Amount” shall mean [†]; provided that to the extent that and for so long as Grantor has not paid the maximum amount of the Grant
Award to Grantee on or before the date any Additional Interest is due and payable hereunder, the Minimum Proceeds Amount shall be adjusted such that the Minimum Proceeds Amount is multiplied by X, wherein: 

X = Funding Amount / (25,000,000 - Grant Award contributed to date). 

  
  

	†	 DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 Page 30 

			
	 LSDF Grant No.: 4580719

Principal Investigator: Gregory A. Demopulos, M.D.

Organization: Omeros Corporation
	  	CONFIDENTIAL TREATMENT

  

 “Net Proceeds” shall mean Gross Proceeds, less the sum, from the Effective Date to the
date of calculation, of all expenses and expenditures, in each case determined in accordance with GAAP, incurred by Grantee or its Affiliates on or after the Effective Date in excess of the Funding Amount and any portion of the Grant Award actually
paid to Grantee by Grantor, in connection with, and to the extent attributable to the conduct of its GPCR Program, including research and development expenses and related overhead, and milestone, royalty and similar payments to Third Parties with
respect to the practicing or exploiting of the Platform or any Products, legal expenses (including legal expenses associated with applying, prosecuting, maintaining and enforcing Intellectual Property), cost of goods sold and Product Sales
Deductions (with respect to Product sold by Grantee and its Affiliates), and amounts paid to acquire relevant technologies (including payments pursuant to the Option Agreement for the acquisition of the Platform) and expenditures for the purchase of
equipment and other tangible assets for the GPCR Program; 
 except, in each case, not including expenses or expenditures to the extent that
such expenses or expenditures are funded with (1) any Consideration received by Grantee or its Affiliates from Government Funding Sources unless such Consideration is comprised of revenue from services of a type generally offered to Third
Parties by Grantee or its Affiliates, royalty payments or sale proceeds, in each case relating directly to any Products and/or the Platform, (2) any Consideration received by Grantee or its Affiliates that is clearly identified in the
underlying agreement as designated for research and development of the Platform or any Products (which research and development funds will be tracked using Grantee’s standard methods or policies of accounting or as may be otherwise required by
the applicable agreement) and related overhead from corporate partners or from other Third Parties and (3) any Consideration received by Grantee or its Affiliates in the form of grants, that is excluded from Gross Proceeds; provided
that, while as to any particular date of calculation, the Net Proceeds may have a negative value, such negative values will be carried forward to the next calculation period, and only positive Net Proceeds will be counted in determining the Share
Payments; and provided, further, [†]. For purposes of determining Net Proceeds, Consideration received or expenditures incurred by any Affiliate of Grantee shall be included pro rata, in proportion to Grantee’s ownership interest in
such Affiliate or such Affiliate’s ownership interest in Grantee, as the case may be. 
 “Option Agreement” shall mean the
Exclusive Technology Option Agreement effective as of September 4, 2009, by and among Grantee, Patobios Limited, Susan George, Brian O’Dowd and U.S. Bank National Association as escrow agent, as amended. 

“Patents” shall mean (a) all national, regional and international patents and patent applications, including provisional patent
applications; (b) all patent applications filed either from a patent or patent application described in clause (a) or from an application claiming priority to a patent or patent application described in clause (a), including 

  
  

	†	 DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 Page 31 

			
	 LSDF Grant No.: 4580719

Principal Investigator: Gregory A. Demopulos, M.D.

Organization: Omeros Corporation
	  	CONFIDENTIAL TREATMENT

  

 
divisionals, continuations, continuations-in-part, provisionals, converted provisionals, and continued prosecution applications; (c) any and all patents that have issued or in the future
issue from the foregoing patent applications (clauses (a) and (b)), including utility models, petty patents and design patents and certificates of invention; (d) any and all extensions or restorations by existing or future extension or
restoration mechanisms, including revalidations, reissues, re-examinations and extensions (including any supplementary protection certificates and the like) of the foregoing patents or patents applications (clauses (a), (b) and (c)); and
(e) any similar rights, including so-called pipeline protection, or any importation, revalidation, confirmation or introduction patent or registration patent or patent of addition as to any such foregoing patent applications and patents.

 “Person” shall mean an individual, corporation, partnership, limited liability company, association, trust or other entity
or organization, but not including a government or political subdivision or any agency or instrumentality of such government or political subdivision. 
 “Platform” shall mean all of the tangible and intangible assets purchased by Grantee pursuant to the Option Agreement and any and all improvements thereto made or acquired by or for
Grantee and its Affiliates (whether before or after such purchase), together with all Intellectual Property protecting such assets or their use or application. 
 “Platform and Product Transfer” shall mean a sale or assignment, whether in one or a series of related transactions, of all or substantially all of the Platform, together with all or
substantially all of the Products not (a) previously sold or (b) subject to a license in favor of a Third Party at the time of such sale or assignment. 
 “Platform Development Agreement” means that certain Platform Development Funding Agreement by and among Grantee, Vulcan and Cougar Investment Holdings LLC, dated as of October 21,
2010. 
 “Proceeds Interest Period” shall mean the period from and including the Effective Date until the earlier of
(a) twenty-one years after the death of the last survivor of the currently-in being (as of the Effective Date) descendants of Joseph P. Kennedy Sr. (father of President John F. Kennedy), and (b) the last to occur of (i) the 35th
anniversary of the Effective Date and (ii) the date that aggregate Net Proceeds are at least the Minimum Proceeds Amount, unless earlier terminated in accordance with the terms of this Agreement. 

“Products” shall mean any product and its derivatives that is in any way and to any extent identified, discovered, developed, tested,
certified, or manufactured through the use or application of the Platform, and any service relating to any such product, together with all Intellectual Property protecting such products and services. 

  
 Page 32

			
	 LSDF Grant No.: 4580719

Principal Investigator: Gregory A. Demopulos, M.D.

Organization: Omeros Corporation
	  	CONFIDENTIAL TREATMENT

  

 “Product Sales Deductions” shall mean the following expenses to the extent incurred
with respect to a sale of Product: 
 (a) returns, rebates, chargebacks and other allowances; 

(b) retroactive price reductions that are actually allowed or granted; 
 (c) sales commissions paid to Third Party distributors and/or selling agents, in amounts customary to the trade; 
 (d) marketing, sales and distribution expenses; and 
 (e) all sales or excise taxes,
transportation and insurance, custom duties, and other governmental charges. 
 “Quarterly Report” shall mean, with respect to
the relevant Fiscal Quarter of Grantee, (i) a report, certified by the Chief Financial Officer of Grantee, providing reasonable detail of the calculation of Net Proceeds for such Fiscal Quarter, including Gross Proceeds, a description of all
deductions from Gross Proceeds pursuant to this Agreement, a description of any Consideration received from Affiliates of Grantee that were characterized as Gross Proceeds in such prior period, a description of any expenses and expenditures
recognized by Grantee from the operations of its Affiliates that reduced Net Proceeds in such prior period, a description of pro rata calculation of such Consideration, expenses and expenditures (in accordance with the “Gross Proceeds” and
“Net Proceeds” definitions set forth above) and a description of all Third Party securities received by Grantee in such prior period that are Illiquid Proceeds, and (ii) copies of each Material Contract entered into, amended, modified
or terminated in such Fiscal Quarter, provided, that such copies may be redacted by Grantee to delete any confidential information of the parties thereto, so long as the financial provisions thereof are not redacted. 

“Realization” shall mean, for a given asset, any time that such asset is liquidated into, is exchanged for, is specifically borrowed
upon for (it being understood that a secured loan that includes such asset along with other non-similar assets shall not be “borrowed upon” for purposes of this definition), is converted into, becomes or pays a dividend of, cash, cash
equivalents or Liquid Securities. 
 “Share Payment Date” shall have the meaning set forth in Section 7.2. 

“Share Payments” shall mean (i) the Applicable Percentage in respect of Net Proceeds and (ii) the Additional Interest.

 “Subsidiary” or “Subsidiaries” shall mean with respect to any Person (i) any corporation of which the
outstanding capital stock having at least a majority of votes entitled to be cast in the election of directors under ordinary circumstances shall at the time be owned, directly or indirectly, by such Person or (ii) any other Person of which at
least a majority voting interest under ordinary circumstances is at the time, directly or indirectly, owned by such Person. 

  
 Page 33

			
	 LSDF Grant No.: 4580719

Principal Investigator: Gregory A. Demopulos, M.D.

Organization: Omeros Corporation
	  	CONFIDENTIAL TREATMENT

  

 “Third Party” shall mean any Person other than Grantor or Grantee or their respective
Affiliates. 
 “Vulcan” means Vulcan Inc., a Washington corporation. 

  
 Page 34

			
	 LSDF Grant No.: 4580719

Principal Investigator: Gregory A. Demopulos, M.D.

Organization: Omeros Corporation
	  	CONFIDENTIAL TREATMENT

  

 Schedule 1A 
 Class A Human Orphan GPCR’s 
  

					
	[†]	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	 
	 	 	 	 	 
	 	 	
	 	 	 	 	
	 	 	
	 	 	 	 	

  
  

	†	 DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 Page 35 

			
	 LSDF Grant No.: 4580719

Principal Investigator: Gregory A. Demopulos, M.D.

Organization: Omeros Corporation
	  	CONFIDENTIAL TREATMENT

  

 Exhibit A: GPCR Program Milestones and Timeline 

Program Milestones and Timelines 
 GPCR Program Milestones 
  

							
	#	  	Milestone	  	Completion
Date	 	Deliverable
	1	  	Pre-Award Costs: [†]	  	Prior to
Effective
Date	 	Invoices or
other
reasonable
evidence, as
requested
by
Grantor
	 	 	 	 
	21	  	 (a) Screen using the Platform at least 75% of all Human Class A Orphan GPCRs using its
standard method of GPCR screening, utilizing, in Grantee’s reasonable judgment, a substantial portion of its applicable and appropriate compound libraries for each such GPCR, which level of effort shall, for each such GPCR screened (other than
where the same is not required, due to any easier method of compound identification for a particular Human Class A Orphan GPCR), be at least commensurate with the activities, resources, facilities or personnel conducted or devoted by Grantee to the
screening of GPCRs within the set of five Human Class A Orphan GPCRs screened prior to the Effective Date; and
  
 (b) Commence a medicinal chemistry development program focused on, and use Commercially Reasonable Efforts in, advancing toward compound optimization for the purpose of developing a clinical candidate
with respect to at least one orphan GPCR for which compounds were identified using the Platform.
	  	19
months
after the
Effective
Date2
(May
2012)
	 	Invoices and
progress
reports

 

	†	 DESIGNATES
PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

	1	 Grantee may submit
invoices to Grantor for reimbursement of costs as incurred, subject to Section 3.5 of the Agreement. 

	2	 Provided, however,
that such 19 month period shall be extended to [†] in
the event that Grantee has screened (as described above) at least [†] of all such Human Class A Orphan GPCRs within 19 months following the Effective Date, and provided, further, however, that the covenants set forth in this Milestone 2 shall expire and be of no
further force and effect automatically upon the date on which Grantor has received aggregate Share Payments of at least
[†]. 

  
 Page 36

			
	 LSDF Grant No.: 4580719

Principal Investigator: Gregory A. Demopulos, M.D.

Organization: Omeros Corporation
	  	CONFIDENTIAL TREATMENT

  

 Exhibit A-2: LSI Milestones and Timeline 

 

							
	#	  	Milestone	  	Completion
Date	  	Deliverable
	
1
	  	Establish organization charter	  	 6 months (March

2011)
	  	Written document mutually acceptable to Grantee and Grantor and
submitted to Grantor
	
2
	  	Establish bylaws	  	 9 months (June

2011)
	  	Written bylaws following generally accepted principles and mutually
acceptable to Grantee and Grantor and submitted to Grantor
	
3
	  	Select directors	  	 12 months (October

2011)
	  	Board of directors mutually acceptable to Grantee and
Grantor
	
4
	  	File Nonprofit Articles of Incorporation with Washington State	  	 12 months (October

2011)
	  	Copy of filed Articles; UBI number
	
5
	  	Apply for Federal tax-exempt status under Section 501(c)(3) of the Internal Revenue Code or other appropriate tax-exemption
provision.	  	 15 months (January

2012)
	  	Good faith application

  
 Page 37

			
	 LSDF Grant No.: 4580719

Principal Investigator: Gregory A. Demopulos, M.D.

Organization: Omeros Corporation
	  	CONFIDENTIAL TREATMENT

  

 Exhibit B: Collaborators 
 None. 

  
 Page 38

			
	 LSDF Grant No.: 4580719

Principal Investigator: Gregory A. Demopulos, M.D.

Organization: Omeros Corporation
	  	CONFIDENTIAL TREATMENT

  

 Exhibit C: GPCR Program Budget 

  
 Page 39

			
	 LSDF Grant No.: 4580719

Principal Investigator: Gregory A. Demopulos, M.D.

Organization: Omeros Corporation
	  	CONFIDENTIAL TREATMENT

  

 Exhibit D: Progress Report Form Content 
 Grantor gathers data to analyze the impact of its awards and assess return on investment to demonstrate responsible stewardship of funds to the Washington State Legislature, the Grantor Board of Trustees,
and the public. Grantor anticipates that the work of its grantees will have a wide variety of impacts – in life sciences competitiveness, health, and the economy – some difficult to measure. To help analyze the impact of its awards,
Grantor requires semi-annual progress reports during the term of a grant. Reports are due immediately after each six-month period following commencement of the award. 
 Attached is the template for submitting progress reports to Grantor via its online progress report system. Unless otherwise indicated, reports shall be made only on Grantor-funded work. Where it is
necessary to describe work not funded by Grantor to answer coherently, this shall be indicated. 
 Unless otherwise indicated, events that have
been previously reported (e.g., a new collaboration) should not be reported; any changes or progress in such events should be reported. Do not report personally identifiable health data that may compromise an individual’s privacy.

  
 Page 40

			
	 LSDF Grant No.: 4580719

Principal Investigator: Gregory A. Demopulos, M.D.

Organization: Omeros Corporation
	  	CONFIDENTIAL TREATMENT

  

 Exhibit E: Conflict of Interest Report Form 

Proposal title: Drug Discovery for Orphan G Protein-Coupled Receptors 
 Principal investigator: Gregory A. Demopulos, M.D. 
 Grantor reference no.: 4580719 

The capitalized terms used within this Exhibit E are as defined in the Life Sciences Discovery Fund LSDF 10-05 Opportunity Grant, Grant Award Agreement
to which it is appended. 
 In executing this Conflict of Interest Report Form, Grantee represents and warrants that it has a financial conflict
of interest policy in place applicable to performing research funded by the United States Public Health Service (the “USPHS”) that it will apply to completing the Milestones and Timeline in the same manner as if completing the Milestones
and Timeline were funded by a USPHS grant. Grantee further represents and warrants that Grantee has taken reasonable steps to inform the Principal Investigator and all personnel working on the Milestones and Timeline of the policy and requirements
for complying with its terms. In accepting this award, Grantee represents that Grantee has advised the Principal Investigator and Grantee’s personnel working on the Milestones and Timeline that they are required to disclose, in accordance with
the foregoing policy, any potential financial conflicts of interest associated with their work on the Milestones and Timeline to Grantee. 
 The
following individuals have disclosed a financial conflict of interest. Grantee attests that in compliance with its conflict of interest policies it has reviewed all such disclosures and that all disclosed conflicts of interest associated with
completing the Milestones and Timeline, including, but not limited to those associated with Grantor’s understandings stated above, have been eliminated or mitigated as follows: 

 

			
	Name:	  	Conflict eliminated      Conflict mitigated     
	Name:	  	Conflict eliminated      Conflict mitigated     

 If no disclosures were made regarding completion of the Milestones and Timeline, please initial below: 
          No financial conflicts of interest associated with completion of the Milestones and Timeline were disclosed to Grantee. 

 

			
	Attested to by:

			
	Signature:	 	  

			
	
	Name: Gregory A. Demopulos, M.D.
	Title: Chairman & CEO
	Date: October 21, 2010

  
 Page 41

			
	 LSDF Grant No.: 4580719

Principal Investigator: Gregory A. Demopulos, M.D.

Organization: Omeros Corporation
	  	CONFIDENTIAL TREATMENT

  

 Exhibit F: Proposal 

  
 Page 42

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00186-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00186-of-00352.parquet"}]]